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Abstract 
Amphotericin B (AmB) is the gold standard treatment of systemic fungal infections. 
It is the secondary treatment of leishmaniasis with 97% cure rate with no reported 
resistance. However, the only dosage form of AmB in the market is parenteral formulations 
as intermittent iv infusion. Sodium deoxycholate (Fungizone

) was the first conventional 
formulation followed by several new lipid formulations since 1990 (Ablecet

, Amphocil

 
and Ambisone

).  These formulations were proved to be very effective, less toxic and 
require shorter course of therapy compared to Fungizone
®
. Unfortunately, all these 
parenteral formulations suffer from the inconvenience of intravenous (iv) administration, 
required hospitalization, more importantly, induce a number of side effects, and are very 
expensive.  
Therefore, the need for oral formulations of AmB is a crucial concern.  During the 
last four decades there have been several published efforts representing different strategies 
in formulating oral delivery system of AmB with reduced toxicity. None of these 
formulations has been introduced into the market yet. 
In this study a novel stealth nanotechnology formulations containing AmB have 
been developed for an oral administration in order to improve its solubility, bioavailability 
an with lower toxicity. The selection of the copolymer used PEGylated poly-lactic- co- 
glycolic acid (PLGA-PEG) was based on the hypothesis that FDA has approved each 
individual component of the copolymers for oral and parenteral administrations of poorly 
soluble drugs. 
The development of these oral formulations of AmB went through several 
optimization steps, including method of preparation, polymer selection, stirring rate, 
cosolvency, pH, particle size reduction, stabilizers, surfactants, absorption enhancer, and 
HPLC assay for in vitro analysis. 
Novel oral biodegradable stealth polymeric nanoparticles have been successfully 
fabricated using the commercially available PLGA-PEG copolymer for AmB by emulsion 
diffusion method. In vitro characterizations of the lyophilized formulations showed that 
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main particles size (MPS) of AmB loaded to NPs ranged from 23.8 ±4.8 to 1068± 489.8 
nm. An increased stirring rate favored AmB NPs with smaller MPS. There was a 
significant reduction in MPS (P < 0.05) and significant increment in the drug content (P < 
0.05) and the amount of drug released (P < 0.05), when AmB-NPs were prepared using the 
diblock copolymer PLGA–PEG with 15% PEG compared to other copolymers investigated. 
The addition of three emulsifying agents poly vinyl pyrrolidone (PVP), Vitamin E (TPGS) 
and pluronic F-68 to AmB formulations led to significant reduction in particle size and 
increase in drug entrapment efficiency (DEE) compared to addition of PVP alone. Fourier 
transform infrared spectroscopy demonstrated a successful loading of AmB to stealth 
PLGA– PEG copolymers. PLGA–PEG copolymer entrapment efficiency of AmB was 
increased up to 56.7%, with 92.7% drug yield. 
The physicochemical characterization done by SEM and TEM images indicate 
spherical particle in nanometer size in isolated and agglomerated state. The FTIR changes 
obtained from different AmB-NPs formulations suggesting some sort of interaction 
between the drug and the polymer. 
A simple, fast, accurate and reliable HPLC method for the in vitro investigations 
(drug content and drug release from the NPs) of AmB has been developed. Intra-day and 
inter-day variability were ≤ 6.2% with excellent linearity(R2=0.9982) and reproducibility. 
All tested formulations have shown slow initial release with 20% to 54% released 
within 24 h in phosphate buffer containing 2% sodium deoxycholate. The release rates of 
AmB from these formulations were best fit to the Korsmeyer–Peppas model. Therefore, a 
diffusion release model is the best to characterize the in vitro release of AmB from these 
formulations. 
A new selective, sensitive and precise LC MS/MS method was developed to 
measure AmB concentrations via electrospray ionization source with positive ionization 
mode. The precision and accuracy of the developed LC MS/MS method in the 
concentration range of 100–4000 ng/ml show no significant difference among inter- and-
intra-day analysis (p > 0.05). Linearity was observed over the investigated range with 
correlation coefficient, R
2
> 0.9943 (n = 6/day).  The assay was able to detect all the drug 
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concentrations for pharmacokinetics and bioavailability estimation after oral dosing of 
AmB loaded to PLGA-PEG compared to its parenteral administration in rats. AmB 
solutions or NPs were kept in refrigerator during the study. 
After PO administration AmB loaded to PLGA-PEG (C6), AmB was rapidly 
absorbed, distributed, and then slowly eliminated. The effect of glycyrrhizic acid (GA) as a 
natural absorption enhancer added during formulation or before administration was 
investigated.  The addition of GA significantly (P<0.05) increased AmB AUC and Cmax (2 - 
3 folds).  There was no significant change (P=0.09) in adding GA during formulation or 
before administration. A tremendous improvement of AmB oral absorption in rats by > 790 
% than Fungizone

is observed after GA Addition.  
AmB formulations have been screened for toxicity using several in vitro assays; 
hemolysis, antifungal activity and analysis of the cell viability by 3-(4,5dimethylthiazoly)-
2,5-diphenyl-tetrazolium bromide(MTT) assay. Fungizone

 was used as the reference 
standard. AmB loaded to PLGA-PEG of the selected formulations showed a significant 
reduction (P< 0.05) in the in vitro hemolytic activity as compared to Fungizone

.  On 
cellular level, AmB loaded to PLGA-PEG showed a potent activity against the in vitroC. 
albicans with a parallel decrease in the cytotoxicity against in the in vitro tested cell lines. 
Additionally, no pathological abnormalities were observed in rats given iv administration 
of AmB protocol except after Fungizone

 administration. 
The in vivo nephrotoxicity and histopathological evaluation of AmB were 
performed in both rats' kidneys and liver using forty eight rats divided into eight groups 
after single and multiple iv administrations of 1mg/kg of the selected formulations or 
Fungizone

for a week. AmB induced nephrotoxicity was also estimated in these rats by 
measuring blood urea nitrogen and plasma creatinine (biomedical parameters). A 
significant (P<0.05) nephrotoxicity was observed after Fungizone
®
 administration 
compared to all AmB loaded to PLGA-PEG formulations. The histopathological study of 
the isolated kidney tissues confirmed this finding.  Furthermore, the incidence of the liver 
toxicity due to the selected AmB loaded PLGA-PEG formulations has been reduced 
significantly as investigated through in vivo analysis (histopathological and biochemical 
tests) in comparison with Fungizone

. 
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In conclusion, a successful novel AmB oral formulation with improved efficacy and 
bioavailability and with less toxicity to the kidney and the liver was developed.  Further 
investigations are needed in the near future for this formulation to be in the market as an 
oral delivery system of AmB. 
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1.1. Nanotechnology and Nanoparticles in Drug Delivery Systems 
A drug delivery system can be defined as macromolecules assemblies of suitable  
carrier in which a drug could be loaded to improve its efficacy.  The development of this 
system for a drug is essential to improve the in vivo performance of its conventional dosage 
form concerning; poor water solubility, low bioavailability, instability, high toxicity, 
increased resistance or lower cellular uptake.  This system is intended to deliver the drug 
mainly to the site of action to enhance its activity with minimal toxicity(Muhamad et al., 
2012). 
While, nanotechnology (particle size reduction technology) is the science of small; 
the very small to nanometers scale; 1.0 nanometer = 10
-9
 meter, nano is a billionth of a 
meter. When reducing the particle size, atoms and molecules behave differently than before 
reduction (Ochekpe et al., 2009, Pehlivan, 2013). The reduction in size significantly 
increases the particles’ surface area leading to increase the solubility (Bawa, 2008).  
A large variety of subjects benefit from the advantages of nanotechnology, such as 
electronics, healthcare,  pharmaceuticals and food processing, etc.(Ochekpe et al., 2009, 
Alok et al., 2013). 
Application of nanotechnology in pharmaceuticals focuses mainly on formulating 
therapeutic agents in biocompatible nanocarriers to be able to provide superior drug 
delivery systems for better management and treatment of diseases.  These nanocarriers 
include polymeric nanoparticle, liposomes, solid lipid nanoparticles, nanoemulsions, 
carbon nanotubes, dendrimers, quantum dots and polymeric micelle (Sahoo et al., 2002, 
Mohanraj and Chen, 2007, Ochekpe et al., 2009, Zhang et al., 2010a, Kumari et al., 2010, 
Parveen et al., 2012).  
Employing nanotechnology in drug delivery system is of utmost importance due to 
its potential to overcome a large number of challenges concerning not only the design of 
new drugs delivery systems, but also for the in vivo optimization of old drugs. Some of the 
drawbacks encountered by pharmaceutical development of most drug delivery systems are 
their poor drug solubility, intestinal absorption, bioavailability, in vivo stability, sustained 
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and targeted delivery to site of action, therapeutic effectiveness, side effects, and plasma 
fluctuations of drug concentration (Ochekpe et al., 2009). 
Polymeric nanoparticle (PNPs) as shown in Figure 1.1, (Radwan and Aboul-Enein, 
2002) as drug delivery system has been extensively investigated due to their targeting 
potential to the wanted site of action (Allémann et al., 1993, Bawa, 2008). PNPs can be 
defined as “solid particles with a size of 10-1000 nm”. This tiny size range leads to a 
significant increase in the drug surface area  and improved efficacy(Ranghar et al., 2014). 
PNPs can be classified according to the shape as spherical shapes, tubules, particles and 
tree like branched shapes.  According to the method of preparation, the drug may be 
entrapped, dissolved, dispersed, encapsulated or attached to the nanoparticle matrix 
(Soppimath et al., 2001). 
 
Figure 1.1. Scanning electron microscope for insulin-loaded polyethylcyanoacrylate 
nanoparticles(Radwan and Aboul-Enein, 2002) 
 
Liposomes were first developed about 40 years ago (Martin, 1990). They are small 
artificial vesicles (50 – 200nm) (Figure 1.2(Xu et al., 2013)) composed of a lipid bi-layer 
membrane, similar to a cell membrane. Liposome can be composed of naturally derived 
phospholipids with mixed lipid chains (like egg phosphatidylethanolamine), or pure 
surfactant like dioleoylphosphatidyl-ethanolamine.  They are used in biology, biochemistry, 
medicine, food and cosmetics. Due to its unique structure, liposome can encapsulate both 
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hydrophilic and hydrophobic molecules(Martin, 1990, Vemuri and Rhodes, 1995, Lemke et 
al., 2005, Ochekpe et al., 2009). 
 
Figure 1.2. Basic component of liposome (Xu et al., 2013) 
 
Solid lipid nanoparticles (SLNs) is shown in Figure 1.3(Uchechi et al., 2014),is 
typically spherical with an average diameter 10-1000 nm. SLN possess a solid lipid core 
matrix that can solubilize lipophilic molecules. These solid lipids are well tolerated by the 
body; however, SLN are suffering from insufficient drug loading, and relative high water 
content of the dispersions. SLN can be applied for parenteral, dermal, ocular, oral, 
pulmonary and rectal routes of administration (Schäfer-Korting et al., 1989, MuÈller et al., 
2000, Müller et al., 2002, Hafner et al., 2014, Uchechi et al., 2014). 
 
Figure 1.3.  Basic component of solid lipid nanoparticles (Uchechi et al., 2014) 
 
Nanoemulsions as shown in Figure 1.4(Uchechi et al., 2014)are emulsions with 
droplet size below 1.0 micron (1 micron= 1000 nm) in diameter. Unlike, 
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microemulsions(white in color) nanoemulsion are transparent. Nanoemulsions are 
biocompatible, biodegradable, reproducible and mainly used as a carrier for lipophilic 
drugs, Nanoemulsion can be applied for parenteral, oral, ocular, pulmonary and dermal 
deliveries(Ganta et al., 2010, Hafner et al., 2014, Caldeira et al., 2015). 
 
Figure 1.4. Basic components for nanoemulsion(Uchechi et al., 2014). 
 
Carbone nanotubes (CNTs),as seen in Figure 1.5,were defined by (Pehlivan, 
2013)as allotropes of carbon, made of graphite and built in cylindrical tubes with 
nanometer in diameter and several millimeters in length. CNTs have been successfully 
applied as therapeutic and diagnostic agents (drugs, genes, vaccines, antibodies, biosensors, 
etc.). They are considered as non-biodegradable drug targeting carrier.  
 
Figure 1.5. Carbone nanotube (Pehlivan, 2013) 
 
Dendrimers (Figure 1.6)(Lee et al., 2005) are defined as synthetic nano-size tree 
like macromolecules with branching emanating from a central core “branched NPs”. Their 
distinctive structures allow drugs to be encapsulated within the central core as well as 
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attached on the surface. Both hydrophilic and hydrophobic drugs can be loaded to 
dendrimers (Hafner et al., 2014, Jain et al., 2015). 
 
Figure 1.6. Basic dendrimers componentsLee et al. (2005) 
 
Quantum dots (QDs) also called as fluorescence nanocrystals (Figure 1.7(Ghaderi et 
al., 2011) range from 2 to 10 nm in diameter. Structurally, some QDs possesses a bimetallic 
crystalline core, which is composed from materials including cadmium–selenium, 
cadmium– tellurium, indium–phosphate or indium–arsenate. A semiconductor shell 
typically zinc sulfide stabilizes the core, further improving the optical, physical properties, 
and bioavailability of the material (Ghaderi et al., 2011). QD shave increasing potential to 
be usedas replacements of organic dyes in imaging of biological systems as a result of their 
exceptional fluorescent properties, reasonable chemical stability and broad excitation 
ranges instead of organic dyes(Ghaderi et al., 2011). 
  
 
 
 
 
Figure 1.7. Structure of quantum dot with bioactive agents (Ghaderi et al., 2011) 
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Spherical polymeric micelles (Figure 1.8, (Xu et al., 2013) are nanoscopic core/shell 
structure formed by amphiphilic block copolymer. The inner core of a micelle is 
hydrophobic which, is bounded by a shell of hydrophilic polymers. Poorly water soluble 
and amphiphilic drugs can be encapsulated in the core, while the presence of hydrophilic 
shell extend their circulation time in the blood and improve their accumulation in cancer 
cells(Hafner et al., 2014). 
 
 
 
 
Figure 1.8.  Polymeric micelles(Xu et al., 2013) 
 
Over the last four decades, nanotechnology technique has been used extensively in 
the field of drug delivery systems resulting in a number of products, including therapeutics 
and imaging agents. Some of these nanomedicines were approved for the treatment of 
cancer, pain, and infectious diseases.  Table 1.1 represents the commercially available 
nanotherapeutic drug delivery systems for oral and parenteral administrations (Murthy, 
2007, Cho et al., 2008, Hafner et al., 2014).   One of the major advantages that 
nanotechnology offers is targeted drug delivery to the site of action. Targeting can be 
categorized into three levels(Blanco et al., 2012) (1) delivery to a specific cancer region, i.e., 
central or peripheral, right or left; (2) delivery to the site of disease; and (3) delivery to 
distinct cell types with biological barrier transport, e.g., epithelial cells, or cells associated 
with lymphatic tissue. This can be achieved either through passive targeting of drugs to the 
site of action or by active targeting of the drug.  Passive delivery refers to transport of the 
formulation through leaky tumor capillary fenestrations into the tumor interstitium and cells 
by passive diffusion or convection by utilizing specific carriers (Figure 1.9)(Blanco et al., 
2012). 
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Table 1.1.  Examples of commercially available nanotherapeutic products* for oral and 
parenteral administration 
Nanotechnology- 
based approach 
Drug Major indication Dosage 
form 
Route of 
administration 
Brand name  
Nanoemulsion Sirolimus Graft rejection, Kidney 
transplantation 
Tablet Oral Rapamune®  
 Aprepitant Postoperative nausea 
and vomiting, Cancer 
Capsule Oral Emend®  
 
 Cyclosporine Organ rejection  
 
Soft 
capsules 
Oral Neoral®  
 Olanzapine Schizophrenia Powder or 
suspensio
n  
iv/IM Zypadhera®  
Nanoparticles Paclitaxel Breast neoplasma Powder or 
suspension  
iv/IM Abraxane®  
Polymeric drugs Sevelamer Hyperphosphat-emia, 
Renal dialysis 
Tablet Oral Renagel®  
Renvela® 
 
 Albumin-
Taxol  
Anticancer Solution iv Abraxane® 
 PGA-Taxol  Anticancer Solution iv Xyotax ® 
 Glatiramer 
(copolymer) 
Multiple sclerosis Solution SC Copaxone®  
 
Polymer-protein 
conjugates 
Pegaspargase 
(mPEG-
asparaginase
) 
Acute lymphobla- 
sticleukemia 
Solution iv/IM Oncaspar®  
 Certolizuma
b 
pegol(PEG-
anti-
TNFFab) 
Rheumatoid arthritis Solution  SC Cimzia™  
Liposomes Amphoterici
n B 
Fungal infections Suspensio
n  
iv AmBisome®  
 Doxorubicin Breast Neoplasms, 
Multiplemyeloma 
Suspensio
n  
iv Caelyx®  
 
 Propofol Anaesthetic Emulsion iv Diprivan®  
Nanocomplex Sodium 
ferric 
gluconate 
Iron deficiency anemia Solution  iv  Ferrlecit®  
 Ferric 
carboxymalt
ose 
Iron deficiency anemia Solution  iv Ferinject®  
Dendrimers  Vaginal microbicidal Gel  SC Viva® 
*(Murthy, 2007, Cho et al., 2008, Hafner et al., 2014) 
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Carriers included in this targeting category are synthetic polymers, some natural 
polymers such as albumin, liposomes, micro (or nano) particles, and polymeric 
micelles(Muhamad et al., 2012). On the other hand, active targeting refers to increasing in 
the delivery of drugs to a specific target through the use of specific interactions at 
target sites where a drug’s pharmacological activities are applied. These interactions 
for example include antigen–antibody and ligand–receptor binding. Alternatively, 
physical signals such as magnetic fields and temperatures that are externally applied 
to the target sites may be utilized for active targeting respectively. Carriers classified 
into this methodology include antibodies, transferrin, ferrite containing liposomes, 
peptides  and thermoresponsive carriers (Blanco et al., 2012). 
 
 
Figure 1.9. Active and passive targeting of foreign macromolecules (Blanco et al., 2012) 
 
One of the major problems with this nanotherapeutic drug carrier is that they are 
rapidly eliminated from the blood stream through phagocytosis by the reticuloendothelial 
system (RES) (Stolnik et al., 1995, Owens and Peppas, 2006, Bawa, 2008).   Avoidance of 
phagocytosis can be achieved through PEGlyation (surface modification, surface coating of 
PNP) using polyethylene glycol (PEG), i.e. formation of the so-called “stealth” PNPs, 
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which abrogate the rapid uptake by phagocytic cells (Greenwald et al., 2003, Jokerst et al., 
2011).  PEGylation can shield active ingredients from recognition and degradation by the 
immune system, can lower their renal filtration and prolong their circulation half-life.  
Therefore, a significant reduction of the overall dosage or frequency of drug administration 
will be achieved.  By providing a hydration layer and steric barrier surrounding the 
polymeric core, PEG grafting can reduce non-specific binding of serum proteins to the 
particles, thereby reducing their clearance by cells of the mononuclear phagocytic system. 
PEGylation technology has the advantages of delivery natural unstable therapeutic proteins 
with short circulating half-lives, such as enzymes, hormones, and antibodies (Jokerst et al., 
2011, Ledet and Mandal, 2012). PEG has been the most common hydrophilic blocking 
agent used since it is readily hydrated; it has a high degree of conformational flexibility and 
is biocompatible. It is approved for internal use in human by the United State Food and 
Drug Administration (US FDA)(Gref et al., 1994, Luo et al., 2002). The inner hydrophobic 
block has shown greater variability depending on the system being studied (Jee et al., 
2012). Figure 1.10 shows PEGlyation with different PNs formulations(Hafner et al., 2014).  
 
Polymeric therapeutic Liposomes 
Water soluble polymers, either as a bioactive itself 
(A) or as an inert functional part of a multifaceted 
construct for 
improved drug, 
protein or gene 
delivery (B). 
 Size < 25 nm 
 
Vesicles composed of one or more concentric 
bilayers of lipid 
molecules (entrapping 
hydrophobic drugs) 
enclosing one or more 
aqueous com-
partments (entrapping 
hydrophilic drugs). 
Size 20-30 nm 
Nanoemulsions  Polymeric micelles 
Oil nanodroplets dispersed within aqueous 
continuous phase 
suitable for 
entrapment of 
hydrophobic drugs  
Size: 20–200 nm  
 
Supramolecular aggregates composed of amphiphilic 
block copolymers that self-assemble into aqueous 
media; inner core 
typically serves as a 
container for hydrophobic 
drugs 
Size: 20–80 nm 
 
Figure ‎01.10. Examples of  PEGlyation of nanotherapeutics (Hafner et al., 2014). 
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Examples of alternative hydrophilic polymers for nanoparticle stealth 
functionalization rather than PEG are presented in Figure 1.11 (Hu et al., 2013) as poly 
(vinyl alcohol) (PVA), poly(4-acryloylmorpholine), poly (N,N-dimethylacrylamide) and 
poly(N-vinyl-2-pyrrolidone) (PVP) (Hu et al., 2013). 
 
Figure 1.11.  Examples of alternative hydrophilic polymers for nanoparticle stealth 
functionalization rather than PEG (Hu et al., 2013) 
 
PNPs are characterized by larger surface area which improves bioavailability, 
unlikely to cause blood vessels blocking and improved therapeutic response.  In addition, 
PNPs, are used as controlled and sustained release of the drug either during drug 
movement or at the site of action affecting its organ distribution and reduce its renal 
clearance leading to improving drug efficacy and reducing its adverse effects (Jawahar 
and Meyyanathan, 2015). The PNPs system can be used for various routes of 
administration, including oral, nasal, parenteral, intra‑ocular, etc(Greenwald et al., 2003, 
Jawahar and Meyyanathan, 2015). 
1.2. Polymeric Nanoparticles 
PNP scan be classified according to method of preparation into two categories; 
nanocapsules and nanospheres which are shown in Figure 1.12 (Jawahar and Meyyanathan, 
2015). Nanocapsules are reservoir in which a liquid or semisolid drug-loaded core is 
enclosed in a polymeric coat. While nanospheres are matrix systems in which a drug is 
uniformly distributed through solid polymer matrix (Brigger et al., 2002, Vauthier and 
Bouchemal, 2009). The term "nanoparticles (NPs) is adopted because it is often very 
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difficult to ambiguously establish whether these particles are of the matrix or a membrane 
type (Branch, 1988, Quintanar-Guerrero et al., 1998a, Fattal and Vauthier, 2002, Jeong et 
al., 2002, Ochekpe et al., 2009, Vauthier and Bouchemal, 2009, Kumari et al., 2010, 
Parveen et al., 2012). 
 
Figure 1.12. Spherical polymeric nanoparticles either nanosphere (left) or nanocapsule 
(right)  (Jawahar and Meyyanathan, 2015) 
Furthermore PNPs for pharmaceutical applications drug delivery systems as shown 
in Figure 1.13, can be classified based on their special orientation in the space; into zero, 
one, two and three dimensions (Hett, 2004, Konwar and Ahmed, 2013). One dimensional 
system, such as thin film or manufactured surface, has been used for decades in electronic 
and chemical engineering. One dimensional PNP include carbon nanotubes (CNTs); it is 
hexagonal network of carbon atoms, 1.0 nm in diameter and 100 nm in length, as a layer of 
graphite rolled up into cylinder.  Three dimensional PNPs include Fullerenes (Carbon 60), 
which consist of spherical cages containing from 28 to more than 100 carbon atoms, 
contain C60. This is like a hallow ball, resemble a soccer ball(Konwar and Ahmed, 2013). 
 
Figure 1.13. Heterogonous PNPs  based on their structural complexity; zero-dimensional (0-
D), one-dimensional (1-D), two-dimensional (2-D), three-dimensional (3-D) and the even 
more complex chiral 3-D nano structural networks  (Konwar and Ahmed, 2013). 
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The benefits of using PNPs, as a drug delivery system, include: increase of the 
solubility, protection against degradation, prolonged release, improved bioavailability, 
targeted delivery and decrease the toxic side effects of drugs. They also offer appropriate 
form for all routes of administration and allow rapid-formulation development (Mohanraj 
and Chen, 2007, Parveen et al., 2012). However, PNPs have some use constraints 
especially in liquid form due to particle-particle aggregation because of their small size and 
large surface area.  In addition, PNPs have lower drug loading and show burst release. 
These real-world problems have to be solved before PNPs are being available in the market 
for clinical utilization(Mohanraj and Chen, 2007, Parveen et al., 2012).  
The ideal polymer for PNPs preparation has to be biodegradable, completely 
eliminated from the body in a reasonable time, long stability in circulation, and apparent 
lack of immunogenicity(Vilar et al., 2012). The polymer must also be compatible with 
different drugs, leading to high drug loading, possesses appropriate properties for easier 
fabrication and its degradation products have to be nontoxic(Mohanraj and Chen, 2007, 
Parveen et al., 2012). To date only a few of the polymers available are approved for drug 
delivery and in vivouse (Vauthier and Bouchemal, 2009). 
The final PNPs delivery systems should be simple and inexpensive, reproducible 
and stable.  No toxic organic solvents should be involved in their formulations.  They are 
appropriate to various groups of drugs; small molecular weight drugs as well as proteins 
and polypeptides.  They are easy to handle and have the ability to be lyophilized and stable 
after reconstitution with the suitable vehicle(Nagavarma et al., 2012). 
PNPs are successfully employed to a wide range of research fields as anticancer, 
anti-inflammatory, immunosuppressant, hormones, antifungals, and vitamins, etc.  PNPs 
can improve the efficacy of different drugs; cover nasty taste, prolong their release, 
improve bioavailability and protect these drugs from degradations(Nagavarma et al., 2012). 
1.2.1. Polymer Types: 
Despite the structure and function diversity of polymers, they are classified in a 
number of ways depending upon various criteria  as shown in Figure1.14 (Vollmert and 
Immergut, 1973, Stevens, 1990, Fried, 2014). On the basis of source or origin, the polymers 
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are classified into three types: natural polymers, semi-synthetic polymers and synthetic 
polymers. Natural polymers (biopolymers) are found in nature, mostly obtained from plants 
and animal sources and they include polysaccharides (starch and cellulose), proteins (α-
amino acids, wool, natural silk, leather, etc.), nucleic acids (RNA and DNA) and natural 
rubber(2-methyl buta-I, 3-diene (isoprene). These natural polymers have been widely 
utilized in drug delivery systems due to their intrinsic biodegradability and 
biocompatibility.  Some disadvantages of their use are poor batch to batch reproducibility 
and their potential antigenicity (Mohanty et al., 2015).  
 
Figure 1.14.  Classification of polymer (Fried, 2014) 
 
Semi-synthetic polymers are mostly derived from naturally occurring polymers with 
further chemical alterations as cellulose derivative.  The most important polymers in this 
class are known as cellulose ethers that can be further classified as nonionic (including 
methyl cellulose, hydroxyethyl cellulose, etc.) and anionic (primarily sodium 
carboxymethyl cellulose). Chitin and starch are derivatized to form water-soluble polymers 
of this class(Mikkelsen, 1994). Chitosan polymers are semisynthetic polymers derived from 
deacetylation of their parent polymer chitin. They have unique structures, multidimensional 
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properties, highly sophisticated functionality and a wide range of applications in 
biomedical and other industrial areas(Dash et al., 2011). 
Synthetic polymers or man-made polymers as polyethylene, polystyrene, 
polytetrafluoroethylene, synthetic rubber, nylon, polyvinyl chloride, bakelite, teflon, orion, 
etc. The synthetic polymers can be further classified as these made up of monomers and 
comonomer units. The main limitation of these carriers is the presence of toxic residues 
such as unreacted free monomer, stabilizers, crosslinking agents, residues from initiators 
surfactants and processing aids, whose elimination requires time-consuming and inefficient 
procedures (Czech and Wesolowska, 2007).  In addition, the anionic nature of the 
monomers may result in a cross-reaction between drug molecules and the acrylic monomer.  
These drawbacks led to the development of methods involving the use of well-
characterized preformed polymers(Fried, 2014). 
More polymers classification can be based on particular considerations (Figure 
1.14, (Fried, 2014) as  structure, molecular forces and mode of polymerization. Additional 
reviews of polymers classification are been published by Vollmert et al., Stevens, and Fried 
(Vollmert and Immergut, 1973, Stevens, 1990, Fried, 2014). 
Polymers classification based on their structures include; linear, branched cross-
linked and network polymers. Figure 1.15(Anadão, 2012)shows schemes of these types of 
polymers. Linear polymer is consisting of a single continuous chain of repeated units. 
Branched chain is a polymer with side chains of repeated units connecting into the main 
chain of repeated units. Cross-linked polymer includes interconnection between chains, 
while network polymer is a cross linked polymer that includes numerous interconnections 
between chains.  
 
 
 
Figure 1.15.  Schematic classification of polymer based on structure(Anadão, 2012) 
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Additionally, polymer can be classified based on molecular forces include; 
elastomer (rubber), fibers, thermoplastics and thermosetting polymers(Anadão, 2012).  
In drug delivery systems, biodegradation plays a major role, so, polymers are 
further classified into two subgroups as biodegradable and non-biodegradable. 
Biodegradable polymers are defined as polymers, which degrade in vitro and in vivo either 
into products that are normal metabolites of the body or into products that can be 
eliminated from the body with or without further metabolic transformation. The 
degradation products should be nontoxic, and the rate of degradation and mechanical 
properties of the material should match the proposed claim. Non-biodegradable 
hydrophobic polymers initially used for drug delivery applications are cellulose derivatives, 
acrylic polymers, silicones and others (Polyvinyl pyrrolidone, ethyl vinyl acetate, 
poloxamers, poloxamines) (Pillai and Panchagnula, 2001).  Degradable polymers do not 
need surgical elimination and hence are favored to non-biodegradable polymers in several 
uses (Bala et al., 2004). Thus, both natural and synthetic biodegradable polymers have been 
extensively investigated for drug delivery applications. 
Natural biodegradable polymers, biopolymers, are biocompatible but some may 
suffer from antigenicity, unstable material supply and batch-to-batch variation(Pillai and 
Panchagnula, 2001). The natural polymers which are commonly used in drug delivery 
systems include polysaccharides (starch, cellulose, chitin, chitosan, alginic acid), cellulose 
esters, as cellulose acetate; modified polysaccharides, and proteins (gelatin, elastin, 
albumin, fibrin and soy protein) (Roy et al., 2009). 
While, synthetic biodegradable polymers are easy to modify and control their 
degradation with high reproducibility. Semi-synthetic biodegradable polymers; the 
fermentation of sugars produces different monomers. Polylactic acid (PLA) is synthesized 
from lactic acid produced via starch fermentation from lactic bacteria. Carbohydrate 
polymers such as xanthan, curdlan, pullulan and hyaluronic acid, produced by fermenting a 
sugar feedstock with bacteria or fungi(Vilar et al., 2012). 
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The most widely used biodegradable polymers are synthetic polymer. They include; 
polyesters, polyamides, polyurethanes and polyureas, poly (amide-enamines), 
polyanhydrides. The polyesters polymer include-  poly (glycolic acid) (PGA), poly(lactic 
acid)(PLA), poly (alkenedicarboxylate), poly (butylene succinate), poly(ethylene 
succinate), polycaprolactone (PCL), poly(butylene succinate) (PBS) and its copolymers. 
Polyesters are the utmost common and popular biodegradable polymers since their 
use as biodegradable sutures.  PGA, PLA and their correlated copolymer poly (D, L-lactide 
– co-glycolide) (PLGA). Their biodegradation is commonly achieved through hydrolysis of 
the ester bond resulting in nontoxic inactive degradation products.   Polyesters are the only 
group approved by Food and Drug administration (FDA) for clinical use as carriers for 
different drugs to prolong their release and improve their in vivo performance (Parveen and 
Sahoo, 2008). They are applied to transdermal delivery systems (Kandavilli et al., 2002), 
oral dosage forms, osmotic pumps(Wong et al., 1986), swellable hydrophilic polymer 
matrices(Korpman, 1984) and parenteral dosage forms(Packhaeuser et al., 2004).  
From the solubility perspective, pharmaceutical polymers can be categorized as 
water-soluble and water-insoluble (oil soluble or organic soluble). Water-soluble synthetic 
polymers are poly (acrylic acid), poly (ethylene oxide), poly (ethylene glycol, PEG) (Figure 
1.16), poly (vinyl pyrrolidone, PVP), poly (vinyl alcohol, PVA), hydroxypropyl methyl 
cellulose (HPMC). They have extensive applications in pharmaceutical industries to improve 
drug bioavailability (Sheen et al., 1995, Sugimoto et al., 1998, Zhang et al., 2014b). PEG is 
the most common used polymer for the drug delivery applications and is widely used as 
drug carrier for various types of drugs. It is known that low molecular weight PEGs are 
easily excreted in humans. 
 
Figure 1.16. Molecular structures of PEG 4000 (left) and  PVP (right)  (Chen et al., 2012) 
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The most used polyesters are the water insoluble biodegradable polymers including; 
PLA, PGA and PLGA. Table 1.2 shows examples of different drug delivery systems in the 
market for drugs utilizing these polymers for various diseases.  Anticancer drugs such as 
cisplatin, doxorubicin and 5-Fluorouracil have been encapsulated using a biodegradable 
polymer such as PLGA. Drugs release profiles and degradation behaviors of these NPs 
have favorable drug release profiles with a short initial burst release, less toxic effect and 
long release time (Ike et al., 1991, Huo et al., 2005, Kumari et al., 2010, Wohlfart et al., 
2011). Additionally, numerous studies have focused on polymer carriers (PLGA) that 
encapsulate peptide hormones and various antibiotics (Sinha and Khosla, 1998, Jain, 2000, 
Gavini et al., 2004, Kumari et al., 2010). The chemical structures of PLA, PGA and PLGA 
are shown in Figure 1.17(Huh et al., 2003).    
 
Figure 1.17. Chemical structure structures of PLA, PGA and PLGA (Huh et al., 2003) 
 
Table 1.1. Commonly used polymers for drug delivery applications 
Polymer Name 
Polymer 
Abbreviation 
Drug Application or Use 
Poly(lactide) 
PLA 
Haloperidol antipsychotic 
Dexamethasone Rheumatoid arthritis 
Poly(lactide-co-glycolide) PLGA 
Taxol Anticancer 
Paclitaxel Anticancer 
Poly(ɛ-caprolactone) PCL 
Tamoxifen Anticancer 
Clonazepam antipsychotic 
Gelatin  Paclitaxel Anticancer 
Chitosan  Cyclosporin A immunosuppressant 
*(Kumari et al., 2010) 
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Various studies have been focused on PLGA as a drug carrier due to its long history 
in medicine as the material for biodegradable surgical sutures (Gilding and Reed, 1979, Oh, 
2011).  It is emerged as the most promising material for drug delivery nanocarriers 
fabrication.  
PLGA copolymers undergoes degradation in aqueous environment (hydrolytic or 
biodegradation)in vitro and in vivo through cleavage of backbone ester linkage. The 
degradation behavior of polymer is also dependent on hydrophobicity of the polymer; the 
more hydrophobic the polymer is the more slowly its degradation. The hydrophobicity of 
the polymer is affected by the ratio of crystalline to amorphous sections, which in turn is 
determined by copolymer configuration and monomer stereochemistry (Mittal et al., 2007). 
Lactic acid is more hydrophobic than glycolic acid.  It is known that PLGA biodegrades to 
form lactic acid and glycolic acid as shown in Figure 1.18(Kumari et al., 2010).  Since 
these two monomers are endogenous and definitely metabolized by the body via the Krebs 
cycle, a negligible systemic toxicity is linked with the usage of PLGA in drug delivery or 
biomaterials applications (Kumari et al., 2010). Lactic acid enters tricyclic acid cycle 
(TCA) and subsequently metabolized to CO2 and H2O and eliminated from the body. 
Glycolic acid is excreted unchanged in the urine or it enters TCA cycle and is eliminated as 
CO2 and H2O. US FDA and European Medicine Agency (EMA) have approved the use of 
PLGA in various drug delivery systems in humans (Administration, 2007).  
 
Figure 1.18.  Hydrolysis of PLGA NPs(Kumari et al., 2010) 
The size of NPs make them easily target for capture by macrophages of liver and 
spleen “reticuloendothelial system (RES)” leading to shorter circulation half-life(Bala et al., 
2004) and constrain their reaching of other organs in the body. Hydrophilic coating of the 
surface of NPs with PEG could modify their biodistribution and uptake with providing 
protection against macrophage and therefore, prolong their circulation time.  
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Gref et al., were the first to describe the effect of PEG on the pharmacokinetics of 
PLGA microparticles externally coated with PEG.  The authors demonstrated that a radical 
increase in half-life of micelles has occurred when these were covered by PEG polymer.  
Only 30% of these micelles were captured by liver after 2 h of injection (Gref et al., 1994). 
Since that, PLGA–PEG were extensively investigated for various applications like 
implantable materials (Yu and Ding, 2008); pharmaceutical products(Kamaly et al., 2012), 
drug delivery systems (Cheng et al., 2007), and the market are expected to continue to grow 
further for more application of  PLGA – PEG (Kamaly et al., 2012). 
PLGA-PEG copolymer shows quite different properties when compared to each 
constituting polymers so it is a new and unique biomaterial. It possess both the 
biodegradability and biocompatibility of PLGA polymer and the stealth behavior of PEG 
but more than this PLGA-PEG can form micelles better than the single PLGA or other type 
of PLGA–PEG copolymers because of its well distinct lipophilic portion (PLGA) and its 
hydrophilic one (PEG) that make the PLGA-PEG an amphiphilic polymer. These two parts 
during micelles formation self-assemble generating a system in which the hydrophobic 
PLGA remains inside the micelles and the hydrophilic PEG goes outside creating a 
stabilizing shell. In this way, it is possible to easy entrap of lipophilic molecules like drugs 
or smaller nanostructures in the inner core constituting of PLGA chains.  Furthermore, it is 
also possible a formation of residual functional groups in the outer shell by previous 
functionalization of the PEG chains that can be used for conjugation of active molecules 
(proteins, peptides, monoclonal antibodies) for targeting desired tissues.  Various functional 
groups can be useful for this and PEG chains of various lengths already functionalized with 
a wide variety of reactive groups such as amino, carboxylic acid, methoxy, maleimido, etc., 
are commercially available (Locatelli and Franchini, 2012). 
 
1.2.2. Amphiphilic Block Copolymers 
Amphiphilic block co-polymers (ABCs) have been in use as pharmaceutical excipients 
in different forms for a long time.  Their application is experiencing a rapid growth in 
modern pharmaceutical sciences (Adams et al., 2003, Letchford and Burt, 2007, Zhang et 
al., 2014a). 
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ABCs consisting of two parts a hydrophobic polyester part and a hydrophilic PEG part 
(Figure 1.19 (Zhang et al., 2014a)).  They are considered as synthetic biodegradable and 
biocompatible with several block assemblies and configurations. These ABCs are 
biocompatible, FDA-approved for clinical use, and biodegradable by enzyme and 
hydrolysis under physiological conditions (Zhang et al., 2014a). Nowadays, ABCs are 
currently available commercially as Resomer

manufactured by Boehringer Ingelheim. 
 
Figure 1.19. The chemical structure of some amphiphilic block copolymer(Zhang et al., 
2014a) 
 
ABC polymer has  a unique self-assembly feature (Figure1.20) and can form various 
kinds of NPs such as polymer micelles, polymersomes and hydrogels (Zhang et al., 2014a). 
ABCs assemble into nano-scaled core–shell structures, micelles, which are of  considerable 
interest for delivering drugs with poor water solubility (Shao et al., 2010a).In aqueous 
media, ABCs solubility is very different.  Their hydrophilic and hydrophobic parts, 
spontaneously form polymeric micelles in which a hydrophobic inner core is surrounded by 
a distinct core-shell structure(Zhang et al., 2014a). 
 
Figure 1.20. Typical structures of amphiphilic polymers and their self-assemblies: polymeric 
micelle, polymersome, and hydrogel (Zhang et al., 2014a) 
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The rapid development of ABC applications in the pharmaceutical sciences is 
mainly due to the chemical flexibility of their assembly, which provides an opportunity for 
the design of multipurpose drug carriers. Diverse types of copolymers based on PLGA and 
PEG were created, such as di-, tri, or multi-block copolymers. Also linear, branched, and 
mixed copolymers, with or without functional ending groups, were investigated, but most 
of all the di-block copolymer (PLGA-PEG) has attracted particular interest due to special 
properties, such as amphiphilicity and easier synthesis, in comparison to the others (Huh et 
al., 2003). 
Block copolymers have been extensively developed to date and can be classified 
according to their block structure as AB diblock, ABA, or BAB triblock, branched block, 
and star-shaped block copolymers, in which A is a hydrophobic block made up of 
biodegradable polyesters and B is a hydrophilic PEG block, as shown in Figure1.21 (Loh 
and Li, 2007). 
 
Figure 1.21. Schematic presentation of block copolymer structure; (A)-A-B diblock, (B) A-
B-A, (C) B-A-B, (D) alternating multiblock, (E) muti-armed structure, and (F) star-shaped 
block(Loh and Li, 2007) 
 
ABCs have been in use as pharmaceutical excipients in different forms for a long 
time and their application is experiencing rapid growth in pharmaceutics and in 
nanomedicine.  
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Several previous studies have shown that loading AmB to different copolymer were 
administered parenterally led to decreased hemolysis and/or nephrotoxicity while retaining 
the antifungal activity of AmB. Development of AmB loaded with copolymers such as 
poly(ethylene oxide)-block-poly(N-hexyl stearate l-aspartame), poly(ethylene oxide)-block-
poly(-benzyl-l-aspartate), PEG-p (caprolactone-co- trimethylenecarbonate), poly(2-ethyl-2-
oxazoline)-block-poly(aspartic acid),  (PEG)3-PLA, poly(ethylene oxide)-poly(_-
caprolactone) and poly(isoprene-b-ethylene oxide)  (Vandermeulen et al., 2006, Wang et 
al., 2009, Jain and Kumar, 2010, Falamarzian and Lavasanifar, 2010b, Pippa et al., 2014). 
Additionally for the oral delivery of drugs, several published papers showed there 
were increased in bioavailability when loading different drugs with either di, or tri-block 
copolymer, such as insulin loaded to PLGA-PEG di- and triblock copolymer (Wang et al., 
2009) curcumin (Pippa et al., 2014) and oral vaccines (Garinot et al., 2007). 
1.3. Polymeric Nanoparticles Preparation Methods 
For the preparation of PNPs drug delivery systems, there are different methods 
employed: solvent evaporation, nanoprecipitation, single emulsion-solvent evaporation,  
double emulsification, salting out, emulsification solvent-diffusion method and spray 
drying technology (Asher and Schwartzman, 1977, Nagavarma et al., 2012, Jawahar and 
Meyyanathan, 2015).  Figure 1.22shows the common technique of the different methods for 
the preparation of these NPs(Bennet and Kim, 2014). Nevertheless, other methods have 
been used for NPs formulations. There are reviews discussing in details these 
methodologies concerning polymers’ selection and the mechanistic fundamentals of each 
methods (Singh and Muthu, 2007, Mora-Huertas et al., 2010). 
The selection of the method of preparation is affected by the physicochemical 
properties of the drugs, mainly its solubility and the therapeutic use of PNPs also the route 
of administration and drug release profile. Method of preparation also can be affected by 
drug stability, stirring speed, solvent used, drug encapsulation efficiency, method 
reproducibility, washing step and time consumption(S en et al., 1998). 
The nanoprecipitation method (solvent displacement) according to Fessi et al. (Fessi 
et al., 1988), consisted of two phases; organic and aqueous phases. Evaporation under 
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reduced pressure is essential to remove the organic solvents and then NPs are recovered by 
a suitable purification process such as centrifugation (Fessi et al., 1988, Barichello et al., 
1999, Singh and Muthu, 2007, Nagavarma et al., 2012, Konwar and Ahmed, 2013).  
Solvent evaporation method in which, the polymer is dissolved in organic solvent 
with or without drug and the resulting mixture is emulsified into a surfactant-containing 
aqueous solution by sonication. Evaporation of the organic solvent and recover the NPs by 
centrifugation or dialysis (Mora-Huertas et al., 2010, Nagavarma et al., 2012, Konwar and 
Ahmed, 2013). 
Single emulsion-solvent evaporation method is primarily used for entrapping 
lipophilic/hydrophilic drugs. In this method, the drug and polymer are first dissolved in a 
volatile organic solvent such as chloroform or dichloromethane. The drug-polymer solution 
is emulsified into an aqueous phase containing an emulsifier such as poly (vinyl alcohol) 
(PVA), gelatin, polysorbate 80, or polaxamer-188 to form an o/w emulsion. Subsequently, 
the formulation is subjected to organic solvent removal/ extraction to harden the 
nanoemulsion droplets into solid NPs (Bennet and Kim, 2014). Reduction of the NPs size is 
achieved by either sonication or high-speed homogenization. Evaporation of organic 
solvent at higher temperature and under pressure with continuous stirring for several hours. 
The time needed for solvent evaporation has significant effects on the porosity of the NPs, 
and then affects the drug release (Arshady, 1991).  Poor drug loading and burst release 
effect of hydrophilic drugs are the most disadvantages of this method (Konwar and Ahmed, 
2013, Mora-Huertas et al., 2010, Nagavarma et al., 2012). 
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Figure 1.22. General methods of preparation of polymeric NPs (Bennet and Kim, 2014) 
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Double emulsion (water/oil/water “w/o/w”) solvent evaporation is the technique 
that commonly involves the formation of a primary water/oil (w/o) emulsion by sonication 
organic phase of the polymer, with/without the drug, and aqueous phase. A surfactant 
containing aqueous solution is then added to the primary emulsion with sonication to obtain 
the double emulsion (w/o/w). Evaporation for the organic solvent either at room 
temperature or under reduced pressure. Recovery of the NPs either by centrifugation or 
dialysis (Mora-Huertas et al., 2010, Nagavarma et al., 2012, Konwar and Ahmed, 2013). 
Salting out is composed of the addition of either highly electrolyte or a non–
electrolyte containing stabilizer to organic phase composed of polymer and the drug. After 
the preparation of the initial w/o emulsion, then phase inversion to o/w emulsion is 
achieved by adding sufficient amount of water.  This induces complete diffusion of organic 
solvent from the organic phase into the continuous external aqueous phase, followed by 
solvent removal and recovery of the NPs (Allémann et al., 1993, Vauthier and Bouchemal, 
2009). 
Emulsification solvent-diffusion method is technique that was developed by Dueler 
and coworker(Quintanar-Guerrero et al., 1996), which involved emulsification of drug-
polymer solution in partially water-miscible solvent (such as ethyl acetate, benzyl alcohol, 
propylene carbonate) pre-saturated with water, in an aqueous solution containing stabilizer 
under vigorous stirring to form o/w emulsion. The process is followed by reduction in 
droplet-size using a high-speed homogenizer/sonicator (Quintanar-Guerrero et al., 1996). 
Subsequently, water is added to the o/w emulsion system under constant stirring causing 
outward diffusion of the organic solvent from the internal phase, which leads to the 
nanoprecipitation of the polymer. Finally, the solvent can be eliminated by evaporation or 
vacuum distillation(Mora-Huertas et al., 2010, Nagavarma et al., 2012, Konwar and 
Ahmed, 2013). One of the main disadvantages of this method is low entrapment efficiency 
for hydrophilic drugs, addition of specific lipids to the aqueous phase could improve this 
limitation (Bala et al., 2004). 
Spray drying offers a relatively rapid and convenient production of NPs that is easy 
to scale-up, involves mild processing conditions and has relatively less dependence on the 
solubility characteristics of the drug and the polymer. In spray drying technique, a solution 
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of a drug in an organic solvent containing the polymer is sprayed from the sonicating 
nozzle of a spray dryer and subsequently dried to yield NPs (Mora-Huertas et al., 2010, 
Nagavarma et al., 2012).  
Dialysis, is very simple and effective method for preparing of PNs  with small, 
narrow size distribution(Nagavarma et al., 2012). Organic solvent contain polymer is 
subjected to dialysis tube. Dialysis is performed against a non-solvent miscible with the 
former miscible. The displacement of the solvent inside the membrane is followed by the 
progressive aggregation of polymer due to a loss of solubility and the formation of 
homogeneous suspensions of NPs. 
One of the fast and reproducible methods for NPs preparation is the emulsion 
polymerization. It is broadly classified to an organic or aqueous continuous microemulsion. 
Dispersion of monomer into an emulsion or inverse microemulsion, or into nonsolvent led 
to formation of continuous organic phase (Nagavarma et al., 2012). Disadvantages of this 
method it is the existence of toxic organic solvents, surfactants, monomers and initiator, 
during preparation process which, then should be removed from the designed NPs, 
additionally usage of non-biodegradable polymer had limited the preparation of NPs by this 
method.  
Purification is the last step required for all previous mentioned NPs preparation 
techniques. One of the following method such as ultracentrifugation, ultrafiltration, gas 
chromatography, dialysis, spray drying, lyophilization or a combination of these methods 
could be used at the purification step. 
Emulsion diffusion evaporation or nanoprecipitation is the most suitable method for 
hydrophobic drugs’ preparation while double emulsion method is appropriate for 
hydrophilic drugs, such as proteins and peptides(Quintanar-Guerrero et al., 1996, 
Quintanar-Guerrero et al., 1998b, Mora-Huertas et al., 2010, Nagavarma et al., 2012). 
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1.3.1. Emulsification-Diffusion Method 
The emulsification-diffusion method (ESD) has been used successfully to prepare 
biodegradable NPs in an effective and reproducible way especially for hydrophobic drugs. 
However, double emulsion method is suited for hydrophilic drugs, such as proteins and 
peptides (Quintanar-Guerrero et al., 1998a, Quintanar-Guerrero et al., 1998b, Mora-Huertas 
et al., 2010, Nagavarma et al., 2012).  The polymer, the drug and an organic solvent which 
are incompletely miscible with water and which should be water-saturated.  This organic 
medium acts as solvent for the different components of the organic phase. The aqueous 
phase encompasses the aqueous dispersion of a stabilizing agent that is prepared using 
solvent-saturated water while the dilution phase is usually water as seen in Table 1.3 and 
Figure 1.23(Mora-Huertas et al., 2010). 
 
Table 1.3.  Suggested composition for preparation of nanocapsules by emulsion–diffusion  
method* 
Material  Suggested composition 
Active substance  10–50mg 
Polymer 1.0–2.0% of inner phase solvent 
Oil 2.5–5.0% of inner phase solvent 
Inner phase solvent 10 ml 
Stabilizer agent 2.0–5.0% of external phase solvent 
External phase solvent 40 ml 
Dilution phase 200 ml 
*(Mora-Huertas et al., 2010) 
 
 
 
 
 
 
Figure 1.23.  Set-up used for preparation of nanocapsules by the emulsion–diffusion 
method (Mora-Huertas et al., 2010) 
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This method is characterized by scale up simplicity, reproducibility, high 
encapsulation efficiencies (>70%), no need for homogenization, and narrow particle size 
distribution (Nagavarma et al., 2012). Time consuming is one of the disadvantages of this 
method since elimination of large amount of water from the suspension takes long time and 
some leakage of water-soluble drug into the saturated-aqueous external phase during 
emulsification may take place(Reis et al., 2006, Mohanraj and Chen, 2007). It is efficient 
method for encapsulating lipophilic drugs (Quintanar-Guerrero et al., 1998a).  Various 
drug-loaded NPs were made by the ESD method, including mesotetra (hydroxyphenyl) 
porphyrin-loaded PLGA (p-THPP) NPs(Vargas et al., 2004), doxorubicin-loaded PLGA 
NPs(Yoo et al., 1999), plasmid DNA-loaded PLA-NPs(Perez et al., 2001), coumarin-
loaded PLA NPs(Lu et al., 2005), indocyanine and with other drugs (Nagavarma et al., 
2012). 
Depending on their composition, physicochemical properties and biopharmaceutical 
behavior, NPs may be designed and applied to several routes of administration, such as 
oral, parenteral, topical, nasal, among others (Heurtault et al., 2003). Although each route 
of administration has its own advantages, the oral route is widely known as the most 
convenient one for the treatment of chronic conditions. However, the delivery of 50% of 
drugs by this route is limited due to the great lipophilicity of the drugs themselves and 
approximately 40% of new drug candidates present low solubility in water leading to poor 
bioavailability and high intra- and inter-subject variability and deficiency of dose 
proportionality (Gursoy and Benita, 2004). 
Drug release from the NPs is a factor of the cross‑linking, morphology, size, 
density of the particulate system and the physiochemical properties of the drug, as well as 
existence of additives(Jawahar and Meyyanathan, 2015).  In vitro drug release is also 
determined by pH, polarity and occurrence of enzymes in the dissolution medium. 
Figure1.24 shows the three common physicochemical mechanisms at which drug is 
released from the polymer (Jawahar and Meyyanathan, 2015). The first mechanism 
involves hydration then swelling of the polymer, followed by release via diffusion of drug 
from the entrapped inner core. The second mechanism is through enzymatic reaction 
causing degradation of the polymer and the release of drug at the intended site. The third 
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mechanism is separation of the drug from the polymer and its release from swelled NPs.  In 
the most cases, drug release tails more than one kind of mechanism (Jawahar and 
Meyyanathan, 2015).  When the drug loaded to NPs subjected to dissolution medium, the 
drug instantaneously dissolves and release from the surface (a burst effect). Away from the 
surface, the drug release is through diffusion, by swelling of the matrix first, followed by 
transformation of the glassy polymer into a rubbery matrix and finally by diffusion of the 
drug from the rubbery matrix. 
 
Figure 1.24. Drug release mechanisms in nanoparticles (Jawahar and Meyyanathan, 2015) 
1.4. Absorption Enhancers 
The selection of proper absorption enhancers, for a successful polymeric NPs 
formulation with high drug loading, is another challenge in NPs formulation improvement 
approach. For oral dosage forms delivery, absorption enhancers can be a viable formulation 
option in improving drug permeability, solubility and hence bioavailability(Khadka et al., 
2014). 
Recently, extensive researches have been published regarding the improvement of 
poorly absorbed drugs administration via oral, rectal or nasal route with the utilization of 
absorption enhancers. Different classes of compounds have been investigated as absorption 
enhancers such as bile salts, cyclodextrins, fatty acids, lipids, polyvinyl pyrolidone (PVP), 
pluronic and vitamin-E (TPGS)(Aungst, 2012).These enhancers can be added to the 
formulations either during the preparation or just before administrations (Aungst, 2012). 
 
 
31 
 
The mechanisms of absorption enhancement could involve preventing degradation/ 
metabolism as for peptides and protein drug molecules.  This could be achieved by 
encapsulation of the drug to protect it, by including a protease-inhibiting excipient in the 
formulation, or by controlling the pH of the environment where the drug is 
released(Aungst, 2012). Addition of an excipient that modulates membrane permeability 
will increase permeability of compounds with poor membrane permeability. Any alteration 
in the tight junction (distension and constriction) available in the gastrointestinal and nasal 
epithelial membranes will alter the movement of water and low-molecular weight 
molecules. Another alternative mechanism of permeation enhancement involves 
stimulating the transcellular permeation of drugs.  This requires disturbing the structure of 
cellular membrane e.g. surfactants. Another mechanism that has been suggested for 
improving absorption is the formation of a membrane permeable complex, with one type of 
complex being an ion pair. Solvent drag when there is coupling of solute and solvent flow 
through transmembrane with hydrostatic pressure or osmotic pressure gradients. The 
studies indicate that either the solute or solvent drag can influence the "passive transport" of 
solutes across the gastrointestinal tract(Aungst, 2012). 
Bile salts are considered as emulsifiers of lipid compound.  These biological 
surfactants involved in the solubilization and delivery of lipophilic drugs from the 
GI(Faustino et al., 2015).They accelerate lipolysis and transport of lipid products through 
the undisturbed water layer of the intestinal mucosa by micellar solubilization (Trotta et al., 
2003, Faustino et al., 2015). 
Shaikh coauthors (Shaikh et al., 2012) have investigated Cyclodextrins for their 
unique structures, of having  hydrophilic external surface and hydrophobic cavity. They 
pointed out that cyclodextrins are capable of forming inclusion complexes with various 
drugs. Therefore, the oral bioavailability of poorly water-soluble drugs was enhanced 
through cyclodextrins complexation.  They also specified that medium to long chain fatty 
acids such as capric, lauric and oleic acids (C10-C18) have been proven to increase the 
absorptivity of a series of hydrophilic and hydrophobic drugs by changing the cytoskeleton 
of the intestinal epithelial cells without noticeable cytotoxicity. 
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Pluronics® (non-ionic surfactants)are characterized by their negligible toxicity. It 
can be utilized as solubilizers and wetting agent. It is well documented that Pluronics® may 
increase the absorption of many drugs(Brüsewitz et al., 2007). 
PVP is the most frequently studied hydrophilic polymeric carrier as an absorption 
enhancer. It improves the dissolution of many drugs by improving their solubility due to its 
presence in the amorphous state (Kelvin’s law), increasing the surface area subjected to 
dissolution due to size reduction of NPs. PVP is also considered as wetting agent;  
decreasing the interfacial tension between the drug and the aqueous medium(Gurunath et 
al., 2014).  
D-α tocopheryl polyethylene glycol 1000 succinate (TPGS)is a water-soluble 
derivative of natural vitamin E, and it contains both a hydrophilic moiety and a lipophilic 
moiety, and therefore it is similar to conventional surfactants. TPGS is also a p-
glycoprotein efflux inhibitor (Collnot et al., 2006).Accordingly, it has been effectively 
applied to advance NPs properties for controlled delivery. Mu and Feng (Mu and Feng, 
2002)have applied TPGS as a surfactant stabilizer for the first time to fabricate paclitaxel-
loaded PLGA nanospheres using solvent evaporation/extraction. They indicated that TPGS 
could be an ideal and effective emulsifier in NPs formulation. McCall and 
coworker(McCall and Sirianni, 2013)have applied TPGS as an emulsifier for the 
preparation of meloxicam loaded PLGA NPs. 
Glycyrrhizic acid (GA) is available as a natural product. It is used in peptic ulcer 
treatment and as an expectorant (Tanaka et al., 1992, Motlekar et al., 2006, Anand et al., 
2010).  GA can be act as surfactant which is similar to bile acids (Motlekar et al., 2006). 
GA has been used to enhance the oral absorption of many drugs such as heparin (Motlekar 
et al., 2006). AmB rectal administration was improved significantly after GA addition to its 
formulation (Tanaka et al., 1992). 
These listed above absorption enhancers are also considered as emulsifying agents 
or emulsifiers for formulations that could alter the characteristics of the resulting NPs. 
During the preparation process emulsifiers also stabilize the produced emulsion, decrease 
particle aggregation and affect the particle size and distribution, morphological properties, 
encapsulation efficiency and drug release characteristics of NPs(Coombes et al., 1998, Mu 
and Feng, 2002, Mitra and Lin, 2003). PVP is the most commonly used emulsifier during 
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the formulation of poly PLGA NPs because this emulsifier generates particles that are 
relatively uniform, small and easy to redisperse in aqueous medium(Sahoo et al., 2002). 
Oral dosing is generally considered to be the most patient approachable and 
convenient route of drug administration. However, many pharmacologically active 
compounds cannot be administered orally because of inadequate oral bioavailability, and 
this may limit the usefulness of these compounds especially if the drug is subjected to 
intensive first pass effect. Poor oral bioavailability can be caused by poor aqueous 
solubility, degradation within the gastrointestinal contents, poor membrane permeability, or 
significant presystemic metabolism(Aungst, 2012). 
In addition to absorption enhancers; cosolvency, pH adjustment and surfactant 
addition are the most commonly encountered pharmaceutical approaches for solubilizing 
drug with low aqueous solubility. Cosolvency (solvent blending) are mixtures of miscible 
solvents often added together which can be dramatically change the solubility of poorly 
aqueous soluble drugs, through reducing the interfacial tension between the aqueous 
solution and hydrophobic solute (Nayak and Panigrahi, 2012). The most commonly used 
cosolvents in pharmaceutical industry are ethanol, propylene glycol, glycerin, acetone,  
polyethylene glycols and dichloromethane(Jouyban, 2008). The combination of acetone 
dichloromethane as cosolvency has been used extensively to solubilize poorly soluble drugs 
(Aragón et al., 2010, Paudel and Van den Mooter, 2012). 
1.5. Amphotericin B 
Amphotericin B (AmB) is a polyene antibiotic, which was first isolated in 1959 
from fermenter cultures of Streptomyces nodosus (Dutcher, 1968).  The chemical structure 
of AmB (C47H73NO17) is depicted in Figure 1.25(Lemke et al., 2005), AmB is amphiphilic. 
The rectangular ring structure is bipolar in nature, at one side is a hydrophobic trans 
conjugated heptane from C1 to C15 and at the other side is a highly hydroxylated 
hydrophilic side (C20 to C33). The structure also contains a carboxyl group (C60) and a 
primary amine (C48) and these have a pKa of 5.5 and 10, respectively, making AmB 
zwitter ionic at physiological pH. AmB is characterized by a large38-membered lactone 
ring linked covalent to an amino sugar moiety. This ring itself is made up of two chains. 
 
 
34 
 
The chain that contains the polyene chromophore is completely hydrophobic, whereas the 
chain that contains the hydroxyl group has a hydrophilic face and a hydrophobic phase, 
rendering it amphiphilic. The asymmetrical distribution of hydrophobic and hydrophilic 
groups for AmB confers an exceptionally low solubility for the drug in water and in many 
organic solvents as shown in Table 1.4(Lemke et al., 2005), which is one of the key factors 
in limiting its oral bioavailability and therapeutic applications. AmB is unstable at acidic 
pH of stomach. The high molecular weight (924.08 Da) and large cyclic structure of AmB 
account for the low intestinal permeability of the molecule (Asher and Schwartzman, 1977, 
Milhaud et al., 2002, Lemke et al., 2005, Jain and Kumar, 2010). AmB becomes extremely 
critical molecule since it has high molecular weight and tendency to form toxic aggregates. 
There is evidence that in water AmB forms a mixture of water-soluble monomers and 
oligomers along with insoluble aggregates(Patel et al., 2013). 
 
Figure 1.25.Chemical structure of Amphotericin (Lemke et al., 2005) 
Table 1.4. Solubility of AmB in different solvents 
Solvent Solubility (mg/l) 
Water < 1 (at pH 6-7) 
Methanol 2,000 
Ethanol 500 
Chloroform 100 
Petrol ether 10 
Dimethyl formamide 2,0 
Propylene glycol 1,0 
Cyclohexane 20 
 *(Lemke et al., 2005). 
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AmB is characterized by insolubility in water, but its water-solubility increases at a 
pH below 2 or above 11, where the drug being unstable and less antifungal activity as 
reported by Lemke et al., (Lemke et al., 2005). Fungizone

 consist of AmB and sodium 
deoxycholate (solubilizing agent)(Lemke et al., 2005). In water, these two molecules (drug 
plus the additives) form micellar colloidal soluble complexes. 
AmB is generally used for treating systemic fungal infections caused by species of 
Candida, Aspergillus, Fusarium, Scedosporium, and Trichosporon. Excellent reviews on 
fungal infections and their therapy have been written by several authors (Ellis, 2002, 
Herbrecht et al., 2003, Idemyor, 2003).  AmB kills the fungal cells via primarily binding to 
ergosterol, which is the main sterol in the fungal cell membrane. These results in the 
destruction of osmotic integrity of the membrane resulting in the leakage of intracellular 
potassium, magnesium, sugars and metabolites thus inducing cell death. AmB has the 
widest antifungal spectrum and is used in clinical practice for almost all systemic fungal 
diseases. Most species of fungi that cause human infections are susceptible to AmB (Lemke 
et al., 2005). 
The Biopharmaceutics classification system (BCS) is a systematic framework for 
categorizing a drug based on its solubility and intestinal permeability (Figure 1.26, 
(Amidon et al., 1995).  Increasing the solubility of poorly soluble drugs can be achieved by 
modifying the shape, size, and functional groups present on the molecule, as well as 
increasing the permeability through the addition of lipid components into the drug. Loading 
drug(s) to NPs can altered the solubility and/or permeability of the entrapped drug (Paiv et 
al., 2013). This technique has been successfully used for drugs that belong to class II (low 
solubility-high permeability)such as Nifidipine (Kim et al., 1997), class III (high solubility-
low permeability) such as Acyclovir (Giannavola et al., 2003), or class IV (low solubility-
low permeability) such as Paclitaxel (Danhier et al., 2009).  Drug loaded to NPs has 
significantly increased bioavailability compared to conventional form of the drug. 
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Figure1.26. The Biopharmaceutics Classification System (Amidon et al., 1995) 
AmB belongs to class IV BCS and it is commercially available as Fungizone® 
(Bristol– Myers–Squibb), which is micellar suspension of 50 mg of AmB and 41 mg of 
sodium deoxycholate available as ivsince1960.   Despite great effectiveness against broad 
spectrum of fungi strains, the use of Fungizone® is restricted due to severe side effects 
associated with its administration (Allémann et al., 1993, Walsh et al., 1995). Mainly, the 
AmB deoxycholate-related toxicity may be classified as acute or chronic. Acute or 
infusion-related toxicity is characterized by fever, chills, rigors, malaise, generalized aches, 
nausea, vomiting, and headache. Hypertension, hypotension, hypothermia, and bradycardia 
are other reported infusion-related toxic effects of administration of AmB deoxycholate 
(Chunn et al., 1977, Janknegt et al., 1996, Deray, 2002). Furthermore, thrombophlebitis 
may occur at the site of infusion due to slow infusion, central venous administration, and 
use of small-bore needles. Ventricular arrhythmias have been associated with 
administration of AmB deoxycholate in the context of hypokalemia, rapid infusion, anuria, 
and renal failure. A direct cardio-toxic effect has also been postulated. Nephrotoxicity is the 
most serious chronic adverse effect of AmB deoxycholate because the serum creatinine 
concentration increases in more than 80% of patients receiving this drug (Sabra and 
Branch, 1990). AmB-associated nephrotoxicity can be classified as glomerular or tubular. 
The clinical and laboratory manifestations of glomerular toxicity include a decrease in 
glomerular filtration rate and renal blood flow.  While tubular toxicity is manifest as the 
presence of urinary casts, hypokalemia, hypomagnesemia, renal tubular acidosis, and 
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nephrocalcinosis (Burgess and Birchall, 1972). Although the exact mechanisms involved in 
AmB-induced azotemia have not been clearly described, investigators have established that 
amphotericin B can cause changes in tubular cell permeability to ions both in vivo and in 
vitro(Walsh et al., 1995). The azotemia may be due to tubuloglomerular feedback 
mechanism where increased delivery and reabsorption of chloride ions in the distal tubule 
initiate a decrease in the glomerular filtration rate of that nephron (Branch, 1988). 
Tubuloglomerular feedback is amplified by sodium deficiency. Other possible mechanisms 
for AmB-related nephrotoxicity include renal arteriolar spasm, calcium depletion during 
periods of ischemia, and direct tubular or renal cellular toxicity (Burgess and Birchall, 
1972). Direct vasoconstriction caused in afferent arteriole by AmB can be another cause of 
nephrotoxicity (Sawaya et al., 1991). The actual mechanism is likely a combination of the 
above events. 
 There have been tremendous attempts to circumvent the poor water solubility and 
toxic side effects of AmB by synthesizing new derivatives or preparing novel carriers for 
AmB. This had led to the development of three lipid-based formulations in 1990  
(Abelcet®, AmBisome® and Amphocil®) as shown in Table 1.5(Robinson and Nahata, 
1999). They offer shorter course of therapy and are claimed to be more effective with lower 
toxicity compared to Fungizone® (Bekersky et al., 1999).   
Table 1.5.Lipid formulations of amphotericin B general characteristics and monthly cost comparison 
Trade name FDA 
approval 
AmB 
:Lipid 
ratio 
Composition Dosage mg Cost** 
US$ 
Fungizone
 
Squibb 
Pharmaceutical 
1958 - Colloidal dispersion 
of AmB and sodium 
deoxycholate 
50 7.5 
Abelcet

Elan 
Pharmaceuticals 
1995 1:3 
 
AmB with 
phosphatidyl choline 
"ribbon structure " 
100 241 
Amphocil
 
Sequus 
Pharmaceuticals 
1996 1:1 Colloidal dispersion 
AmB with cholesteryl 
sulfate 
50 and 100 90-180 
AmBisome
 
Nextar 
Pharmaceuticals 
1997 1:9 AmB phospholipid 
liposome 
50  189 
 **Prices represent cost per unit specified, are representative of average wholesale price. 
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Severe adverse reactions, such as anaphylaxis, cardiactoxicity, and respiratory 
failure, following administration of all three lipid formulations of AmB have been reported. 
In most reported cases, switching to a different lipid formulation of AmB was well 
tolerated (Burgess and Birchall, 1972, Deray, 2002). Beside their adverse effects, they 
available only as expensive parenteral therapy and so, AmB-lipid formulations is failing to 
spread all the infected patients in many areas and death rate keeps rising.  
AmB-loaded-polymers have been studied extensively to enhance the solubility and 
bioavailability of the drug after iv administration. Several PEG conjugates of AmB have 
been designed and have demonstrated reduced toxicity in comparison to conventional AmB 
in vivo. The first PEG-AmB conjugate contained two molecules of AmB attached to PEG 
(Conover et al., 2003) and in this conjugate there was a reduction in toxicity in vivo. A 
second PEG-AmB conjugate with a pH sensitive imine linkage was then 
investigated(Sedlák et al., 2007). The conjugate was designed for site-directed drug release 
at pHs is 5.5, either in the intracellular compartments or at sites of localized fungal 
infection. This conjugate was 5 times less toxic in vivo than AmB delivered as Fungizone®, 
with a maximum tolerated dose of 45 mg/kg, whilst maintaining in vivo antifungal 
effectiveness against Candida albicans. 
The oral route of administration remains the most convenient and widely used 
means of systemic drug delivery. Physicochemical properties of the drug molecule and 
gastro-intestinal physiology play vital roles in the design of an oral drug delivery system. 
Low aqueous solubility and permeability are the prime reasons accountable for the poor 
oral bioavailability of AmB.  Therefore, its encapsulation in a suitable drug carrier, which 
is capable of shielding unfavorable biopharmaceutical properties of the drug and enhances 
the intestinal uptake, presents a possible solution. The formulation must also improve the 
stability of the drug in the harsh gastric pH as well as protect it from enzymatic degradation 
in the gastro-intestinal tract. Effective release of AmB from the carriers in its active 
monomeric form after entering into the body is also the pre-requisite to achieve desired 
therapeutic effect. All these factors must be balanced to develop a successful oral 
formulation of AmB. 
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1.6. Oral Amphotericin B Delivery Systems 
 The poor bioavailability of AmB can be contributed to its current parenteral 
administration for the treatment of systemic fungal infection or visceral leishmaniasis.  
To date, there is no oral AmB formulations have been marketed due to is poor 
solubility and permeability. Therefore, developing an oral AmB formulation is a viable 
means of improving patient access to treatment worldwide. 
A massive number of literatures have been reported to improve the delivery of 
AmB; as seen in Table 1.6.  However, limited researchers have been published on its oral 
delivery.  
AmB is also unable to cross the mucosal barrier of the GI to blood stream.  The 
critical need for an oral drug delivery of AmB has steered several endeavors found in the 
literature about the development of AmB oral delivery systems to improve its antifungal 
activity and toxicity.  These include formulating AmB as nanosuspension (Kayser et al., 
2003), as poly(lactide-co-glycolide) nanoparticles (NPs) employing vitamin E-TPGS as a 
stabilizer (Italia et al., 2009, Italia et al., 2011), as lipid-based oral formulation using Peceol 
(Sachs-Barrable et al., 2008) or as liquid antisolvent precipitation NP(Zu et al., 2014).  
AmB was loaded to Peceol and PEG-phospholipids (iCo-009).These lipid-based AmB 
formulations were made as a self-emulsifying drug delivery system (SEDD) using 
proprietary mixture of mono- and diglycerides with phospholipids. This system was 
reported to improve the aqueous solubility of AmB, improve bioavailability and also 
exhibit significant anti-fungal activity upon oral and parenteral administration (Risovic et 
al., 2003, Amarji et al., 2007, Gershkovich et al., 2009, Wasan et al., 2009a, Sivak et al., 
2011). 
Furthermore, AmB was formulated with carbon nanotubes (Wu et al., 2005, 
Prajapati et al., 2011a, Prajapati et al., 2011b), or with gelatin coated lipid NP(Jain et al., 
2012). 
Different tactics were also applied such as chitosan–EDTA conjugate (Singh et al., 
2013), cubosomes lipid-based delivery (Yang et al., 2012, Yang et al., 2014), nano-
emulsions (Wasan et al., 2009a), polymeric nanoparticles (Italia et al., 2012) and solid lipid 
nanoparticles (Zhang et al., 2013).  
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Table 1.6.Formulation strategies (classes) of AmB* 
Class Microorganisms References 
Liposomes Leishmania spp (Davidson et al., 1996) 
(Oliva et al., 1995) 
(Yardley and Croft, 2000) 
 C. albicans (Carrillo-Munoz et al., 1999) 
Polymer particles   
Polylactide-co-
glycolide  
L. donovani  (Venier-Julienne and Benoit, 1996) 
 
Polymethylacrylate   (Sen et al., 1998) 
Polyethylenimindextran  (Tiyaboonchai et al., 2001) 
Nanosuspensions  Leishmania spp  (Kayser et al., 2003) 
 
Solid lipid nano- L. donovani  (Kayser et al., 2003) 
Cyclodextrins   (Just-Nübling, 1993) 
Emulsions  L. donovani  (Lamothe, 2001) 
Detergents  (O'Neil and Lapointe, 1997) 
Micellar systems  (Ramos et al., 1994) 
Cochleates  L. donovani  
 
(Santangelo et al., 2000) 
 C. albicans  (Santangelo et al., 2000) 
   *(Lemke et al., 2005) 
The latest formulations were AmB liposomes containing ceramides (Skiba-Lahiani 
et al., 2015) and AmB encapsulated with chitosan derivative (Serrano et al., 2015).  These 
oral drug deliveries were developed to enhance the solubility and gastrointestinal 
permeability of AmB, but none of them has been introduced to the market yetmarket 
(Heurtault et al., 2003, Wasan et al., 2009a, Thornton and Wasan, 2009, Ibrahim et al., 
2012, Yang et al., 2012).    
 
1.7. Objectives of the Study 
  Hypothesis; AmB currently available asiv solution for parenteral administration. 
Utilizing nanotechnology to load AmB to the commercially available biodegradable 
Amphiphilic Block Copolymer (PLGA-PEG; Resomer) will enhance the oral delivery of 
AmB in terms of encapsulation, release pattern, improve bioavailability, antifungal activity 
and reduce toxicity. The obtained novel oral AmB-NPs stealth could provide a long-
circulating drug reservoir of AmB from which the drug can be released into the vascular 
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compartment in continuous and controlled manner for optimum drug targeting and 
minimizing the toxic effects. This can provide an effective use of AmB while curtailing its 
toxicity. 
The aim of the present study is to formulate a novel oral dosage form containing AmB 
using PLGA-PEG copolymer to achieve the following benefits 
1. Formulate an oral dosage form to avoid painful administration parenteral of AmB. 
2. Enhance the permeability of the drug due to its loading into the polymer 
3. Improve the oral bioavailability of the drug. 
4. Decrease the nephrotoxic potential of the drug.  
5. Decrease the adverse side effects of the drug. 
6. Increase or no change of the therapeutic value of the drug. 
Therefore, the main objectives of this investigation can be highlighted as follows: 
1. To optimize the formulation composition of AmB-NPs prepared by emulsification 
diffusion method utilizing main particle size reduction and drug loading as a 
parameters. 
2. To study the influence of process variables/parameters on the formulation 
characteristics. 
3. To characterize the different physicochemical properties of the prepared AmB-NPs 
dosage form. 
4. To study the surface morphology of the prepared formulation through SEM and TEM. 
5. To study the Fourier Transfer Infra-red (FTIR) spectrum and differential scanning 
calorimetry (DSC) of pure drug, polymer, excipients and their mixtures to study 
chemical interaction between the drug and the polymer or between the drug and the 
excipients. 
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6. To study in vitro drug release through the polymeric NPs, analysis of drug release data 
by different kinetic models like I) Zero order, II) First order, III) Higuchi matrix, and 
IV) Korsmeyer and Peppas. 
8. To develop analytical method for in vitro and in vivo analysis.  
9. To conduct a comparative oral bioavailability study of the developed nanoparticle 
dosage form with a marketed formulation in animal model. 
10. To carry out an in vivo nephrotoxicity study of the developed formulation in order. 
11. To determine the nephrotoxic potential. 
12. To determine the in vitro antileishmanial activity of the developed nanoparticle 
formulation containing amphotericin B. 
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Chapter II. Oral Formulations of Amphotericin-B Nanoparticles and 
their In Vitro Characterization 
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2.1. Introduction 
The rate of opportunistic systemic fungal infections is increasing unavoidably, 
particularly in patients with cancer, recipients of  organ transplants, diabetes and with 
congenital and acquired immune-deficiencies (Italia et al., 2011). In severely immune-
compromised patients, it may involve other organs, such as brain and sinus, or even cause 
disseminated infection (Upton et al., 2007). 
AmB is the gold standard drug for the treatment  of systemic fungal infections, 
since 1953 (Dutcher, 1968).  Fungizone®, the first conventional iv dosage, is formulated as 
a deoxycholate-soluble salt of AmB. However, its  AE can lead to  nephrotoxicity in 30% 
of the patients after dosing (Torrado et al., 2008, Van de Ven et al., 2012). 
The amphoteric nature of AmB is responsible for its poor solubility in both aqueous 
and organic solvents.  As a class IV compound (Ménez et al., 2007), according to BCS, 
AmB is characterized with limited solubility and permeability properties and with its high 
molecular weight, 924 Da, resulting in low (0.3%) bioavailability if given orally(Ouellette 
et al., 2004, Italia et al., 2009, Patel et al., 2013, Manyes et al., 2014). 
Different tactics have been investigated to reduce AmB associated nephrotoxicity 
and other AE during Fungizone® administration.  These include saline loading, alternative 
day dosing and dose reduction; all procedures were with limited success.  Even  the recent 
generation of AmB lipid formulations (Abelcet®, Amphocil® and AmBisome®) with 
improved therapeutic indexes than Fungizone®, their high cost of these formulations (12 to 
40 times-more expensive than Fungizone® Table 1.5), the need of hospitalization for 
parenteral administration and the acute AE have restricted their widespread use (Adler‐
Moore and Proffitt, 2008, Ibrahim et al., 2012).  
For oral administration, the drug must be able to cross the gastrointestinal (GI) 
epithelium.  AmB has intrinsic low solubility, low intestinal permeability and shows poor 
oral bioavailability (< 0.3%). Recently, the literature are full of several attempts of the 
development of AmB oral delivery systems which, claim effective antifungal activity and 
with minimum toxicity.    
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It should be mentioned that only two oral AmB formulations were submitted to the 
FDA for clinical trials.  The first one was an oral cochleate formulation (Biooral AmB, 
BioDelivery Sciences, International, USA) and its phase I clinical trial has been completed 
(Wasan et al., 2009b).   
The second one was consisted of three oral lipid based formulations of AmB, 
namely iCo-009, iCo-010 and iCo-011 to enhance the absorption and efficacy of AmB. The 
improved efficacy of oral AmB lipid-based formulations was due to the resulted better 
absorption of AmB (Wasan et al., 2009a, Gershkovich et al., 2010, Sivak et al., 2011). Both 
iCo-010 and iCo-011 contain lipid, Peceol, surfactant, Gelucire 44/14, and VIT-E “TPGS” 
as a co-surfactant.  Both formulations could be considered as SEDDS and are capable of 
forming instant nano-size emulsion in the GI fluids(Ibrahim et al., 2012). 
However, neither of these two formulations have any published further clinical 
trials results, phase II, and to date, it is unclear whether these formulations of AmB will 
lead to commercially available pharmaceuticals (Yang et al., 2012). 
Recently, there is an increasing interest in utilizing polymeric biodegradable 
polymers either natural or synthetic  to prepare PNPs formulations, to improve the delivery 
of drugs(Barratt, 2003, Ma et al., 2008). Polyesters are the most widely used polymers 
which include PLA, PGA, polycaprolactone (PCL) and their copolymers such as PLGA 
which have been approved by the FDA (Parveen and Sahoo, 2008).  
The rapid elimination of the polymeric drug carrier from the blood stream through 
phagocytosis by the RES is the one of the major problems of parenteral drug delivery 
systems (Stolnik et al., 1995, Owens and Peppas, 2006).  Therefore, PEGylating using PEG 
would avoid phagocytosis.  PEG is approved for the internal use in human by the FDA 
(Luo et al., 2002).  
AmB has been loaded to PEG alone(Greenwald et al., 2003, Sedlák et al., 2007), to 
PEG derivative (Poly(benzyl-L-aspartate)-b-PEG) (Bawarski et al., 2008), to lipoprotein 
derivative-PEG (Shao et al., 2010b), to PEG-phospholipid micelles (Vakil and Kwon, 
2005), to lipid and phospholipids formulations (Wasan et al., 2009a) and to PEG-liposomes 
composed of phospholipids and cholesterol (Moribe et al., 1999). 
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 AmB loaded to PLGA alone (Sahoo et al., 2002, Sánchez-Brunete et al., 2005, Italia 
et al., 2009, Nahar and Jain, 2009, Souza et al., 2015, Yan et al., 2015), to PLGA and TPGS 
(Tang et al., 2014)to a combination of PLGA and lipid (Amaral et al., 2009, Gharib et al., 
2011)and encapsulated in PLGA-dextran (Bang et al., 2008, Choi et al., 2008). 
 Amphiphilic block copolymers (ABCs) have the ability to form various types of 
NPs referred to as micelles, nanocapsules, nanospheres or core-corona NPs (Adams et al., 
2003, Shuai et al., 2004).  ABCs are biocompatible nano-containers in the size range of 10–
100 nm characterized by a core-corona architecture in which the core serves as a reservoir 
for the incorporation of poorly water-soluble drugs, while the hydrophilic corona provides a 
protective interface between the core and the external medium (Gaucher et al., 2010).  
Several studies reported AmB attached to ABC  for parenteral administration such 
as AmB loaded to PEG-PLA(Jain and Kumar, 2010) AmB-(PLA-b-PEG) NPs coated with 
polysorbate 80 (Tween-80)(Ren et al., 2009), encapsulation of AmB in PEG-poly(ɛ-
caprolactone)to form polymeric micelles (Vandermeulen et al., 2006). All previous studies 
showed significant increase bioavailability of AmB. 
Furthermore, syntheses carboxylated PLGA-PEG copolymer encapsulated with 
AmB as a parenteral drug delivery of AmB using nano precipitation method (Kumar et al., 
2015). As well as encapsulation of AmB with another performulated PLGA-PEG- NPs 
showed nanometric size (<200 nm) and to have low PDI (<0.162) and good entrapment 
efficiency (%DEE >53.0%) with enhanced antifungal activity (Nahar and Jain, 2009). 
Paclitaxel loaded to pegylated PLGA NPs using a nanoprecipitation method, 
demonstrated enhanced NP delivery to prostate tumors as compared to equivalent non-
targeted NPs (Cheng et al., 2007).  Nanoparticles were prepared for etoposide-loaded 
PLGA-PEG using nanoprecipitation or single-emulsion solvent evaporation. Combining of 
TPGS and PVA led to increase in encapsulation efficiency (∼90%) and significantly 
prolong duration of release and improved the bioavailability(Saadati and Dadashzadeh, 
2014, Robbie, 1998). 
Doxorubicin––PLGA–PEG micelles have been formulated and tested as a treatment 
for hepatocellular carcinoma. The drug-loaded micelles showed cytotoxicity on tumor cells 
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in vitro and in vivo. Application of the targeted micelles resulted in significant 
improvement in therapeutic response (Preacher et al., 2006). 
The anti-tuberculosis drug Isoniazid (INH) loaded to PLGA-PEG-PLGA triblock 
polymer NPs have been prepared by sonication followed by a double emulsification 
technique. The drug loading efficiency significantly increased and uniform release for the 
drug for longer duration.  
Accordingly, after literature review, these ABCs PLGA-PEG copolymer "PLGA-
PEG copolymer® PEG" Copolymers), that have been shown to be biodegradable and 
biocompatible were employed in this study, as an AmB carrier for oral delivery 
formulations to enhance AmB solubility and bioavailability.  
Optimization of AmB loaded to PLGA-PEG copolymer was achieved by utilizing 
several approaches including: polymer selection, cosolvency, pH adjustment, particle size 
reduction and addition of different surface active gents and absorption enhancer. The 
formulated AmB-NPs were subjected to in vitro analysis. Screening processes have 
included differential scanning calorimetry, particle size determination using zetasizer, 
surface morphology using scanning electron microscopy and transmission electron 
microscopy as well as Fourier Transform Infra-Red (FTIR) characterization. AmB-NP 
yield, drug loading and in vitro AmB release have been also studied.   
2.2. Materials and Apparatus 
2.2.1. Polymers and Chemicals 
All material and chemicals are of analytical grade and used as received. Table 2.1 
and 2.2 show the list of materials and polymers, used in this study and their manufacturer, 
respectively. 
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Table 2.1. Chemical used during formulation of AmB loaded nanoparticles 
Chemical Supplier Address 
Amphotericin B (99.8% purity) Sigma–Aldrich 
 
St. Louis, MO, USA 
 
 
Nicardipine Hydrochloride (98% purity) 
Dimethylsulfoxide (DMSO) 
Triethylamin 
PLGA-PEG copolymers polymer Boehringer Ingelheim Ingelheim, Germany 
Acetone Fisher, Chemical 
 
Fisher, UK 
 Dichloromethane 
Hydrochloric acid 
Methanol-HPLC grade 
Acetonitrile- HPLC grade 
Acetic acid 
Polyvinyl pyrrolidone (PVP) BASF Ludwigshafen, 
Germany 
Miglyol®-812 Sasol GmbH, Germany 
Vitamin E (TPGS) Peboc Eastman, UK 
Pluronic F68 Ruger Chemical New Jersey, USA 
Water was deionized and purified by a 
Milli-Q Reagent Grade water system 
Millipore Corporation Bedford, MX, USA 
Formic acid (Methanoic acid) Avonchem UK 
 
Table 2.2. Composition of the use PEGlyated PLGA-PEG copolymers types 
Symbol Commercial 
Name 
Polymer type Composition Lactic to 
glycolic 
acid ratio 
Content 
of PEG 
(%) 
Molecul
ar 
weight 
(Dalton) 
A RGP d 50105 Diblock PLGA–PEG 
6000 
1:1 10 5000 
B Rgp t 50106 Triblock PLGA–PEG 
6000-PLGA 
1:1 10 6000 
C RGP d 50155 Diblock PLGA–PEG 
6000 
1:1 15 6000 
D RGP d 5055 Diblock PLGA–PEG 
6000 
1:1 5 5000 
E R 203 H * Monoblock Poly(D,L-
lactide) 
1:1 - 24000-
38000 
*Non Peglyated PLGA-PEG copolymers. 
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2.2.2. Apparatus 
Table 2.3 shows a list of the apparatus used in this study and the manufacturer. 
Table 2.3. Apparatus used during the study 
Apparatus Manufacturer 
Analytical balance  
Mettler Toledo-AG285 
Sartorius –ME36S- MicroBalance 
 
Mettler, Greifensee, Switzerland  
-Sartorius AG, Goettingen, Germany 
pH meter, Model 72 Beckman Instruments, Fullerton, USA 
Thermostatically-controlled magnetic stirrer, 
SP46920, Cimarec® 2 
 
Barnstead/Thermolyne, Iowa, USA 
High speed stirrer (Ultra-Turrax T25) IKA Labotecnik, Staufen, Germany 
Oven, TV 10b Memmert, Germany 
Freeze dryer (Labconco-Free zone 4.5) Kansas, US 
Dissolution apparatus, ERWEKA DT 600 
GmbH 
Heusenstamm, Germany 
Malvern Zetasizer Nano ZS, Malvern Instruments, UK 
Fourier Transform Infra-Red (FTIR) 
spectrophotometer 
Perkin–Elmer-Spectrum 1600, Norwalk, 
USA 
Scanning Electron microscopy (SEM, JEOL 
JSM-6060 LV, 
Jeol Ltd., Tokyo, Japan 
 
Transmission electron microscopy (TEM, 
JEM- 1011 
Differential scanning calorimeter (Perkin 
Elmer DSC7 
Perkin Elmer Ltd., Norwalk, USA 
Waters HPLC system equipped with a 
Waters 484 variable UV absorbance detector 
Waters 515 solvent delivery system and a 
Waters 717 plus autosampler 
Waters, USA 
 
300 l glass autosampler vials presplit 
septum 
0.45 m millipore filter 
Digital pH meter, Model 72, Phasar-1 Beckman Instruments, Fullerton, USA 
Centrifuge, Biofuge Stratas Heraeus, Japan 
Vortex mixer Whirlmixer-fission Scientific equipment, 
UK 
Nitrogen Evaporator-OA-sys, multivap-118 Organomation Associates, INC, Berlin, 
Germany 
1.8 ml Eppendorf tube Eppendorf, Germany 
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2.3. Preparation of Amphotericin B loaded-Nanoparticles 
  This study employed the preparation of AmB-NPs by a modified emulsification-
diffusion technique (Mora-Huertas et al., 2010).  The material composition used in the 
study compared to the literature’s are presented in Table 2.4. The schematic presentation 
for the preparation method is shown in Figure 2.1.  The method requires the preparation 
of three phases: organic, aqueous and dilution phases. The organic phase was prepared 
by dissolving 20 mg of AmB in 5 ml of the organic phase (Acetone/Dichloromethane; 
(ACN/DCM: 6/1, v/v)) containing aliquot of PLGA-PEG copolymer and 200 µl of 5N 
HCl. The composition of the studied AmB-NPs formulations is listed in Table 2.5. 
 
 
Table 2.4.Composition comparison of the material used in this study and the literature of the 
emulsion–diffusion  method* 
Material  Literature 
composition 
This study composition 
Active substance, mg  10–50 AmB 20–40 
Percentage of Polymer in the 
inner phase 
1.0–2.0 4.0 
Percentage of Oil in inner phase 2.5–5.0 2.5 
Inner phase solvent, ml 10.0 5.0 
Percentage of Stabilizer  and 
surfactant agents 
2.0–5.0 1-4% PVP, 0.5% F-68 and 5% TPGS 
External phase solvent, ml water 40 30 
Dilution phase, ml water 200 200 
* (Mora-Huertas et al., 2010) 
   
 
 
Figure 2.1. Set-up used for preparation of NPs by the emulsion–diffusion method 
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Table 2.5.Composition of amphotericin B- NPs produced by emulsion–diffusion method (n=6) 
No. Copolymer type Phases 
Aqueous phase 
a
 
Organic phase 
b
 Dilution 
phase  
Stirring 
Rate 
Drug 
(mg) 
Miglyol 
(%) 
PVA 
(%) 
TPGS 
(%) 
Water 
(ml) 
rpm 
A1 Diblock, PLGA–PEG 
6000;  Lactic to 
glycolic acid ratio  
(1:1) with 10%PEG , 
5000 Dalton 
molecular weight  
(RGPd 50105)  
20  --- 1 --- 200 8000  
A2 20 --- 1 --- 200 13500 
A3 20  --- 1 --- 200 24000 
A4 20 2.5 1 --- 200 24000 
A5 20 2.5 1 5 200 24000 
A6 20 2.5 4 5 200 24000 
B3 Triblock, PLGA–
PEG 6000-PLGA;  
Lactic to glycolic acid 
ratio  (1:1) with 10% 
PEG , 5000 Dalton 
molecular weight  
(RGPt 50106) 
20 --- 1 --- 200 24000 
B4 20 2.5 1 --- 200 24000 
B5 20 2.5 1 5 200 24000 
B6 20 2.5 4 5 200 24000 
C3 Diblock PLGA–PEG 
6000;  Lactic to 
glycolic acid ratio  
(1:1) with 15%PEG , 
6000 Dalton 
molecular weight  
(RGPd 50155) 
 
20 --- 1 --- 200 24000 
C4 20 2.5 1 --- 200 24000 
C5 20 2.5 1 5 200 24000 
C6 20 2.5 4 5 200 24000 
C7 40  2.5 4 5 200 24000 
E Monoblock 
Poly(D,L-lactide)  
(R 203 H) 
40  2.5 4 5 200 24000 
D3 Diblock PLGA–PEG 
6000;  Lactic to 
glycolic acid ratio  
(1:1) with 5% PEG , 
5000 Dalton 
molecular weight  
RGPd 5055 
20 --- 1 --- 200 24000 
D4 20 2.5 1 --- 200 24000 
D5 20 2.5 1 5 200 24000 
D6 20 2.5 4 5 200 24000 
a 
Two hundred milligram of PLGA – PEG Copolymer and 200 µl of 5 NHCL were added 
to each formulation, except in case of C7-C8 500 µl was added. 
b 
Addition of 0.15 gm of Pluronic-68  to all formulation. 
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 All the vehicles used in this study were protected from light, either by using Amber 
containers or through covering containers with aluminum foil.  Miglyol was added to the 
organic phase, then sonicated for 5 min and stirred until a clear solution was obtained using 
a magnetic stirrer.  The aqueous phase was prepared by adding polyvinyl pyrrolidone 
(PVP), pluronic (F-68) and TPGS as stabilizers.  The organic solution was added drop wise, 
over 5  min, to the aqueous phase using a high speed stirrer with Ultra-Turrax. The organic 
emulsion was added to 200 ml of distilled water to induce diffusion of the organic phase 
into the continuous phase, with mechanical stirring at 60
0
C for 3 h.  Each batch was 
prepared in six duplicate. All formulations were freeze-dried under vacuum (1.25 mBar) at 
-52 
0
C until complete dryness. Formulated dry NPs were stored in the freezer (-20 
0
C) prior 
to further investigation. 
Four PLGA-PEG copolymers were investigated throughout the study, RGP d 50105 
(A), RGP t 50106 (B), RGP d 50155 (C) and RGP d 5055 (D). Note, the letter indicates the 
copolymer used, while numbers were used to indicate the composition of the formulation; 
the same composition will have same number. 
For optimizing the formulation process, the effect of each factor used on the AmB-
NPs final formulations was investigated.  The stirrer speed (8000, 13500, 24000 rpm) effect 
on four different PLGA-PEG copolymers prepared NPs were studied. The effect of PVP 
miglyol
®
-812 and TPGS concentrations on the final formulations were also studied. 
Furthermore, in this study polymer R 203 H (poly(D,L-lactide))was included as 
formulation (E) to assess the effect of PEGylated copolymer.  
Usually lyophilization of NPs required addition of cryo-protectant or lyo-protectant 
to be added to the formulation just prior to lyophilization. Typical lyo-protectant are listed 
in Table 2.6.  Lyophilization of pure AmB required the addition of sucrose 10% before 
lyophilization to prevent aggregate formation. However, the formulated loaded AmB-
PLGA-PEG copolymer NPs formulations were lyophilized without the addition of cryo-
protectant during this study.  The NPs formulations could be resuspended freely in aqueous 
solution after lyophilization. It was published that poly (ε-caprolactone) nanocapsules 
prepared with 2.5 or 5% of PVA could be freeze-dried without adding cryo or lyoprotectant 
(Abdelwahed et al., 2006, Singh et al., 2014).  In another study,  formulation of poly 
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(isobutylcyanoacrylate) and poly (isohexylcyanoacrylate) NPs could be freeze-dried 
without any modification of their size, in presence of 2% of pluronic®, without cryo 
protector (Abdelwahed et al., 2006, Balabathula et al., 2013). 
During this study, AmB loaded to PLGA-PEG copolymer, formulations included 
the addition of PVP (1-4%) and pluronic (0.5%). These stabilizers could act as cryo-
protectant.  
Table 2.6.  Examples of commonly used excipients in freeze-drying of pharmaceutical products* 
Type Function Substance 
Bulking 
agents  
Offer bulk to the formulation 
particularly for very low  
concentration to freeze dried 
Hydroxyethyl starch, trehalose, 
mannitol, lactose, and glycine. 
Buffers Regulate pH variations during 
freezing 
Phosphate, tris HCl, citrate, and 
histidine 
Stabilizers Shield the product during freeze-
drying against 
the freezing and the drying strains 
Sucrose, lactose, glucose, trehalose, 
glycerol, mannitol, sorbitol, glycine, 
alanine, lysine, polyethylene glycol, 
dextran, and PVP. 
Tonicity 
adjusters 
Yield an isotonic solution and 
control osmotic pressure 
Mannitol, sucrose, glycine, glycerol, 
and sodium chloride 
Collapse 
temperature 
modifiers 
Increase collapse temperature of the 
product to get higher drying 
temperatures 
Dextran, hydroxypropyl-β-
cyclodextrin, PEG, poly (vinyl pyro-
lidone) 
* (Abdelwahed et al., 2006) 
2.4. Physicochemical Characterization of the Nanoparticles 
2.4.1. Particle Size Analysis and Polydispersity Index (PDI) 
The cumulative mean of particle size and polydispersity index (PDI) were 
determined by dynamic light scattering using zetasizer. Typically, after freeze drying of 
formulated formulation of AmB-NPs, the dried powder samples were suspended in 
deionized water and sonicated before measurement. The obtained homogeneous colloid 
was examined to determine the mean diameter, size distribution and polydispersity index. 
Viscosity and the refractive index of the continuous phase were set to those specific to 
water. 
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2.4.2. Zeta Potential Measurement 
Zeta potential (ZP), which reflects the electric charge on the particle surface, is a 
useful parameter to calculate the physical stability of colloidal systems. ZP was determined 
by a Malvern Zetasizer. Diluted samples of 1.0 mg were diluted with Milli-Q® water.  A 
fresh disposable folded capillary cells was used each time for measurement.  
An average of 100 measurements at 25
0
 C with prior equilibrate on of 1.0min was 
taken as a record.  
2.4.3. Fourier Transform Infra-Red Spectroscopy (FTIR) 
FTIR spectra of each pure component as well as the prepared freeze-dried AmB-
NPs formulations were analyzed using a FTIR spectrophotometer. The measurements were 
performed from 450 to 4000 cm
-1
 at constant rate of 10 
0
C/min under an argon purge. AmB 
samples were diluted with KBr powder. The IR spectra were obtained in a KBr disc at 
ambient temperature. 
2.4.4. Morphology of the Nanoparticles 
2.4.4.1. Scanning Electron Microscopy (SEM) 
SEM was used to examine the surface characteristics of the formulated NPs. The 
dry samples of each prepared AmB-NPs formulation were mounted onto metal stubs using 
double-sided adhesive tape. The stubs were vacuum coated with gold using fine coat ion 
sputter under reduced pressure prior to examination by SEM. The accelerating voltage was 
kept constant at 15 KV under an argon atmosphere. The SEM images were done in research 
center-King Saud University- female section with technical support from them.  
2.4.4.2. Transmission Electron Microscopy (TEM) 
TEM was used to examine the morphology of each prepared AmB-NPs 
formulation.  The aqueous (water) dispersion of the freeze-dried NPs was placed over a 400 
mesh copper grid covered with carbon film. After 2min, excess solution was wicked away 
by touching the edge of the grid with a filter paper and negative staining of the sample was 
conducted by a drop of 1% alkaline phosphotungstic acid (PTA) for 1min. The excess stain 
was wicked with filter paper and grid was allowed to air dry before observations, then 
 
 
55 
 
loaded the dry samples to the TEM. The TEM images were done in research center-King 
Saud University- female section with technical support from them. 
2.4.5. Differential Scanning Calorimetry (DSC) 
Samples of AmB loaded NPs were scanned to determine the thermal properties of 
the AmB in its NP formulations.  Approximately 2 mg samples were weighed and placed 
into standard aluminum pans, which, were hermetically sealed. An empty pan was used as a 
reference. The transition temperature (Tc) and enthalpy of transition (∆H) were determined 
from the thermogram, generated by a DSC. The heating rate was 10
0
C/min from 30 to 
200
0
C, with a closed-pan system under a stream of argon gas flow, after which the system 
was cooled down at the same rate from 200 to 30
0
C.  The apparatus was calibrated with 
indium 99.99%. In addition, DSC scans were also performed for each pure component of 
the formulations. All the samples were freeze-dried before the measurements. The DSC 
images were done in research center-King Saud University- female section with technical 
support from them. 
2.5. Determination of Drug Entrapment Efficiency and Nanoparticles Yield 
 Drug entrapment efficiency (DEE) of AmB in the NPs was calculated by 
determining the amount of AmB entrapped in the NPs.  An aliquot of 10 mg sample of the 
freeze-dried NPs was first dissolved in 5 ml of DCM: ACN (1:6, v/v), 200 µl of 5N HCl 
and the volume were made up to10 ml with methanol: water (75:25, v/v).  An aliquot of 
1.25 ml of the stock solution was mixed with 1ml of Nicardipine (IS, 10 µg/ml) and the 
final volume was 10ml with methanol: water (50:50, v/v).  Transfer it into a glass 
autosampler vial with pre-slit septum where, 75 µl were injected into the HPLC 
instruments. This experiment was performed in triplicate. Absorbance at 382 nm of diluted 
stock solution was measured using a validated high performance liquid chromatography 
(HPLC) method and the AmB concentration was calculated as described below. 
DEE (%w/w) =100*(Mass of recovered AmB-NPs / Initial mass of drug used in 
formulation) 
Yield (% w/w) = (mass of AmB-NPs / total mass of polymer, excipient and drug added) 
x100 
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2.6. HPLC Assay for In vitro Study 
A new sensitive method for AmB was developed in this study.  It involveda simple 
procedure suitable for routine work.  The concentration of AmB was measured using a 
Waters HPLC system. Waters 515 solvent delivery system was used for the gradient flow 
through a Novapak C18 column (3.9x150 mm) packed with 5 µm spherical particles. The 
mobile phase consisted of acetonitrile: methanol:  acetic acid: triethylamine (40.5: 4.5: 0.2: 
0.1 % v/v, respectively). The mobile phase was prepared on a daily basis during the study, 
filtered through 0.22 µm millipore filter and degassed under vacuum.  The mobile phase 
flow rate was 1.2 ml/min and the run time was 5.0 min. The injection volume was 75µl and 
detection was at 382 nm.  Data were analyzed with an Empower Pro Chromatography 
Manager Data Collection System. The HPLC system was operated at ambient temperature.  
A stock solution containing 0.2 mg/ml of AmB  was preparedby dissolving 2.0 mg 
of the AmB  in 10 ml mixture of DMSO and methanol (1:9, v/v) and stored in 4.0 ml 
polypropylene vials at −20oC, since AmB adsorbs to glass (Lee et al., 2001), and covered 
with aluminum foil to protect AmB from light.   
A stock solution containing 0.5 mg/ml of Nicardipine in methanol was used as the 
internal standard (IS)and it was stored at −20oC.  A daily standard calibration curve (n=3) 
ranging from 0.25 to 5.0 µg/ml containg 10µg/ml of the IS was prepared to determine the 
unknown AmB concentration for DEE and drug release.  The standards were transferred to 
plastic autosampler vials with pre-slit septum (Waters, USA), where 75 µl were injected 
into the HPLC system for analysis. 
2.6.1. Assay Validation 
 The developed method was validated in regards to linearity, precision, accuracy, 
according to ICH Harmonized Tripartite Guidelines(Guideline, 2005).  
2.6.2. Assessment of Linearity, Accuracy and Precision 
Three standard calibration lines were prepared in different times (at least three 
months) to evaluate the linearity, precision, accuracy and stability. The linearity of each 
standard curve was assessed by plotting the peak area ratio of AmB to IS versus AmB 
concentration.  
 
 
57 
 
Accuracy of the process stated in term of bias (percentage deviation from the 
nominal concentration= [100*(actual concentration-nominal concentration)/ actual 
concentration].The accuracy was assessed by examination of multiple replicates (n = 6) of 
AmB concentration.  
Precision of a measurable technique is the degree of agreement among individual 
tests, when the technique is applied repetitively to analyze multiple replicates in three 
different occasions. The intraday precision was assessed by analysis of the calibration 
curves of 6 replicates of different concentrations of AmB within the same day. The inter-
day precision was determined by the analysis of 6 replicates of different concentrations of 
AmB in 3 different days. The total precision of the method expressed as the relative 
standard deviation (RSD%). 
Low, medium and high concentration quality control (QC) samples at 
concentrations of 0.25, 1.0 and 5.0 µg/ml of AmB with 10µg/ml of IS were analyzed, in 
three different occasions within at least three months, as described above.  
The limits of detection (LOD) and of quantification (LOQ) were measured based on 
the analysis of 6 replicates. The LOQ was well-defined as the lowest drug concentration of 
the calibration daily curve which can be calculated with an accuracy <15% and precision < 
12%. The LOD was defined as 0.5 times of the limit of quantification. In addition, the LOD 
presents a peak signal to noise of baseline ratio equivalent to 3:1, while the LOQ shows a 
ratio of 10:1. 
2.7. Drug Dissolution in Phosphate Buffer 
The quantitative in vitro release test was performed using US Pharmacopeia XXXII 
dissolution apparatus 2 (paddle).  The dissolution was carried out in 500 ml phosphate 
buffer containing 2% sodium deoxycholate (pH 6.8 ±0.1) at 50 rpm and the temperature 
was maintained at 37 ± 0.5 
o
C. A sample of AmB NPs equivalent to 5.0 mg of AmB was 
placed on the surface of the dissolution medium. At appropriate time intervals (0.25, 0.5, 1, 
2, 3, 4, 5, 6 and 24 hours), 2.0 ml samples were withdrawn from each vessel, mixed with 
1.0 ml of IS (10µg/ml) and  made up to 5.0 ml with methanol: water (75:25, v/v). The 
solution was filtered through a 0.22 μm Millipore membrane filter, transferred to an 
autosampler vial with pre-slit septum (Waters, USA)and 75 µl was injected and analyzed 
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by HPLC. This experiment was done in triplicate. The withdrawn volume was replaced 
each time with 2 ml of fresh medium kept at 37 ± 0.5 
o
C to maintain a sink condition.  
2.8. Drug Release Kinetics 
Drug release kinetics of AmB formulations were analyzed using various dissolution 
models including; zero, first, Higuchi and Korsmeyer–Peppas order (Table 2.7). Release 
profile data were processed and plotted according to the equations of different models 
followed by regression analyses. The criterion for selecting the most appropriate model was 
based on best goodness-of-fit (R
2
 values). The slope of each plot and its release rate 
constant for each particular model were used to describe the release rate mechanism. 
Table 2.7. Drug release kinetics equation and comments 
Model Equation  The order 
Zero order* Qt = Q0- K0 t 
 
This equation is for drugs with no aggregation in the 
dissolution media and the drug release is slowly:  
Qt :  The amount of drug released in time t,  
Q0:  The cumulative amount of drug released 
K0:  Zero order release rate constant  
First order* Ln Qt = Ln Q0 – 
Kt  
Qt and Q0:  As above.   
K:  First order release constant 
Higuchi 
model** 
Qt= Kt
1/2 
Where Qt is as above and K is the Higuchi rate constant 
Korsmeyer-
Peppas 
model*** 
 
Qt / Q∞ = Kt
n 
 
Qt / Q∞: The fraction of drug released at time t,  
K: The release rate constant 
n:  The release exponent. n< 0.5:  Fickian diffusion;  
0.5<n<1: Anomalous diffusion(non- Fickian 
transport),n=1: Zero-order release  
*(Costa and Sousa Lobo, 2001)  **  (Dash et al., 2010) *** (Shoaib et al., 2006) 
 
 
2.8.1. Data and statistical analysis 
In vitro results were expressed as mean ± SD of at least three replicates. The HPLC 
results of AmB were calculated using linear regression without weighting, according to the 
equation: Y= 0.379X -0.041, where, Y is the area under the peak (AUP) ratio of the drug to 
the internal standard and X is the concentration of AmB.  The RSD % was calculated for all 
values.  The Student’s t-test was used to inspect the concentration difference at each day 
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and one-way analysis of variance (ANOVA) was used to assess the reproducibility of the 
assay and the drug dissolution from batch to batch using IBMSPSS Statistics 21.  The level 
of confidence was 95%.   
2.9. Results and Discussion of in vitro Characterization 
2.9.1. Optimization of AmB-NPs Formulation Process 
The choice of a specific method of NPs preparation is a factor of the 
physicochemical properties of the drug to be loaded as well as the intended route of drug 
administration. For hydrophobic drugs, nanoprecipitation (Barichello et al., 1999, Peltonen 
et al., 2004, Bilati et al., 2005, Vauthier and Bouchemal, 2009) or an emulsion–diffusion 
method are best suited for NPs preparation (Kwon et al., 2001, Soppimath et al., 2001, 
Hans and Lowman, 2002, Dillen et al., 2006, Italia et al., 2009, Mora-Huertas et al., 2010, 
Mora-Huertas et al., 2011). 
Two steps are involved in emulsion diffusion evaporation method. The first step 
involves formation of primary emulsion with small droplet of organic solvent containing 
drug and polymer in aqueous phase (oil/water).  In the second step, the emulsion was 
homogenized at high speed to decrease the particle size before the removal of the organic 
solvent by evaporation, resulting in formation of NPs.  In contrast, the nanoprecipitation 
method involves a single step in the formation of NPs.  The organic phase containing drug 
and polymer was added to the aqueous phase, resulting in rapid de-solvation of the polymer 
due to diffusion of solvent into the aqueous phase. This precipitation of polymer with the 
drug caused an instantaneous formation of NPs of the drug loaded to the polymer matrix. 
The emulsification-diffusion method has been used successfully to prepare 
biodegradable NPs in an efficient and reproducible manner especially for hydrophobic 
drugs(Quintanar-Guerrero et al., 1996, Quintanar-Guerrero et al., 1998a, Kwon et al., 2001, 
Soppimath et al., 2001, Hans and Lowman, 2002, Galindo-Rodriguez et al., 2004, Dillen et 
al., 2006, Mora-Huertas et al., 2010, Mora-Huertas et al., 2011).  Similar finding was 
observed with AmB in this study since it isa hydrophobic drug. 
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Selection of the proper organic solvent was the most challenging issue to overcome 
AmB poor solubility in organic solvent (Table 1.4). After acidification with 200 µl of 5N 
HCL, ACN/DCM (6:1, v/v) was found to be the most suitable cosolvents for AmB and the 
copolymer used during the study. 
2.9.2. Factors Affecting Nanoparticles Formulations 
2.9.2.1. Shearing Rate 
Different speeds of mechanical stirring ranging from 8000 to 24000 rpm were tested 
in this study.  The relationship between stirring speed and mean particle size (MPS) is 
shown in Table 2.8. Several publications correlate the stirring speed (mixing speed) with 
the MPS of NPs.  They found that increasing the stirring speed, significantly reduces the 
size range of the NPs This range is controlled and considerably narrowed at higher stirring 
speed(Eldem et al., 2001, Brime et al., 2003, Balabathula et al., 2013, Ibrahim et al., 2013).  
The NPs size was inversely proportional to the stirring speed.  A significant reduction in 
NPs size range (from 1068.1 ± 489.8 to 400.2 ± 62.1 nm) was observed on increasing the 
shearing rate from 8000 to 24,000 rpm for the “A” formulations.  The same results were 
obtained with the other tested formulations of different polymers (B, C and D). At the 
lowest stirring speed (8000 rpm), the A1 showed the highest MPS (1,068.1 ± 489.8 nm) 
while C1 showed the lowest MPS at this speed. While, at the highest speed (24000 rpm) D3 
formulation showed the highest MPS 515.6 ± 30.7 in comparison to C3 with the lowest 
MPS (57.2 ± 7.5 nm). It should be mentioned that at higher stirring speed, the NPs 
formulations were arranged in the following order C > D> B> A, according to MPS 
reduction. Therefore, throughout this study, the 24,000 rpm stirring rate was used for the 
NPs preparation. 
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Table 2.8. Influence of shearing rate on the mean particle size and poly dispersity index of AmB-
NPs prepared by emulsification –diffusion method 
Batch 
number 
Particle size 
(nm) ± SD 
Polydisper-
sity Index ± 
SD 
Stirring 
Speed 
rpm 
DEE % Yield% 
A1 1,068.1 ± 489.8 0.46 ± 0.1 8,000 18.5±3.3 67.3± 2.1 
A2 451.2 ± 84.2 0.46 ± 0.1 13,500 21.4± 3.4 73.7±1.2 
A3 400.2 ± 62.1 0.64 ± 0.3 24,000 23.3± 7.3 75.0±1.4 
B1 336.5 ± 60.4 0.40 ± 0.1 8,000 17.2 ± 2.3 70.1± 2.1 
B2 257.1 ± 13.6 0.40 ± 0.1 13,500 18.4± 3.5 77.4±1.2 
B3 107.4 ± 62.0 0.50 ± 0.2 24,000 20.4 ± 1.4 74.8 ±1.5 
C1 274.2 ± 30.1 0.40 ± 0.1 8,000 21.5± 4.3 76.3± 2.1 
C2 226.9 ± 17.2 0.40 ± 0.1 13,500 23.4± 3.4 79.4±1.2 
C3 57.2 ± 7.5 0.30 ± 0.1 24,000 25.9 ± 0.5 82.5 ± 1.1 
D1 630.9 ± 67.4 0.40 ± 0.1 8,000 18.5± 3.1 70.7± 2.1 
D2 538.6 ± 41.9 0.40 ± 0.1 13,500 21.4± 2.9 74.3±1.2 
D 3 515.6 ± 30.7 0.40 ± 0.1 24,000 24.3 ± 2.3 85.5 ± 1.4 
 
2.9.2.2. Addition of Surfactant and Emulsifier 
Several papers report that the addition of surfactant or emulsifier significantly 
reduces the MPS due to its adsorption on the surface of the NPs, preventing the NPs 
aggregation by static repulsion and special hindrance (Santra et al., 2001, Schubert and 
Müller-Goymann, 2005, Kvitek et al., 2008, Balabathula et al., 2013). However, other 
studies suggest that the addition of a combination of more than one surfactant or emulsifier 
is better choice to reduce the aggregation (Mu and Feng, 2002, Mei et al., 2009, Chaudhari 
et al., 2012, Saadati and Dadashzadeh, 2014).  In this study, more than one surfactant was 
incorporated to increase the reduction of the MPS and improve the stability of the NPs.  
Therefore the addition of PVP; hydrophilic surfactant, pluronic F-68 non-ionic surfactants 
and TPGS were investigated. 
The main basic constituents of AmB-NP formulations were AmB (20 mg), PVP 
(1%) and F-68 (0.5%). The different composition of NPs investigated during the study and 
 
 
62 
 
their effect on the DEE%, yield% and the MPS of the NPs were summarized in Tables 2.8 
and 2.9. All the AmB-NP formulations have homogenous distribution with PDI of< 0.5, in 
the nanometer size range with narrow size distribution and without polymer flakes or 
visible oil droplets.  
Table 2.9.  Influence of different composition parameters on the mean particle size and poly 
dispersity index of AmB-NPs prepared by emulsification –diffusion method 
Batch 
number 
Particle size  
(nm) ± SD 
poly dispersity 
Index ± SD 
Zeta Potential 
 ± SD 
DEE % Yield% 
A3 400.2 ± 62.1 0.64 ± 0.3 -21.9 ± 2.5 23.3± 7.3 75.0±1.4 
A4 126.8 ± 27.3 0.53 ± 0.2 -24.8 ± 1.3 23.9 ± 1.1 81.3±2.2 
A5 105.2 ± 9.3 0.26 ± 0.1 -24.0 ± 2.0 24.8 ± 4.1 82.5±1.3 
A6 93.3 ± 5.7 0.51 ± 0.3 -23.7 ± 1.3 37.8 ± 7.5 83.7 ±1.4 
B3 107.4 ± 61.9 0.53 ± 0.3 -22.5 ± 3.0 20.4 ± 1.4 74.8 ±1.5 
B4 97.4 ± 10.2 0.39 ± 0.1 -25.0 ± 3.2 21.2± 7.1 77.1 ±2.3 
B5 69.4 ± 14.7 0.24 ± 0.1 -25.4 ± 4.1 36.9 ± 2.4 78.9 ±2.4 
B6 55.4 ± 5.9 0.26 ± 0.1 -25.3 ± 5.3 37.5± 1.7 80.9 ± 1.7 
C3 57.2 ± 7.5 0.25 ± 0.1 -25.2 ± 3.5 25.9 ± 0.5 82.5 ± 1.1 
C4 36.8 ± 7.6 0.28 ± 0.1 -30.2 ± 3.3 29.9 ± 6.2 83.8 ± 1.2 
C5 27.0 ± 5.6 0.34 ± 0.1 -28.5 ± 1.2 40.6 ± 10.9 87.5 ± 1.1 
C6 23.8 ± 4.8 0.31 ± 0.0 -29.9 ± 1.7 48.3 ± 4.2 90.6 ± 0.5 
C7 25.3± 2.7 0.31 ± 0.0 -29.8 ± 2.1 56.5 ±  3.9 93.2 ± 0.5 
E 539.9± 51.1 0.35 ± 0.1 -23.3 ± 3.5 27.2 ± 3.2 67.4 ± 0.8  
D3 515.6 ± 30.7 0.37 ± 0.0 -23.9 ± 1.7 24.3 ± 2.3 85.5 ± 1.4 
D4 418.8 ± 28.2 0.32 ± 0.1 -25.1 ± 2.4 24.4 ± 2.7 86.9 ± 2.2 
D5 344.4 ± 38.4 0.26 ± 0.10 -25.5 ± 2.7 27.4 ± 2.5 88.1 ± 1.7 
D6 318.4 ± 36.8 0.36 ± 0.10 -25.8 ± 2.8 39.4 ± 9.2 89.6 ± 1.0 
A: RGPd 50105, B: RGPt 50106, C: RGPd 50155, D: RGPd 5055, E: R 203 H polymer 
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The size of different formulations were observed after varying one parameter at a 
timeand keeping other parameters constant. Selection of the particularparameter out of the 
set was based on; smaller size,size distribution (PDI-polydispersity index),  and highest 
yield of drug loaded to the polymer used. 
Among the tested basic component formulations, AmB loaded to copolymer C has 
the lowest MPS. On the other hand, AmB loaded to copolymer D has the highest MPS as 
shown in Table 2.9. 
A significant reduction in MPS (P<0.05) was observed after the addition of miglyol-
812 (2.5%) to the basic component of each copolymer (Formulations A4, B4, C4, D4).  The 
size reduction was in the order of A (68 %) > C (35%) > D (18.9%) > B (8.5%) (Table 2.9). 
Therefore, miglyol-812 (2.5%) was added to the basic composition of the AmB-NPs 
starting from formulations with number 5. 
The addition of the TPGS (5% w/v) causing further reduction in MPS of A (16.6%), 
D (17.9%), B (27.8%) and C (27%) (Table 2.9). Therefore, TPGS was also added to the 
basic component of the AmB-NPs formulation starting from formulations with number 6. 
Moreover, increasing the concentration of PVP from 1% to 4%, the MPS of AmB-
NPs formulation was also decreased in the order B, A, C, D (21.5%, 11.5 %, 11.1%, and 
7.5% respectively) as shown in Table 2.9. 
Interestingly, changing the PLGA-PEG copolymer to R 203 H polymer (non-
peglyated) formulation E, caused a significant increase in the MPS > 95%.  It should be 
mentioned that no more than 40 mg of AmB could be incorporated in these formulations 
(C7), with no significant effect on MPS. Therefore, formulations A6, B6, C6, C7, E and D6 
with the lowest MPS were selected for in vitro characterizations. 
Particle size of drug-loaded NPs is an important determinant affecting the in vitro 
drug release as well as its in vivo performance (Kim et al., 1998, Couvreur and Vauthier, 
2006, Jin et al., 2007, Xin et al., 2010, Pham et al., 2013). 
AmB –PEG nanoparticles formulations showed reduce MPS and improve drug 
release profiles associated with no toxic effect as compared with conventional solution 
formulation, Fungizone
®
(Tiyaboonchai et al., 2001, Kayser et al., 2003, Angra et al., 2009). 
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The size of AmB-NPs was determined by dynamic light scattering (NanoZS, 
Malvern Instruments, UK) as an average of 3 measurements.Measurment of the particle 
size is done through dynamic light scattering technique (Cegnar et al., 2004, Xu et al., 
2006). Since suspended particles in solution move in Brownian motion, when subject to   
irradiation with a monochromatic laser there will be fluctuations in the intensity of 
scattered light. The autocorrelation function was then processed to determine the diffusion 
coefficient from which the average radius can be determined (Böschel et al., 2003, Vega et 
al., 2003). 
 
2.9.3. Drug Encapsulation Efficiency and Nanoparticles Yield 
DEE of the AmB NPs was found to be inversely proportional to the MPS (Table 
2.9). The minimum DEE for all formulated formulation was 20% (B3) while the maximum 
encapsulation was 56.5 % (C7). Meanwhile, for the selected formulations the DEE was in 
the following order C7>C6> D6> A6 > B6 corresponding to 56.5 %, 48 %, 39 %, 37% and 
32 %, respectively.  The non-peglyated polymer (E) showed a DEE of 27 %.  Howeverو the 
highest yield of AmB-NPs was 93% (C7) while the lowest one was 74% (B6).  
2.9.4. Poly Disparity Index (PDI) 
PDI values ranged from 0 to 1.0 PDI represents the particle size distribution within the 
formulations with values below 0.3 indicating a narrow size distribution and thus good 
long-term stability, while a higher value indicates a less homogenous NP size distribution. 
Tables 2.8 and 2.9 indicate that PDI in all formulations is < 0.5; which means that all 
formulations have homogenous and have narrow size distribution associated with good 
long-term stability in water.  These findings are consistent with literature reports that NPs 
with cystatin incorporated in PLG-NPs (Cegnar et al., 2004, Xu et al., 2006). 
Moreover, it is interesting to report that the addition of any surfactant or stabilizer to 
the basic composition of the NPs showed no trend of change in PDI value with no 
correlation between the MPS and the PDI values. 
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2.9.5. Zeta Potential Analysis of AmB- NPs Formulations 
The change in electrical charge between the layers of ions around the NPs and that 
of the bulk of the surrounding fluid is known as zeta potential (ZP) (Chouhan and Bajpai, 
2009). Several factors affecting the ZP measurement such as polymer composition(Tobıo et 
al., 2000), physicochemical characterization of the drug entrapped as well as stabilizer used 
during NPs formulation(Betancourt et al., 2007).  The ZP is a measure of the degree of 
repulsion between similarity charged particles in the dispersion, thus, colloids with a high 
ZP (positive or negative) are electrically stable. It is reported that the stability of NPs 
mainly related to a high ZP (high surface charge), while low ZP values correlate NPs 
aggregates and instability (Betancourt et al., 2007, Feng et al., 2007).  
Nanoparticles with ZP values greater than +25 mV or less than -25 mV typically lead 
to repulsive forces between the droplets which may improve the physical stability of the 
dispersion system, while system with a low ZP value will eventually aggregate due to Van 
Der Waal inter-particle attractions (Dobrovolskaia et al., 2009). 
A negative surface charge was observed for all measured AmB loaded to PLGA-
PEG NPs.  Their ZP values are negative and in the range of -21.9 ± 2.5 to -30.2 ± 3.3 mV 
(Table 2.9).  This finding was in agreement with other studies using polyesters polymers 
for NPs preparations  such as paclitaxel loaded to PLA-TPGS and antiestrogen RU58668 
loaded to PLGA-PEG, both show negative ZP measurements (Ameller et al., 2003, Xu et 
al., 2006, Pan and Feng, 2008).  
It is interesting to report the addition of any surfactant or stabilizer to the basic 
composition of the NPs showed no trend of change in ZP value and there was no 
correlation between the MPS and the ZP values.  
 
2.9.6. Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) can produce high-resolution images of the 
specimen surface (in the nm range) and images can be viewed to determine their three 
dimensional appearance, thus showing the morphology of the specimen. SEM instruments 
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work by the measurement of electrons emitted from the surface after itis bombarded by an 
electron source.  
The representative SEM analysis was also performed to complete the information 
about particle size and morphology. Figure 2.2 showed that formulation A6 (contain three 
surfactant) were the best spherical NPs with minimal aggregation in comparison to other 
formulations. Figure 2.3, formulations containing polymer B, indicate that polymer used 
did not improve the spherical structure of NPs than obtained when utilize polymer A in the 
formulation. The C polymer formulation (Figure 2.4) showed nanosized spherical with no 
aggregate NPs. Meanwhile Figure 2.5 although triblock polymer (D) were used showed 
nanosized spherical NPs with no aggregates. Figure 2.6, comparing formulations number 6 
in all polymers used displayed that polymer E (non PEGlyated) showed the highest particle 
size in comparison to other polymers. While C6 followed by C7 were morphologically the 
best.  
In conclusion, the SEM images (Figures 2.2-2.6) indicate that the presence of fairy 
spherical shape and discrete NPs with a variation in size distribution (in the nanometer size 
range) including both isolated and agglomerated particles. Figure 2.6, showed the SEM 
images for the selected formulation, which will be used for further in vivo study. 
 
2.9.7. Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) is currently the technique most widely 
used to study nanomaterial morphology, providing a two-dimensional picture of these 
materials. The specimens for analysis were prepared by scraping few milligrams of a 
sample to form a thin film deposited on a glass microscope slide. The TEM analysis 
provided additional evidence regarding the spherical geometry of AmB-NPs formulations. 
The TEM photographs showed that all AmB-NPs formulations were spherical in 
shape and in the nanometer size range (Figures 2.7-2.10). Furthermore, the surface 
morphology of these formulated AmB-NPs was found to be smooth with minimal 
aggregation. Formulation containing polymer C and B where the best in morphology and 
formulation number 6 is the best in all types of polymer use. Figure 2.11, is the TEM image 
of the selected formulation which will be used in vivo study. 
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Figure 2.2.SEM images for AmB-NPs prepared by RGPd 50105 copolymer (A) formulations 
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Figure 2.3.SEM images for AmB-NPs prepared by RGPt 50106 copolymer (B) formulations 
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Figure 2.4. SEM images for AmB-NPs prepared by RGPd 50155 copolymer (C) and (E) with R 
203 H polymer formulations 
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Figure 2.5.SEM images for AmB-NPs prepared by RGPd 5055 copolymer (D) formulations 
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Figure 2.6. SEM images for AmB-NPs prepared by RGPd 50105 copolymer (A6); RGPt 50106 
copolymer (B6); RGPd 50155 copolymer (C6) and GPd 5055 copolymer (D6) formulations 
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Figure 2.7. TEM images for AmB-NPs prepared by RGPd 50105 copolymer (A) formulations 
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Figure 2.8. TEM images for AmB-NPs prepared by RGPt 50106 copolymer (B) formulations 
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Figure 2.9. TEM images for AmB-NPs prepared by RGPd 50155 copolymer (C) formulations 
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Figure 2.10. TEM images for AmB-NPs prepared by RGPd 5055 copolymer (D) formulations 
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Figure 2.11. TEM images for AmB-NPs prepared by RGPd 50105 copolymer (A6); RGPt 
50106 copolymer (B6); RGPd 50155 copolymer (C6) and GPd 5055 copolymer (D6) 
formulations 
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2.9.8. Fourier Transform Infra-Red (FTIR) Analysis 
FTIR was used to identify AmB and to detect any change in the drug in the 
formulations compared to the pure drug.  Therefore, the analysis was carried out for both 
pure AmB and pure copolymer used throughout the study, and then compared to the freeze 
dried formulations of AmB-NPs.  
The spectra of the AmB was similar to those found in the literature (Asher and 
Schwartzman, 1977).  The functional groups (the important bands) characteristic of AmB 
of the FTIR spectroscopy are shown in Figure 2.12 and listed in Table 2.10. The FTIR 
spectrum of AmB confirmed the presence of carboxylic, amine and ester groups.  
The peak at 3500 cm
–1
 was due to the N–H stretching of the amine groups. The 
peak at 3390 cm
–1
 was due to the C–H stretching of the polyene and O-H stretch. The peaks 
at 3030, 2988 and 2824 cm
–1
 represent the C–H stretching vibrations of the alkene and 
alkane groups, and C–N stretching vibration appears at 1350 cm–1. The peak at 1585 cm–1 
can be assigned to the N–H stretching vibration of amine groups and C=C of alkene groups. 
The peaks at 1670, 1480 and 1242 cm
–1
 represent C=O, OH and C–O stretching vibrations 
of carboxylic groups. The peaks at 1750 and 1150 cm
–1
 represent C=O and C–O bonds, 
respectively, indicating the existence of an ester group. The peak at 1050 cm
–1
 was 
associated with the C–OH bond present in AmB (Asher and Schwartzman, 1977). 
 
Figure 2.12.FTIR spectra of AmB alone 
 
 
78 
 
Table 2.10. Important bands of IR spectrum of Amphotericin B* 
Frequencies (cm
-1
) Functional group present 
3500 C-N stretch of the amine group 
3390 C-H stretch (polyene) and O-H stretch (strongly H-bonded)  
3030 C-H stretch vibrations of the alkenes 
2940 C-H3 asymmetric shoulder stretch band 
1691 Sharp C=O stretch band, NH2 in-plane bend 
1557 Polyene C=C stretch band 
1402 C-H bend in polyene ring 
1069 C=O asymmetric stretch 
1009 C-H bend out of plane bend (trans polyene) 
851 C-H bend in pyranose ring vibration 
*(Nahar and Jain, 2009) 
Figure 2.13 shows the FTIR of pure product of AmB and the copolymer used 
(PLGA-PEG copolymer).  This Figure indicates that AmB has characteristic sharp bands at 
1691, 1557 and 1009 cm
-1
, responsible for the sharp C=O stretch band; NH2 in-plane bend, 
polyene C=C stretch band and C-H bend out of plane bend (trans polyene), respectively.  
The PLGA-PEG copolymer produces minor IR absorption in this region. Therefore, any 
change in this region could be used to detect any sort of interaction between AmB and 
copolymer in any formulation tested. 
 
Figure 2.13. FTIR spectra of AmB and the four different type of PLGA-PEG copolymer each 
one alone. 
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Figure 2.14-2.17 display the FTIR spectra for AmB NPs prepared by RGPd 50105 
copolymer (A); RGPt 50106 copolymer (B); RGPd 50155 copolymer (C) and RGPd 5055 
copolymer (C). The FTIR spectrum for the pure AmB is different compared to that of 
AmB-NPs.  The pure AmB crystals shows characteristic sharp bands at 1691, 1557 and 
1009 cm-1, due to a C=O stretch band; NH2 in-plane bend, polyene C=C stretch band and 
C-H bend out of plane bend (trans polyene), respectively. This is in agreement with FTIR 
of pure AmB published by the following authors (Asher and Schwartzman, 1977, Nahar 
and Jain, 2009). 
In case of the freeze-dried formulations of AmB-NPs, in particular, the carbonyl-
stretching band was lost likely due to an interaction between the AmB and the polymer 
used. Similar interactions were observed with all the copolymers used. 
 
 
Figure 2.14.FTIR spectra for AmB-NPs prepared by RGPd 50105 copolymer (A) formulations. 
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Figure 2.15. FTIR spectra for AmB-NPs prepared by RGPt 50106 copolymer (B) formulations. 
 
 
Figure 2.16.FTIR spectra for AmB-NPs prepared by RGPd 50155 copolymer (C) formulations. 
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. 
Figure 2.17.FTIRspectra for AmB-NPs prepared by RGPd 5055 copolymer (D) formulations. 
 
2.9.9. Differential Scanning Calorimetry (DSC) 
DSC is an important tool to determine the compatibility and stability of the drug 
with the used excipients. Figure 2.18 shows the thermogram of AmB and the copolymer, 
each separately. AmB is hygroscopic in nature; therefore, starting from 30°C to 100°C, 
AmB has a broad endothermic peak due to the loss of moisture of adsorbed water. The two 
characteristic endothermic peaks were observed for AmB at 168.5°C and 213.4 °C which 
closer to the melting point of AmB crystal as indicated in the literature(Asher and 
Schwartzman, 1977, Janoff et al., 1988, Madden et al., 1990, Salerno et al., 2013).  
The DSC traces for the pure copolymers did not show any endothermic peak in the 
melting region of AmB.  Meanwhile, characteristic peaks for the copolymer at 66.3 - 68.7 
°C were detected, corresponding to its phase transition temperature (Tm).  AmB- NPs 
formulations showed a shift to the right in AmB endotherm (Figure 2.19), which is 
indicative of shielding of AmB by the matrix constituents (Al-Assady et al., 2013).  This is 
due to the loss of the crystalline lattice of AmB and the formation of an amorphous state as 
a result of the incorporation of AmB inside the copolymer. Many studies have reported that 
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the amorphous form enhances the dissolution and bioavailability of drugs because of higher 
Gibbs free energy in the amorphous form(Kim et al., 2008, Khadka et al., 2014). Patterson 
et al. prepared the amorphous forms of  three poorly water soluble drugs (carbamazepine, 
dipyridamole and indomethacin) with  PVP. Their dissolution rates were higher than their 
non amorphous form(Patterson et al., 2007). 
 
 
Figure 2.18. DSC thermograms of Amphotericin B and pure copolymer used. 
 
Figure 2.19.DSC thermograms of Amphotericin B and AmB-loaded NPs with RGPd 50105 
copolymer (A6); RGPt 50106 copolymer (B6); RGPd 50155 copolymer (C6) and GPd 5055 
copolymer (D6) formulations. 
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2.9.10. Chromatographic Analysis for Amphotericin B 
Since AmB is only available as parenteral dosage form, only one HPLC method has 
been published for the determination of AmB in pharmaceutical dosage forms (Zhan-rui et 
al., 2009).  
High-performance liquid chromatography (HPLC) developed during the 1960s and 
it is perhaps the most versatile analytical technique available to the modern analysts.  
A new sensitive HPLC method for AmB with Nicardipine as IS was developed in 
this study. This method was used for the quantitative determination of AmB concentration 
for its in vitro studies as drug content analysis, percentage yield and amount of AmB 
released during the dissolution study. 
It was noticed that decreasing the proportion of acetonitrile in the mobile phase than 
the amount used was resulted in peak broadening.  In the meantime, increasing the 
proportion of acetonitrile led to early elution of AmB along with other interfering peaks. 
The method was found to be specific for AmB with no interfering peaks from any 
constituents of the NPs were co-eluted, during In vitro studies, with AmB or IS peaks 
which are a further confirmation of the specificity of the method. 
Although there is no structural similarity between AmB (Lemke et al., 2005) and 
Nicardipine (Fernandez et al., 1990) (Figure 2.20), they have shared similarity in the 
solubility behavior in the mobile phase used and detected at the same wavelength, which 
makes Nicardipine is an appropriate choice as the IS for this study. 
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Figure 2.20. Chemical structure of amphotericin B (Lemke et al., 2005) and Nicardipine as 
IS(Fernandez et al., 1990). 
 
It is known that maximum UV absorbance for AmB at 383 and 407 nm. The HPLC 
analytical methods reported in the literature often detect AmB either at 407nm or 383 nm. 
In this study, AmB was better detected, with better sensitivity, at 382nm wavelength. 
Therefore, 382 nm was selected to identify AmB in the HPLC assay. 
 
Figure 2.21, shows the chromatogram A, for the blank, mobile phase, and 
chromatogram B represents AmB and IS with the average retention times of 2.87 ± 0.05 
and 4.20 ± 0.09 min, respectively with no interfering peaks. This is an indication the 
specificity of the HPLC assay method.  Others published HPLC methods for AmB 
determinations need longer time for detection of AmB alone, with exception of Balbathula 
et al., (Balabathula et al., 2013)where the retention time is 2.7 minutes but the method 
required careful sample preparation in order to reduce the chances of errors during analysis. 
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chromatogram A                                       chromatogram B 
 
Figure 2.21. HPLC chromatograms of mobile phase (chromatogram A) and HPLC 
chromatograms of mobile phase containing 0.5 µg/ml amphotericin B and 10 µg/ml 
Nicardipine as internal standard (chromatogram B). 
 
2.9.10.1. HPLC Methodology Validation 
A calibration curve of peak area ratios, of AmB to IS, versus concentrations, 
ranging from 0.25 to 5.0 μg/ml, was plotted in Figure 2.22.  Each point on the calibration 
curve represents a mean of six determinations. A linear curve was obtained for the range of 
concentration tested with a correlation coefficient (r) of 0.999.. The regression equation 
was Y = 0.379X – 0.04.Therefore, good linear relationships between the AmB peak area 
ratios and its tested concentrations. 
 
Figure 2.22. Standard calibration curve of in vitro AmB in methanol at λ 382 nm (n = 6) 
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2.9.10.2. Precision and Accuracy 
 The closeness or similarity in a series of measurements derived from multiple 
sampling of the same homogenous solution under similar conditions is an indication of an 
assay precision. The interday and intraday precision are measures of method variability that 
can be expected when it is used for analysis (Shaikh et al., 2008) and is expressed by the 
RSD. %. The intraday precision (Table 2.11) was determined by analyzing six replicates 
each of 0.25, 1.0 and 5 μg/ml concentrations of AmB solution. For interday precision 
determination (Table 2.12), six replicates each of concentrations of AmB were analyzed on 
three different days. The relative standard deviations were determined. For the 
determination of accuracy, the relative error was calculated (Health and Services, 2001). 
The relative standard deviation RSD% values obtained range from 4.4 – 6.2 for intraday 
precision and 4.2 – 5.8 for interday precision respectively and indicate good precision for 
the developed method.  
Table 2.11.  Intraday precision determination (n = 6) 
Concentration (µg/ml) 0.25 1 5 
Average 0.071 0.350 1.825 
SD 0.004 0.015 0.114 
RSD% 5.193 4.436 6.278 
 
Table 2.12.  Interday precision determination (n = 6) 
Concentration (µg/ml) 0.25 1 5 
Average 0.071 0.353 1.82 
SD 0.003 0.015 0.105 
RSD% 4.225 4.323 5.789 
 
The accuracy, calculated as the relative error of the average concentrations 
determined by HPLC compared to standard solutions of AmB was determined at low, 
medium and high concentrations (i.e. 0.25, 1.0 and 5.0μ g/ml, respectively) of AmB 
solution. The relative standard deviation RSD % values ranging from 3.3 to 6.1for intraday 
accuracy (Table 2.13) and 2.7 to 5.66 for interday accuracy (Table 2.14) indicate that the 
method is sufficiently accurate for determination of AmB in solutions.  
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Table 2.13.Intraday accuracy determination (n = 6) 
Concentration (µg/ml) 0.25 1 5 
Average 0.29 1.03 4.92 
SD 0.009 0.04 0.30 
RSD% 3.29 3.97 6.14 
 
Table 2.14.  Interday accuracy determination (n = 6) 
Concentration (µg/ml) 0.25 1 5 
Average 0.29 1.04 4.91 
SD 0.008 0.04 0.28 
RSD% 2.68 3.87 5.66 
 
2.9.10.3. Robustness 
The assay method was robust, since a small-intended change in assay conditions 
as changing the column or the HPLC system has not shown any significant effect on 
the chromatographic performance of AmB.  Even a little difference in the mobile phase 
composition did not show any noticeable effect in peak area ratio of AmB.  
 2.9.11. In vitro Release of Amphotericin 
In vitro drug release profiles an imperative test to predict the in vivo performance of 
a drug delivery system.  An in vitro drug release study is indeed a prerequisite for a drug 
design optimal effect (Kumari et al., 2010). The drug release pattern was studied for 24 
hours for all formulations. 
AmB is not available as oral dosage form in the market, therefore, there is no 
available official dissolution medium for it.  Several authors have been investigated 
different dissolution media for AmB in vitro release studies. Simulated intestinal fluid with 
pancreatic enzymes (SIFe) (pH = 7.5) was used as the dissolution medium (Tiyaboonchai et 
al., 2001, Zu et al., 2014). Furthermore, dissolution medium can be 500 ml of 0.1 N HCl 
(Singh et al., 2013).  For the lipid-based formulations, the simple dissolution assessment 
media would not be appropriate to evaluate the absorption of these preparations. Ibrahim 
and his group have indicated that the presence of phospholipids, bile salts and lipase 
enzyme in dissolution media maintained  at 37 
0
C and at constant pH are essential for their 
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dissolution(Ibrahim et al., 2012).Other researches, used equilibrium dialysis membrane  for 
AmB dissolution studies (Nahar et al., 2008). The release medium used in this work is 
consisted of  2% sodium deoxycholate (SDC) in phosphate buffer (0.1 M, pH 7.4) which is 
similar to the one reported by Jain and Kumar(Jain and Kumar, 2010). 
The in vitro release profiles of AmB in phosphate buffer with 2% sodium 
deoxycholate are depicted in Figure 2.23- 2.26. The differences observed in release profiles 
may be due to differences in the type of polymer used, percentage of PEG in the polymer, 
and presence of different additives in the formulations. 
Figure 2.23. In vitro drug release behavior for AmB-NPs prepared by RGPd 50105 copolymer(A) 
in phosphate buffer with sodium deoxycholate (2%).  
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Figure 2.24. In vitro drug release behavior for AmB-NPs prepared by RGPt 50106 copolymer (B) 
in phosphate buffer with sodium deoxycholate (2%).  
 
Figure 2.25.In vitro drug release behavior for AmB-NPs prepared by RGPd 50155 copolymer (C) 
and R 203 H (E) in phosphate buffer with sodium deoxycholate (2%).  
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Figure 2.26.In vitro drug release behavior for AmB-NPs prepared by GPd 5055 copolymer (D) in 
phosphate buffer with sodium deoxycholate (2%).  
 
Figure 2.27.In vitro drug release behavior for AmB-NPs prepared by selected copolymer in 
phosphate buffer with sodium deoxycholate (2%).  
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The release profiles of AmB from NPs formulations indicate biphasic release.  
Where, in the first phase (6 h, R
2
>0.9) there was an initial rapid release of about 21-51%, 
depending on the formulation, followed by a slower phase, from 6-24 h, where only about 
11% was released.  No lag time was observed (4-10% release in the first 15 min) which 
could be attributed to the existence of some of the AmB adsorbed on the surface of the NPs 
or the ability of the dissolution medium, containing the surfactant, to aid the initial release 
of the drug from the polymer.  It should be mentioned that, removal of the surfactant from 
the dissolution medium resulting in minimum release AmB (< 7 %).  The highest drug 
release within 24 h was obtained with C6 (61%), while the lowest one was A3 (24.8%).   
Regarding the release of AmB loaded to PLGA-PEG copolymer (A) formulations 
as shown in Figure 2.23, a significant (P<0.05) increment in the order of A3 (24.8%) < A4 
(27%)<  A5 (30.7%)< A6 (31.9%) was obtained. The same pattern was observed with other 
PLGA-PEG copolymer used (B, C and D). The existence of this unique pattern because of 
the different stabilizers added to the AmB-NPs formulations.  
Comparing the six different formulations of the four PLGA-PEG copolymer, 
formulations number 3 (A3, B3, D3 and C3) showed the lowest AmB release among them 
A3 (24.8%) < B3 (26.9%) < D3 (30%) < C3 (50%). While the highest AmB release among 
them C6 (61.2%) > B6 (40.9%) < D6 (38%) > A6 (31.9%).  
The addition of miglyol-812 (2.5%) to the basic component of each copolymer 
(Formulations A4, B4, C4, D4) during the preparation process has led to a significant 
(P<0.05) increase in AmB release.  The same trend was observed on adding TPGS (5% 
w/v) causing further increment in release behavior of A4 (27%) < D4 (27%) < B4 (40.4%) 
< C4 (46.3%). Moreover, increasing the concentration of PVP from 1% to 4%, the drug 
release of AmB from the NPs formulations was also increased < D5 (29%) <A5 (30.7%) <, 
B5 (40.9%) < C5 (46.1%) significantly (P<0.05). A similar trend was reported for several 
hydrophobic drugs after the addition of miglyol-812, such as ketoprofen (Patil et al., 2004), 
simvastatin(Zhang et al., 2010b) and lacidipine (Basalious et al., 2010).The same 
observation, of noticeable improvement, in the in vitro release of drugs was recorded upon 
the addition of TPGS to different formulations (Mu and Feng, 2002, Mu and Feng, 2003, 
Zhang et al., 2008, Tang et al., 2014). 
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Increasing the PVP content from 1 to 4% in AmB loaded to PLGA-PEG increased 
the release rate (32%) C6 > (32%) D6> (28.8%) C7 > (3.67%) A6 > (1.15%) B6. This 
finding is in agreement with the results of different researchers group for drug such as 
terbinafine and protein (Arunprasad et al., 2010, Shakeri et al., 2015). 
The more the reduction in the MPS, the larger surface area in contact with the 
dissolution medium, the higher the drug release will be.  There was doubling AmB content 
in the NPs from 20 mg to 40 mg in formulations C7.  showed non-significant (P= 0.887) 
difference in the AmB release rate between C6, with 20 mg AmB, and C7, with the 40 mg 
AmB, formulations. This means that the dissolution media could not be able to dissolve 
more than the amount of AmB released from C6 i.e. the maximum solubility in this 
dissolution medium could be reached.  It should be mentioned that the increase of AmB 
content in the NPs shows insignificant (P=0.654) reduction of MPS between C6 and C7 
which could be another explanation of the no change in the release rate as a result of 
increasing the drug content. 
It is interestingly notice that changing the PLGA-PEG copolymer to R 203 H 
polymer (non-peglyated) formulation E caused a significant (P< 0.05) reduction in release 
rate by 95 % as compared to peglyated polymer. 
Therefore, formulations A6, B6, C6, C7, E and D6 with the lowest MPS and the 
highest release rate were selected for further in vivo characterizations. 
2.10. Drug Release Kinetics 
 To fit the release pattern of AmB-NPs different kinetic models were tested.   The 
coefficient of determination (R
2
) and release rate constant (K) were analyzed using 
different established models to find out the release mechanism 
 Table 2.15, represent the results of modeling of release profile, R
2
 and K are 
correlation coefficient and release rate constant for particular formulation. As per 
expectation, AmB loaded to NPs tested formulations were found to have maximum R
2
 in 
case of Korsmeyer–Peppas (n = 0.5) as well as Higuchi model for 24 h profile. This can be 
explained and the formulated AmB- NPs were considered as a matrix type system and drug 
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is anticipated to release by diffusion mechanism. Similar finding were by Jain and Kumar, 
2010 (Jain and Kumar, 2010), when AmB loaded to (PEG)3-PLAco-polymers. 
 The drug release depends upon: adsorption through the nanoparticles matrix, 
diffusion through the nanoparticles matrix, particles erosion, a combined erosion and 
diffusion process and polymer degradation (chemical or enzymatic hydrolysis). The 
application of the correct mathematical model allows us to analyze about release rate, 
points of dissolution change and mechanisms of drug release. 
If the diffusion process is Fickian, n is equal to 0.5, 0.45 and 0.43 for thin films, 
cylindrical and spherical matrices, respectively. When n exceeds these thresholds, the 
release is non-Fickian (Ritger, Peppas, 1987). Korsmeyer Peppas constant ‘n’ = 0.245 
which is the beyond the limits of Korsmeyer Peppas model. It cannot be predicted clearly. 
It may be due complex mechanism of swelling, diffusion and erosion. 
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Table 2.15.  Modeling of amphotericin release from different formulations in 24 hour study 
Formulation 
code 
Zero- Order First- Order Higuchi Korsmeyer-Peppas 
R² K R² K R² K R² K n 
A1 -0.1863 1.538 0.0395 0.020 0.7824 6.909 0.8816  9.649  0.358  
A2 -0.4214 1.203 -0.2271 0.015 0.7861 5.433 0.9479  7.993  0.334  
A3 0.1271 1.307 0.2817 0.016 0.9268 5.694 0.9740  7.275  0.396  
A4 -0.1558 1.510 0.0613 0.020 0.8232 6.784 0.9209  9.411  0.361  
A5 -0.1974 1.676 0.0651 0.023 0.8599 7.459 0.9704  10.442  0.356  
A6 -0.7106 1.777 -0.3564 0.025 0.7121 8.059 0.9532  12.493  0.311 
B3 -0.3081 1.538 -0.0615 0.020 0.7751 6.959 0.9033  9.990  0.346  
B4 -0.2749 1.941 0.0538 0.028 0.7967 8.750 0.9199  12.480  0.348  
B5 0.0139 2.211 0.3448 0.034 0.8860 9.772 0.9501  12.895  0.382  
B6 -0.4388 2.172 -0.0314 0.033 0.8120 9.634 0.9808  14.197  0.333  
C3 -0.4744 2.785 0.1308 0.054 0.7705 12.604 0.9487  18.783  0.329  
C4 -0.5561 2.696 0.0627 0.053 0.7019 12.365 0.8922  18.703  0.323  
C5 -0.4713 2.671 0.1123 0.051 0.7341 12.200 0.9049  18.172  0.329  
C6 0.0243 3.448 0.6637 0.089 0.8373 15.362 0.8943  20.120  0.386  
C7 -0.2879 3.229 0.4004 0.071 0.8329 14.378 0.9642  0.9642  0.346  
E  0.2356 2.007 0.4714 0.029 0.8872 8.767 0.9108  10.578  0.421  
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R
2
, is the coefficient of determination; K, is the release rate constant for respective model. Where, Qt is the amount of drug 
released at time t, Q∞ is the initial amount of drug, and k is release rate constants of respective equation. 
 
D3 -0.2474 1.622 0.0041 0.022 0.8471 7.235 0.9727  10.293  0.349  
D4 -0.3310 1.491 -0.0866 0.019 0.8234 6.680 0.9630  9.624  0.344  
D5 -0.0910 1.576 0.1378 0.021 0.8829 6.984 0.9704  9.515  0.368  
D6 -0.4197 2.094 -0.0324 0.032 0.8111 9.410 0.9786  13.861  0.334  
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2.11. Conclusion 
The first challenge in developing an oral drug delivery system of AmB was to cope 
with its poor solubility in any solvents.  This has been overcome by co-solvation and 
through lowering of the pH(Venier-Julienne and Benoit, 1996, Nahar and Jain, 2009).  
Several other approaches have been utilized in this study to solubilize AmB loaded to  
PLGA-PEG copolymer including particle size reduction, addition of different absorption 
enhancer, the type of polymer used and the technique of preparation. The use of co-solvents 
is a highly effective technique to enhance the solubility of poorly soluble drugs (Millard et 
al., 2002, Vemula et al., 2010). The addition of a polar solvent like acetone to the dispersed 
organic phase decreases mean nanoparticle size and narrows the size distribution, as 
reported with (Venier-Julienne and Benoit, 1996). An organic  mixture of both solvent 
ACN/DCM  have been used successfully in solubilizing lipophilic drug (Hosotsubo et al., 
1988). 
The second challenge was to improve the drug loading efficacy (DEE) which 
determines the effectiveness of the system to hold the drug as well as overall amount of 
polymer in the carrier system required to deliver a particular amount of drug. The optimum 
formulation in this study has a DEE of 56.5% which is > 5 fold better compared to the 
liposomal AmB (AmBisome) currently used clinically, with a DEE of 11.72%(Jain and 
Kumar, 2010).  Therefore, a novel oral AmB-NPs has been developed using a modified 
emulsification diffusion method using peglyated (PLGA-PEG15% -diblock copolymer) 
which is characterized by a simple preparation procedure, high encapsulation efficiency and 
high reproducibility.   
Incorporation of AmB-NPs loaded to PLGA-PEG for oral delivery, displayed 
reduction in MPS to nanometer scale. This is in agreement with Kumar et al., (Kumar et al., 
2015)study. 
AmB formulation with PLGA-PEG diblock copolymer, formulation C especially 
which contain RGPd 50155 with 15% PEG copolymer, produced a significant (P <0.05) 
reduction in the MPS(> 70%) compared to the other developed AmB-NPs. This could be 
attributed to the higher percentages of the PEG loaded in the copolymer.  Similar trend was 
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observed by Busske and his co-authors (Buske et al., 2012).  In addition, the same polymer 
has shown the highest drug content in comparison with other developed formulations. This 
is in agreement with (Schwach et al., 2004, Buske et al., 2012)where, the percentage of 
PEG had a significant effect on the size reduction of the formulated NPs.  Meanwhile, in 
comparing diblock versus triblock with the same percentage of the PEG (10%), this study 
has shown that triblock copolymer was better in dissolution rate by about 30% than the 
diblock copolymer. This is in agreement with Buske and ZU groups (Buske et al., 2012, Zu 
et al., 2014).  Therefore, PLGA-PEG 15% diblock copolymer was the best optimal 
formulations polymer in this study for the preparation of the AmB- loaded NPs.  
The addition of miglyol to the organic phase could lead to further reduction in 
particle size due to the fact that miglyol®-812 (caprylic/capric triglyceride mixture) 
increases emulsification associated with the production of finely dispersed emulsions 
(Pouton, 1985). Additionally, solvent capacity for less hydrophobic drugs can be improved 
by blending with triglycerides, so miglyol could dissolve higher amounts of AmB. This 
conclusion is in agreement with the finding of (Patil et al., 2004) with ketoprofen and 
triglyceride tripalmitin (Garcia-Fuentes et al., 2005).The addition of a surfactant (TPGS) 
reduce the MPS significantly and enhanced the release of the AmB-NPs. It is reported that 
TPGS was necessary for stabilization of AmB-NPs suspension from aggregation in 
comparison to formulation without TPGS (Italia et al., 2011).  
Increment of PVP from 1 to 4% has significant effect on MPS reduction and rise of 
release rate. 
A simple, fast, accurate and reliable HPLC method for measuring AmB in in vitro. 
The developed analytical method was sensitive for AmB, could quantify as low as 250 
ng/ml, and it capable for measurement of AmB concentration in all tested formulations. 
Under the assay conditions described, retention times for AmB and IS were around 2.87 ± 
0.05 and 4.2 ± 0.09 min, respectively. The correlation coefficient was found to be ∼0.998. 
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Chapter III. Pharmacokinetics of the Selected Oral Amphotericin-B 
Nanoparticles Loaded to PLGA-PEG Diblock Copolymer 
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3.1. Introduction 
AmB is the gold standard treatment for sever systemic life-threatening fungal 
infections since 1959 (Bekersky et al., 1999, Cifani et al., 2012). It is currently used as the 
secondary treatment for leishmaniasis, with a 97% cure rate with no reported resistance 
(Wasan et al., 2009b).  It is currently used as the secondary treatment for leishmaniasis, 
with a 97% cure rate with no reported resistance (Wasan et al., 2009b).  Unfortunately, 
AmB is available in the market only for parenteral administration.  
AmB state (monomers or aggregates) affects its efficacy and toxicity, since 
monomers forms are responsible for the therapeutic activity, while the aggregates forms are 
accountable for drug toxicity (Nishi et al., 2007).   
Nephrotoxicity is the most serious chronic adverse effect of AmB; the serum 
creatinine concentration increases in more than 80% of patients receiving this drug (Sachs-
Barrable et al., 2008, Tonomura et al., 2009).  
AmB has an unknown metabolism and tissue distribution (Egger et al., 2001).   The 
primary route of its elimination is not known (Drew, 2013). 
The amphipathic nature of AmB significantly reduces its solubility in water and 
most organic solvents. Its aqueous solubility was improved by adding sodium deoxycholate 
to its formulation to produce a colloidal dispersion after reconstitution for intermittent 
intravenous (iv) infusion (Fungizone®).  Severe side effects are associated with the 
administration of Fungizone

, such as nephrotoxicity, have restricted its clinical uses 
(Burgess and Birchall, 1972, Chuealee et al., 2011). 
The development of parenteral AmB lipid-based formulations, Abelcet®, 
Ambisome® and Amphocil®, which have shorter course of therapy (3–5 days), highly 
effective and exhibit lower toxicity when compared to Fungizone® (Clements Jr and 
Peacock Jr, 1990, Baginski et al., 2005, Torrado et al., 2008). Regrettably, their cost is a 
great barrier to their common use (Sachs-Barrable et al., 2008, Falamarzian and 
Lavasanifar, 2010a).  
AmB is also characterized by instability at gastric pH and is unable to cross the 
mucosal barrier of the GI to blood stream.  The critical need for an oral drug delivery of 
AmB has steered several endeavors found in the literature about the development of AmB 
oral delivery systems to improve its antifungal activity and toxicity.  These include 
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formulating AmB as nanosuspension (Kayser et al., 2003), as Poly(lactide-co-glycolide) 
nanoparticles (NP) employing vitamin E-TPGS as a stabilizer (Italia et al., 2009, Italia et 
al., 2011), as lipid-based oral formulation using Peceol (Sachs-Barrable et al., 2008) or as 
liquid antisolvent precipitation  NP (Zu et al., 2014).  Furthermore,  AmB was loaded to 
Peceol and PEG-phospholipids (iCo-009) (Wasan et al., 2009a, Gershkovich et al., 2010, 
Sivak et al., 2011), to carbon nanotubes (Prajapati et al., 2011b), to gelatin coated lipid NP 
(Jain et al., 2012), to Chitosan–EDTA conjugate (Singh et al., 2013) or to Cubosomes 
lipid-based delivery (Yang et al., 2012, Yang et al., 2014).   The latest formulations were 
AmB liposomes containing ceramides (Skiba-Lahiani et al., 2015) and AmB encapsulated 
with chitosan derivative (Serrano et al., 2015).  These oral drug delivery were developed 
to enhance the solubility and gastrointestinal permeability of AmB, but none of them has 
been introduced to the market yet (Heurtault et al., 2003, Thornton and Wasan, 2009, 
Wasan et al., 2009a, Ibrahim et al., 2012, Yang et al., 2012).    
The addition of glycyrrhizic acid (GA) as absorption enhancer was evaluated. GA is 
a major constituent of licorice with steroid-like, anti-allergic and antiviral activities 
(Pompei et al., 1980).  It has been used orally as a sweetener and component of oriental 
medicines (Imai et al., 1999, Anand et al., 2010).  In the field of drug delivery, GA is 
reported as a low-toxic oral absorption enhancer to improve the oral bioavailability of 
different drugs(Radwan and Aboul-Enein, 2002, Chen, 2009, Yang et al., 2015). 
It was assumed that loading AmB to PLGA-PEG NP would improve its solubility 
and decrease its toxicity since the drug would be slowly released from the delivery system.  
It could also prevent AmB aggregation and thereby decrease its toxicity toward mammalian 
cells, while maintaining it in a monomeric form that favors  antifungal activity (Brajtburg 
and Bolard, 1996, Torrado et al., 2008).  
Lately, two published reports on the use of PLGA-PEG NP as AmB parenteral 
delivery systems. The first study was concerning about delivering AmB as a mannose-
anchored engineered nanoparticulate for macrophage targeting (Nahar and Jain, 2009), 
while the second paper  encapsulated AmB in PLGA-PEG NP to increase AmB solubility 
and to target the macrophage of infected tissues during visceral leishmaniasis (Kumar et 
al., 2015). To our knowledge, no published data about the development of  AmB loaded to 
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PLGA-PEG NP for oral AmB delivery other than mentioned in chapter II.  The in vitro 
studies of the developed formulations have indicated promising oral drug delivery system 
with acceptable drug content and dissolution rate. Therefore, after physical characterization 
of the developed selected PLGA-PEG NP formulations, the aim of this study was to 
confirm the practicability, safety and efficacy of using these novel AmB formulations as 
oral AmB delivery system in rats.  The objective of this part of the study was to carry out 
pharmacokinetics screening of these formulations after iv and oral administrations to rats. 
The feasibility of glycyrrhizic acid as an absorption enhancer to improve AmB 
bioavailability was part of the investigation.   
Several HPLC, reverse phase methods for AmB have been described in serum, 
plasma, tissue (Granich et al., 1986, Bekersky et al., 1996, Polikandritou Lambros et al., 
1996, Echevarrı́a et al., 1998, Zhan-rui et al., 2009, Chakrabarty and Pal, 2011).  Table 3.1 
list the HPLC assays published in the literature for the analysis of AmB in biological 
samples with the corresponding references. Proein precipitation (deproteinization) were the 
mostly utilized  method for extraction, where C18 and acetonitrile were the most commenly 
used column and solvemt respectively. UV Dectection were manliy at 382 and 405 nm.    
Advanced hyphenated technique such as liquid chromatographic tandem mass 
spectrometry (LC MS/MS) as shown in Table 3.2, is the revolution technique of traditional 
HPLC assays for determination of AmB in biological samples. Generally, the use of 
MS/MS as the detector has demonstrated better selectivity and sensitivity than the use of 
ultraviolet detector of conventional HPLC methods.  It overcomes the effect of the yellow 
components in plasma, such as bilirubin (Xiong et al., 2009).  These HPLC methods show 
either lake of sensitivity with minimum detection limits of 2 µg/ml in plasma (Xiong et al., 
2009, Deshpande et al., 2010) or take longer run time >5.0 min, or use too many steps of 
clean up in extraction (Lee et al., 2001).  Although the LC MS/MS techniques are 
characterized by a faster run time, to our knowledge no published data is reporting an assay 
of AmB using LC MS/MS with retention time < 3.5 min, with simple and efficient 
extraction technique.  The present study was undertaken to develop a fast, robust, selective, 
sensitive, and precise LC MS/MS method for the monitoring of AmB in rats plasma using 
clopidogrel as IS.   
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Table 3.1. The literature reported HPLC for amphotericin B determinations in biological samples 
Analytical 
technique 
IS Column Mobile phase Detection 
(UV-nm) 
Retensionti
me (min) 
References 
Deproteinization - CLC-trime-
thylsilyl 
acetonitrile :10 mM acetate buffer 
(pH 7.4)(40:60, v/v) 
 382  7.8  (Hosotsubo et al., 
1988) 
Solid-phase 
extraction 
N-
acetylamphoter
i-cin B 
C18 acetonitrile : 2.5 mM Na, 
EDTA (45:55, v/v) 
382  6.76 (Wang et al., 1992) 
Deproteinization piroxicam Ultrabase-C  acetonitrile: acetic acid (10%) : 
water (41:43:16, v/v/v) 
405 5.7-5.9 (Echevarrı́a et al., 
1998) 
Deproteinization 1-amino- 4-
nitronaphthale
ne 
 acetonitrile : 10mM sodium acetate 
buffer( pH 4) (11:17, v/v) 
408  (Otsubo et al., 1999) 
Solid-phase 
extraction  
- LiChrosorb-
RP-8 
acetonitrile:methanol:0.010 M 
NaH2PO4 buffer (41:10:49, v/v/v) 
405 6.7 (Egger et al., 2001) 
Deproteinization 1-amino-4-
nitronaphtalene 
Bondapak C-
18 
acetonitrile-disodium EDTA (20 
mM) (45:55, v/v pH 5) 
382 - (Eldem et al., 2001) 
Solid-phase 
extraction 
1-amino-4-
nitronaphtalene 
Sep-Pak  
C-18 
methanol: 11 mM phosphate buffer 
(pH 7.4) (40:60, v/v) 
407 - (Eldem et al., 2001) 
Deproteinization natamycin Reverse phase 
column 
acetonitrile: 0.05 N sodium acetate 
(34:66, v/v) 
405 - (Bekersky et al., 
2002a) 
Deproteinization 1-amino-4-
nitronaphthale
ne 
 acetonitrile : 10mM sodium acetate 
buffer, pH 4.0 (11:17, 
v/v) 
408  (Otsubo et al., 1999, 
Fukui et al., 2003a) 
Deproteinization - Econosphere 
C18 
acetonitrile: 0.02 M EDTA (55:45, 
pH 4.5) 
405 - (Malone et al., 2013) 
Deproteinization  ODS-Hypersil 
C18 
acetonitrile :2.5 mM EDTA  (45:55, 
v/v) 
382 4.7 (Manosroi et al., 
2004) 
Deproteinization  - Lichrosorb® 
RP-8  
- 405 - (Brime et al., 2003) 
Deproteinization p-nitroaniline  Sep-Pak Vac 10 mM sodium acetate buffer with 405 - (Hong et al., 2007) 
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C18 10 mM EDTA (pH 3.6): 
acetonitrile (60:40) 
Deproteinization 1-amino-4-
nitro 
naphthalene 
Nucleosil® 
C18 
acetonitrile: 10mM 
acetate buffer (pH 4) 
407 6.8 (Italia et al., 2009) 
Deproteinization - Luna C18  acetonitrile: tetrahydrofuran: o-
phosphoric acid (60:30:10, v/v/v pH 
6.0) 
287 7.72 (Balamuralikrishna 
and Syamasundar*, 
2010) 
Deproteinization - BDS 
Hypersil C18 
acetonitrile: acetic acid: water 
(57:4.3:38.7, v/v/v) 
407 15 (Wasan et al., 2010) 
Deproteinization Lornoxicam Hypersil ODS 
C18 
10 mmol phosphate buffer : 
acetonitrile (65:35, v/v) 
407 5.2 (Chakrabarty and 
Pal, 2011) 
Deproteinization - Phenomenex 
luna C18 
organic phase methanol/ 
acetonitrile/tetrahydrofuran 
(41/18/10) to buffer (2.5mmol/L 
EDTA-2Na) (55/45, v/v) 
383, 303 >15 (Eldem et al., 2001) 
Deproteinization 1-amino-4-
nitronaphthale
ne 
BDS Hypersil 
C18  
5 mM of sodium acetate at pH 4.2 225 - (Ibrahim et al., 2013) 
Deproteinization 4-nitro-1-
naphthylamine 
symmetry C18 acetonitrile : 0.1 M acetate 
buffer(pH 4.2) 
405 10.8 (Malone et al., 2013) 
Deproteinization No IS XBridgeTM 
C18 
acetic acid (0.73%) : acetonitrile 
(60:40, v/v) 
408 2.7 (Balabathula et al., 
2013) 
Deproteinization - Spheri-5, 
CYANO  
10 mM sodium acetate (pH 4) : 
acetonitrile (72:28, v/v)  
408 5.9 (Kumar et al., 2014) 
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Table 3.2. The literature reported LC MS/MS for amphotericin B determinations in biological samples using protein precipitations for extraction 
IS Column Mobile phase Detection 
(UV-nm) 
Retension 
time 
(min) 
References 
Natamycin Symmetry 
C18 
methanol:water:acetic acid (69:29:2, 
v/v/v) 
 924 →906 
m/z 
- (Bekersky et al., 
2002b) 
Natamycin Phenomene
x Synergi 
Max-RP 
10 mM ammonium acetate 
(pH 3.6):acetonitrile (620:380) 
924→ 
906.5  m/z 
- (Hong et al., 2007) 
Rifaximin Sunfire C18 
column 
0.1% formic acid :  methanol (0.1% 
formic acid) (40:60%, v/v) 
924→ 
906.6 → 
743.4 m/z 
4.3 (Xiong et al., 2009) 
Natamycin 
  
RP18e mobile phase"A"  5mM ammonium 
acetate buffer (pH 6):Acetonitrile : 
methanol (48:20:32, v/v) mobile 
phase"B"  5mM ammonium acetate 
buffer (pH 6): acetic acid: acetonitrile: 
methanol (25:5:5:70, v/v/v/v) 
924.5→ 
906.6 m/z 
5.1 (Deshpande et al., 
2010) 
Natamycin Luna CN 3.5 mM ammonium acetate (pH 4): 
methanol (10:90, v/v) 
922.7 
→183.3 m/z 
3.37 (Bhatta et al., 2011) 
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3.2. Materials and Apparatus 
3.2.1. Materials 
All material and chemicals are of analytical grade and used as received. Table 3.3 
shows the list of materials and polymers, used in this study and their manufacturer, 
respectively. 
Table 3.3.New chemicals used in this part of the work  
Chemical Supplier Address 
Amphotericin B (99.8% purity) Sigma–Aldrich 
 
 
St. Louis, MO, USA 
 Clopidogrel (98% purity) 
Glycyrrhizic acid 
Dimethylsulfoxide (DMSO) 
Triethylamin 
Formic acid- Mass grade 
Ammonium formate 
PLGA-PEG copolymers polymer Boehringer Ingelheim Ingelheim, Germany 
Acetone Fisher, Chemical 
 
Fisher, UK 
 Dichloromethane 
Hydrochloric acid 
Methanol-HPLC grade 
Acetonitrile- HPLC grade 
Acetic acid 
Polyvinyl pyrrolidone (PVP) BASF Ludwigshafen, Germany 
Miglyol®-812 Sasol GmbH, Germany 
Vitamin E (TPGS) Peboc Eastman, UK 
Pluronic F68 Ruger Chemical New Jersey, USA 
Formic acid (Methanoic acid) Avonchem UK 
Milli-Q Reagent Grade water 
system 
Millipore Corporation Bedford, MX,  USA  
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3.2.2. Apparatus 
Table 3.4. shows a list of the apparatus used during LC MS/MS analysis of AmB in 
biological samples. 
Table 3.4. Apparatus used during analysis of Amphotericin B  
Apparatus/components  Purpose Manufacturer 
Mettler Toledo-AG285 
Sartorius –ME36S- 
MicroBalance 
Analytical balance  
 
Mettler, Greifensee, 
Switzerland  
-Sartorius AG, Goettingen, 
Germany 
pH meter, Backman, Model 72 Measure pH Beckman Instruments, 
Fullerton, USA 
Waters Aquity UPLC
TM
 LC MS/MS system Waters Corp., Milford, 
USA 
Aquity UPLC
TM
 BEH C18 
column 50mm x 2.1mm, 1.7 µm 
triple quadropole tandem-mass 
detector 
Separation column – 
maintained at 40 
o
C 
Waters Corp., Milford, 
USA 
MassLynx
TM 
V 4.1 software with 
TargetLynxTM V 4.1 program  
Data recording and 
processing   
Waters Corp., Milford, 
USA 
 
3.3. Preparation of AmB-Loaded PLGA-PEG Copolymer 
AmB loaded to PLGA-PEG was formulated according to previously mentioned in 
Chapter II with slight modification by adding GA. Diblock, 15% PEG RGPd 50155 
copolymer formulation (C6) was selected as the base formulation for this part and is named 
F1. To investigate the feasibility of PLGA-PEG polymer versus non peglyated polymer, R 
203 H, poly (D,L-lactide), AmB-NPs was prepared  by the same technique. All 
formulations were prepared at least in triplicate.   
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When GA was added to F1 just prior to administration the formulation is called F2-
GA-out-1, F2-GA-out-2 and F2-GA-out-3, where, 1,2 and 3 refer to the percentage of GA 
added.  When GA 2% was added to the organic phase during F1 preparation, the resulted 
formulation is called F2-GA-in-2.    
Doubling the amount of AmB in the formulation with addition of GA inside the 
formulation is called F3-GA-in-2, while F3-GA-out-2 is the same composition but the GA 
was added just prior to administration. 
Table 3.5 shows the composition and method of in vivo administration of the 
formulations tested in rats. 
Immediat0ly before administration, the specific weight of the lyophilized AmB-
loaded PLGA-PEG NPs were dispersed in water solution either alone or in combination 
with GA as 1 and 2 %.  The volume of the PO suspension dose was 1.0 ml. 
Table 3.5. The composition and method of administration of the developed formulations used 
during the study 
Animal 
Group 
Route Formulation Carrier/ Polymer Drug 
Amount, 
mg 
GA 
% 
IN 
GA 
% 
OUT 
Dose 
mg 
/kg 
I PO Fungizone
®
 Sodium deoxycholate 50 - - 10 
II iv F1 Diblock, 
PLGA-PEG (Lactic to 
glycolic acid ratio1:1 
molar ratio)with 15% 
PEG; molecular weight 
6000 Dalton 
RGPd 50155 
20 - - 1 
III PO F1 20 - - 10 
IV PO F2-GA-out-1 20 - 1 10  
V PO F2-GA-out-2 20 - 2 10  
VI PO F2-GA-out-3 20 - 3 10 
VII PO F2-GA-in-2 20 2 - 10  
VIII PO F3-GA-in-2 40 2 - 10  
IX PO F3-GA-out-2 40 -  2  10 
X PO Non PEG Poly (D,L-
lactide)Monoblock R 203 
H 
40 - - 10 
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3.4. Animals Dosing and Blood sampling 
 All the experiments were performed in accordance to the ethical guidelines 
established and approved by the committee on the use and care of laboratory animals at 
King Saud University.  Sixty albino Sprague-Dawley rats (353.17 ± 26.61 gm) were 
provided from the animal house of King Saud University.  Animals were housed in 
polypropylene cages in an animal facility with a 12 h light-dark cycle and controlled 
temperature and humidity. The rats were given free access to water ad libitum and fasten 
for 10 h before the study. Standard rat chow was given after 2 h of dosing for the duration 
of the study.  The rats were randomly divided into ten groups (I –X, n=6) and were dosed 
according to Table 3.5. 
  
 After dosing, blood samples (600 µl) were withdrawn from the venous-orbital 
plexus from each rat in heparinized tubes. Blood samples from the same rats were collected 
at 0, 1, 3, 6, 12 and 0.5, 2, 4, 8, 24 h after drug administration in two different occasions, 
separated by 3 weeks.  The animals were slightly anesthetized with carbon dioxide during 
blood sampling. Plasma samples were separated by centrifugation at 4000 rpm for 15 min 
and were stored at -20
o
C prior to drug assay.  
3.5. LC MS/MS Chromatographic system and conditions 
Analysis was carried out on a Waters Acquity UPLC
TM
 system with the components 
listed in Table 3.6. For chromatographic conditions’ optimization, different mobile phases 
were examined at different pH using a variety of columns.  AmB has two pKa values, a 
basic pKa (8.12) due to amino group at position 48 and acidic pka (3.72) due to an acidic 
group at position 15 (Figure 1.25). Therefore, a pH of 3.0±0.2, was suitable for keeping 
AmB in one ionic state for mass analysis.  Ammonium formate was selected to avoid 
overloading of ionization source with buffer (Deshpande et al., 2010). The gradient elution 
for LC MS/MS analysis consisted of two solvent compositions: Solvent A: Methanol: 
Acetonitrile (50:50, v/v) containing 0.1% formic acid and solvent B: 10 mM ammonium 
formate (pH 3±0.2), containing 0.2% formic acid and 1% acetonitrile.  The gradient began 
with 35.0% eluent A and increased to 90% and over 2.0 min prior to return to 35.0% A at 
2.7 min.  Throughout the process, the flow rate was set at 0.3 ml/min at the start of the run 
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and increased to 0.4 ml/min within 2 min, returning to 0.3 ml/min at 2.7 min.  The total run 
time was 3.2 min.  Data were collected in multi-channel analysis (MCA) mode.  
The LC MS/MS was connected to a triple quadropole tandem-mass detector, with 
an electrometry ionization (ESI) source for mass spectroscopy detection. The ESI source 
was set in positive ion mode and quantification was performed using multi-reaction 
monitoring (MRM) mode for the most suitable mass transitions. The optimal mass 
spectrometry parameters are listed in Table 3.6 Most prominent and stable fragments for 
AmB and internal standard (IS), with scan time of 0.10 s per transition. The optimized 
collision energy for AmB and IS were 15 and 37 eV, respectively. 
Table 3.6. Setting for LC MS/MS detection of Amphotericin B 
Source (ESI +) and Analyzer Settings 
Capillary voltage (kv) 3.5 
Cone voltage (v) 15 
Extractor (v) 2.0 
Radio frequency lens (v) 0.10 
Source temperature (C)  115 
Desolvation temperature (C) 400 
Cone gas flow (L/h) 6 
Desolvation gas flow (L/h) 800 
Collision energy (eV) 15 
Collision gas flow (ml/min) 0.25 
3.6. Preparation of Amphotericin B Standards and Quality Control 
All solutions of AmB were stored in polypropylene vials to minimize adsorption of 
AmB to glass (Lee et al., 2001).  Stock standard solution of AmB was prepared in 
methanol: DMSO (9:1, v/v) at a concentration of 0.2 mg/ml and stored in 4.0 ml plastic 
vials at −20 oC covered with aluminum foil to protect AmB from light.  For IS stock 
solution, 5.0 mg was dissolved in 10 ml methanol and stored at −20 oC in 3 of 4 mL amber 
vials.  Different working standard solutions of AmB (100-4000 ng/ml) and the IS 
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(1.5µg/ml) were prepared by dilution of the above mentioned stock solutions with pure 
methanol and were kept at −20 oC.   
3.6.1. Plasma Sample Preparation 
The plasma calibrations standards were prepared in six replicates at different 
concentrations between 100 - 4000 ng/ml in a 1.8 ml Eppendorf tube. Blank Rat plasma 
was withdrawn from healthy rats by cardiac puncture in the laboratory.  This technique 
were done in the presence of a veterinary technician who will be able to assess that 
animals are handled properly and are not subjected to unnecessary pain and/or 
distress.  Blank rat plasma (250 µl) was spiked with aliquots of AmB working solutions 
and 20 µl (30 ng) of the IS. Low, medium and high concentration quality control (QC) 
samples at concentrations of 100, 1000 and 4000 ng/ml of AmB with 120 ng/ml of IS.  The 
prepared plasma samples were subjected to protein precipitation by the addition of 1 ml of 
methanol; the mixture was vortexed at high speed for 1 min followed by centrifugation at 
20,000 rpm for 15 min at 10 
0
C.  The supernatant was transferred into a clean 5 ml Pyrex 
glass tube and evaporated to dryness under a gentle stream of nitrogen. The residue was 
reconstituted in 150 µl of 90% methanol solution. After vortexing for 1 min, centrifuging at 
4000 rpm for 4.0 min, and transferring into a plastic autosampler vial with pre-slit septum 
(Waters, USA) 2.0 µl were injected into the LC MS/MS system for analysis. 
 
3.6.2. Ion Suppression Study 
The absence of ion suppression was demonstrated by the method of Matuszewski et 
al. (1998). Six different formulations of drug-free and IS-free rat’s plasma were extracted. 
The extracts were reconstituted with AmB at three nominal concentrations 100, 1000, and 
4000 ng/ml (low, medium, high). The peak areas of the samples were compared to that of 
the unextracted reference standard solutions containing the equivalent nominal amount of 
AmB in the mobile phase (n = 6). The mean area ratios (reconstituted extracts/reference 
solutions) were 0.95 for AmB with R.S.D. of < 3.9%. Thus, no ion-suppression was 
observed. 
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3.7. Method Validation 
Selective and sensitive analytical methods for the quantitative evaluation of drugs 
and their metabolites are critical for the successful conduct of preclinical and/or 
biopharmaceutical and clinical studies.  Bioanalytical method validation includes all of the 
procedures that demonstrate that a particular method used for quantitative measurement of 
analyte in a given biological matrix, such as blood, plasma, serum or urine, is reliable and 
reproducible for the intended use.  The developed method was validated in regards of 
selectivity, linearity, precision, accuracy, carry over, extraction recovery and stability in 
accordance with FDA guidelines and United State Pharmacopeia XXX III (Administration, 
2007). 
The selectivity of an analytical method is its ability to measure accurately an analyte 
in the presence of endogenous compounds. Therefore, six blank, drug-free, plasma samples 
obtained from six rats were analyzed according to the procedure described above. The 
corresponding chromatograms were tested for possible interferences at the retention times 
of AmB and the IS. 
The specificity of the method was investigated by comparing the chromatogram of 
blank plasma spiked with standard solutions to the samples collected from rats after AmB 
administration. 
Intra-day precision and accuracy were determined within one day by analyzing six 
replicates of the QC samples at concentrations of 100, 1000, and 4000ng/ml of AmB.   The 
inter-day precision and accuracy were determined on three separate days. The intra- and 
inter-day precision were defined as the relative standard deviation (R.S.D. %). The 
accuracy was presented as percent relative error, R.E. [(measured concentration−nominal 
spiked concentration)/ nominal spiked concentration] ×100. Extraction efficiency was 
determined for the QC samples at the three concentrations levels (low, medium, high) with 
those of post-extraction spiked blank plasma samples for AmB concentrations. The 
absolute extraction recoveries were calculated by comparing the peak areas of the samples 
to that of the unextracted standard solutions containing the equivalent amount of AmB (n = 
6).  The nominal value of AmB concentration (ng/ml) in plasma was plotted as a function 
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of the peak area ratio obtained of AmB and the IS. The day curve was accepted, if the 
R.S.D. % was <20% for all the tested concentrations (low, medium and high).  
The limit of detection (LOD) was defined as the lowest concentration of the analyte 
resulting in a signal-to-noise (S: N) ratio of >5:1. The lower limit of quantitation (LLOQ) 
was defined as the lowest drug concentration of the analyte resulting in an S: N ratio >10 
which can be determined with a R.S.D. <20% and an accuracy of 100±20% on a day-to-day 
basis.  
Accuracy and precision at the LLOQ were estimated. The robustness of the method 
was determined, by using two different Acquity HUPLC
TM
BEH RP18, 1.7µm column, 2.1 
mm x 50 mm (Waters Corp, Milford, MA, USA). 
3.8. Stability 
Drug stability in a biological fluid can be affected by the storage conditions, the 
chemical properties of the drug and the container used. Stability measures should assess the 
stability of the analytes throughout sample collection and management, after short-term in 
autosampler waiting for analysis, and after going through freeze and thaw cycles during the 
analytical process. Stock solutions of the analyte for stability assessment should be 
prepared in an appropriate solvent at known concentrations. 
Freeze–thaw stability of the plasma samples were evaluated by exposing plasma 
extracted samples to freeze (−20 0C) – thaw (room temperature) cycles immediately after 
reconstitution, after 0, 3,7 and 14 days of storage at -20 
0
C of the processed samples. The 
stability of the processed samples in autosampler was also evaluated by keeping the sealed, 
with parafilm, samples in the autosampler condition at 10 
0
C for 72 h.  The samples were 
analyzed at 0, 24, 48 and 72 h. 
AmB was also subjected to a drastic conditions, in amber volumetric glass by 
diluting it in water, 1M solution of NaOH and 2N HCL solution (n=6) and AmB area under 
the peak (AUP) was measured as the zero AUP.   Each solution was carefully heated to 
boiling and left to cool down and the AUP of AmB after boiling was measured.    
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3.9. Data and Statistical Analysis 
All data in this study were expressed either as the mean ± SD of six replicates for 
the assay or seven replicates for the rats study.  The standard curves were calculated by 
linear regression without weighting, using the equation Y = 0.0007X – 0.127, where Y is 
the AUP ratio of the drug to the IS, – 0.127 is the intercept, 0.0007 is the slope, and X is 
AmB concentration. The RSD was calculated for all values. 
The plasma AmB concentration vs time data of the rats were analyzed using a 
model-independent method for the main purpose of this study (Gibaldi and Perrier, 1982, 
Preacher et al., 2006). The mean maximum concentration (Cmax) and the time to reach Cmax 
(Tmax) were derived directly from the individual plasma levels.   
The elimination rate constant (k) was calculated from the slope of the regression line that 
best fit the terminal part (last three or four points) of the log–linear concentration–time 
profile of AmB. The terminal half-life (t1/2) was calculated from 0.693/k.  The area under 
the curve from time 0 to 24 h (AUC0–24) was estimated by linear trapezoidal rule and was 
extrapolated to time infinity (AUC) by the addition of Cn/k where, Cn is concentration of 
the last measured plasma sample.   The total body clearance (Cl) was estimated using the 
equation Cl=dose/AUC. The volume of distribution (V) was determined from the equation 
k = Cl/V.  For oral data, the absorption rate constant ka was estimated by the method of 
residual(Tozer and Rowland, 2006).  The absolute bioavailability (F) was calculated by the 
equation (AUCpo/Dosepo) / (AUCiv/Doseiv) after the iv of F1 and oral administration of the 
tested formulations, while the relative bioavailability (Frel) was calculated using (AUCPO 
formulation / (AUCF1-PO) or Frel to Fungizone using (AUCPO formulation / (AUCFungizone-PO).  
The student t-test was used to examine the concentration difference at each day, and 
one-way analysis of variance (ANOVA) was employed to evaluate the reproducibility of 
the assay.  Other tests were used using IBM SPSS Statistics 21. A P value < 0.05 was 
considered significant.   
All statistical differences in data were evaluated using IBM SPSS Statistics 21.  The 
Student t-test was used to examine the concentration difference at each day and one-way 
analysis of variance (ANOVA) was employed to assess the reproducibility of the assay and 
other tests were used when needed.   P< 0.05 was considered significant. 
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3.10. Results and Discussion 
3.10.1. Liquid Chromatography Assay of AmB 
Mass spectroscopy (MS) parameters were optimized for selectivity and sensitivity 
in positive ion mode. Both the analyte and internal standard (IS) have ability to accept 
protons and generate [M+H]+ ions. Protonated parent ions for AmB and IS quantification 
were achieved using MRM of the transitions of m/z 925.1 ± 1.2742.3 ± 0.9 for AmB and 
m/z 321.8 ±0.5 →155 ±0.6 for IS (Figure3.1). 
 
 
Figure 3.1.  MS/MS ion spectra fragments of amphotericin B  
 
Figure 3.2 is a representative chromatograms of AmB and IS after extraction of 
plasma samples.  The chromatogram of blank rats plasma is shown in Figure 3.2, A1 and 
the MRM of AmB and IS are in A2; the MRM blank rat plasma spiked with the AmB at the 
LLOQ (100 ng/ml) and IS are shown in Figure 3.2 as B1 and B2 respectively The retention 
times of AmB and IS are 1.7 ±0.05 and 2.1± 0.04 min, respectively, showing proper 
separation.  The assay run time was 3.2 min which is the shortest among AmB published 
separation assays (Xiong et al., 2009, Deshpande et al., 2010).  During the 7 months of 
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validation, there was no significant change (P= 0.299) in the observed retention time of 
AmB or the IS (R.S.D. < 0.4 %).  
 
 
Figure 3.2.MRM transition of extracted chromatograms of blank rat plasma and its transition 
(A1 and A2) MRM transition of extracted chromatograms of standard spiked AmB in rat 
plasma at 250 ng/ml and IS and its transition (B1 and B2) 
 
Figure 3.2 is an indication of no endogenous plasma components eluted at the 
retention times of either AmB or the IS in any of the spiked blank plasma samples collected 
from different rats or pooled rats’ plasma, which proves the assay specificity.  
Excellent separation between AmB and IS, minimal background baseline noise was 
obtained as shown in Figures 3.2.  It was also observed that the representative 
chromatogram of rat plasma samples showed similar chromatographic behavior to spike or 
quality control samples which is another proof of good assay selectivity. 
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The LOD of this assay was 50 ng/ml in rats plasma with the corresponding R.S.D. 
% of about 20 % at a signal-to-noise ratio of >5 while, the LLOQ was 100 ng/ml at a 
signal-to-noise ratio of >10, with the corresponding R.S.D. of about 14 % at injection 
volume of 2.0 µl. The peaks of AmB and IS are well resolved and LLOQ was sensitive 
enough to detect AmB at all sample time points used. 
 
Figure 3.3.Standard calibration curve of amphotericin B 
 
Excellent linear relationships (Y=0.0007X - 0.12) with R
2
> 0.994 (Figure 3.3) was 
demonstrated between AUP ratio of AmB to the IS in rats plasma over the studied 
concentration ranges.  The mean R
2
 was > 0.99 and the R.S.D. % of the slopes of the three 
standard plots was <13.3%.  Analysis of variance of the data (n=18) indicated no 
significant difference (P > 0.05) in the slopes, intra- and inter-day, of the calibration curves. 
The results confirmed the reproducibility of the assay method. 
 The mean percentage recovery of AmB was 93.7 ± 7.2 with R.S.D. of ≤ 10%.  
There was no significant difference (P > 0.05) in the extraction efficacy of the present assay 
over the range of concentrations studied. The accuracy and precision results are shown in 
Table 3.7.  Precision is represented as R.S.D. % and accuracy was calculated as relative 
error (R.E. %).  The intra-run and inter-run precision (R.S.D. %) was <13% and accuracy 
y = 0.0007x - 0.1266 
R² = 0.9943 
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as R.E. was < 8%.  There was no evidence of sample carry-over from run to run. In 
addition, the matrix effect assessed by spiking samples post-processing showed R.S.D. < 
8% difference from spiked injection solvent.  
Table 3.7.   Inter- and Intra-day statistics 
Measured 
concentration  (ng/ml) 
Day 1 98 970 4126 
 
 106 991 3974 
  110 955 4140 
  97 985 3960 
   111 1010 4148 
  99 970 3874 
 Day 2 111 980 4100 
  101 992 3970 
   94 900 4020 
  98 1250 3992 
   103 1130 3900 
  105 980 4080 
 Day 3 99 1100 3950 
  101 1050 4020 
   106 1040 4150 
  110 1045 4090 
   107 995 4020 
  98 980 3950 
Intra-day 
(on day3)  N 6 6 6 
 Mean 103 1017.9 4025.8 
 SD 5.4 78.7 86.7 
 Accuracy (RSD %) 5.2 7.7 2.1 
 Recovery (%) 97 100.7 100.7 
 Recovery (RSD %) 8.2  
7.3 
 5.2 
Inter-day statistics n 6 6 6 
 Mean 103.5 1035 4030 
 SD 4.85 42.9 78.7 
 Accuracy (RSD %) 4.7 4.1 1.9 
 
 
Recovery (%) 97.8 100.4 99.7 
 Recovery (RSD 
%) 
7.3 9.8 7.8 
 
Recovery (RSD %) 7.3 9.8 7.8 
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Figure 3.4 shows that AmB was stable in the processed samples held in the 
autosampler at 10 
0
C for 24 h with mean calculated values within 6.7% of the nominal 
concentration. However, the samples lost 67.3% (R.S.D. of 7.9%) of its nominal 
concentration within three days if stored protected from light in the autosampler.  
Therefore, it is not recommended to keep AmB in the autosampler more than overnight 
analysis to ensure reproducibility of the assay.  The freeze-thaw temperature cycles did not 
significantly (P>0.05) affect the stability of AmB in first cycle, after 72 h, with the mean 
calculated values within 2.3% of the nominal concentration. While after the third cycle, 
42% of AmB was lost with R.S.D. of 5.6%.  Unexpectedly, exposing AmB to drastic 
conditions revealed that AmB is stable in 2N HCl solution even after boiling, losing only 
5.7% (R.S.D. of 7.3%) of its nominal value.  In the meantime, both water and 1N NaOH 
showed complete loss of AmB even without boiling for all tested samples (n=6).  
Therefore, the use of small volume of 2N HCl (200 µL) to solubilize it in the preparation of 
its formulations was not significant to affect its stability as was mentioned in literature of 
its instability in acidic medium. 
 
 
Figure 3.4.  Stability of Amphotericin in autosampler and after freezing –thawing cycles 
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3.10.2. Amphotericin-B Pharmacokinetics in Rats 
Novel oral biodegradable stealth polymeric nanoparticles of AmB have been 
successfully fabricated by an emulsification diffusion method using PLGA-PEG Diblock 
copolymer. Drug loaded to PLGA-PEG NPs has been previously in vitro characterized in 
Chapter II. Rats were used in this study since it is an appropriate animal model to 
investigate the GI absorption due to the similarities in intestinal characteristics between rats 
and humans (Risovic et al., 2003). 
The hypothesis that loading AmB to PLGA-PEG diblock copolymer would 
significantly improve its GI tract absorption without increasing its induction of 
nephrotoxicity was the driving force of developing AmB oral formulation. 
Nowadays, PLGA-PEG and PLA-PEG-PLA were being used to improve the release 
rate of different classes of drugs from NPs systems intended for both parenteral (Allémann 
et al., 1998, Huh et al., 2003, Packhaeuser et al., 2004, Cheng et al., 2007, Saadati and 
Dadashzadeh, 2014, Teekamp et al., 2015) and oral administrations (Yoo and Park, 2001, 
Garinot et al., 2007, Fernandez-Carballido et al., 2008, Khalil et al., 2013, Yan et al., 2015). 
Figure 3.5 shows the semi-logarithmic mean plasma concentration–time profiles of 
AmB following F1 formulation, single dose study, given as 1.0 mg/kg (F1-iv) and 10 
mg/kg (F1-PO) to two different groups of rats via iv and PO administrations, respectively.  
Fungizone
®
, 10 mg/kg was given to the third group of rats via PO administrations 
(Fungizone
®
-PO) which was used for comparison.  After iv administration, a two 
compartment open model seems adequately describes the kinetics of AmB in rat plasma 
with a fast distribution, over the first 4 h, followed by slow elimination. A similar 
disposition model of AmB was previously described in rats after iv and PO administrations 
(Robbie, 1998, Echevarría et al., 2000).  However, a model-independent method was used 
instead for the main purpose of this study and for simplicity (Eldem et al., 2001, Brime et 
al., 2003, Gershkovich et al., 2009).  The pharmacokinetic parameters of AmB after the 
administrations of F1-iv, F1-PO and Fungizone®-PO in rats are summarized in Table 3.8. 
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Figure 3.5. Semi-logarithmic plasma AmB concentration-time profiles (mean ± SD) after 
intravenous administration of Fungizone® and F1-iv at dose of 1.0 mg/kg and after oral 
administration of C6-PO at dose of 10 mg/kg to rats (n=6). 
 
Table 3.8. Pharmacokinetic parameters of Amphotericin B after iv and oral administrations of 
AmB -Loaded PLGA-PEG formulations and Fungizone in rats (n=6) 
Tested Parameters F1-iv 
 
F1-PO Fungizone
®
-PO 
Dose, mg/kg 
 
1 10 10 
Cmax, ng/mL - 480.2± 38.7 298.2± 28 
AUC0- 
(µg.h/l) 
84211.2 ± 33935 12325.1 ± 1511.3 9836.3 ± 1654.1 
k (h
-1
) 0.0208 ± 0.0084 0.0298 ± 0.0060 0.0019 ± 0.0015 
Cl (ml/h/kg) 13.8 ± 6.1   
t1/2 (h) 38.1 ± 14.8 24.0 ± 4.4 35.3 ± 2.6 
V (ml/kg) 666.1 ± 109.7   
F - 0.0.0145 0.0115 
Frel Fungizone - 1.25  
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After iv administration of F1-iv, AmB shows a relatively long elimination t1/2 
ranged from one to two days in rats due to its low Cl (8 to 23.2 ml/h/kg) and Large 
apparent volume of distribution in the range of 552.7 to 806.3 ml/kg.Although the iv dose 
was one tenth the PO doses of either F1-PO or Fungizone
®
-PO, F1-iv shows a pronounced 
higher plasma concentrations of AmB (P<0.05).  This could be attributed to either 
incomplete absorption of AmB or the drug is subjected to a significant first pass in the 
liver.   A statistically significant higher Cmax of AmB was observed following F1-PO than 
that after following Fungizone
®
-PO administrations. The observed mean plasma AUC0-
24hand AUC0-∞ afterF1-PO were about 63.7% and 36.4%, respectively, higher than that of 
Fungizone
®
-PO.  The bioavailability (F) of F1-PO was 36.4% higher than that of 
Funzizone
®
-PO due to the improvement of AmB release when loaded to PLGA-PEG 
diblock but the results were not satisfactory. 
Several literatures show that AmB polymeric nanoparticles formulations, have 
proved antifungal efficacy and lower toxicity with increase accessibility of the drug to 
organs and targeted tissue (Amaral et al., 2009, Laniado-Laborín and Cabrales-Vargas, 
2009, Souza et al., 2015).  It was also reported that some carriers added during the 
formulation process  affect the aggregation state and hence AMB activity(Legrand et al., 
1992). Barwicz etal. have demonstrated the ability of surfactants to reduce the toxicity of 
AMB via decreasing the aggregation state of the drug (Barwicz et al., 1992, Adams and 
Kwon, 2003). 
Currently, PLGA and PLGA-PEG are being used to improve the release rate of 
different classes of drugs from NPs systems intended for both parenteral (Allémann et al., 
1998, Huh et al., 2003, Packhaeuser et al., 2004, Cheng et al., 2007, Saadati and 
Dadashzadeh, 2014, Teekamp et al., 2015) and oral administrations (Yoo and Park, 2001, 
Garinot et al., 2007, Fernandez-Carballido et al., 2008, Khalil et al., 2013, Yan et al., 
2015).The ability of PLGA-PEG to enhance bioavailability of hydrophobic drugs, have 
been demonstrated for different classes of drugs. Curcumin potential efficacy is limited by 
its lack of solubility in aqueous solvents and poor oral bioavailability. PLGA–PEG NPs 
were able to increase curcumin bioavailability by 3.5-fold compared to curcumin loaded 
PLGA NPs alone (Anand et al., 2010). While insulin-loaded PLGA–PEG NPs show pH 
sensitivity. There were large extent of insulin released from NPs in intestine and fewer in 
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gastric; thus, copolymer has ability to protect insulin from enzymes in the gastric 
environment (Hosseininasab et al., 2014).Moreover, loading AmB to non PEGylated 
polymer (poly(D,L-lactide), R 203 H), showed no absorption of AmB at all time points. This 
is a confirmation of the importance of the PEG in PLGA polymer to promote the absorption 
of AmB after PO administration. 
GA and its derivatives have been utilized in enhancing drug absorption (Tanaka et 
al., 1992, Anand et al., 2010, Imai et al., 1999, Cho et al., 2004, Radwan and Aboul-Enein, 
2002).  Significant enhanced rectal absorption of AmB suppositories in rabbits following 
GA addition in comparison to formulation containing no GA  (Tanaka et al., 1992, Anand 
et al., 2010).  Insulin nasal spray formulations for nasal delivery containing GA showed 
improve bioavailability (Khalil et al., 2013).  Additionally oral delivery of heparin is 
achieved by addition of GA (Motlekar et al., 2006). 
To investigate the effect of GA as an absorption enhancer, F1 and F2 were given to 
rats with GA, added just prior to administration or were included in the organic phase 
during AmB loaded to PLGA-PEG NP preparation.  AmB mean plasma concentration-time 
profile after single oral doses of AmB-loaded PLGA-PEG formulations with and without 
the addition of the absorption enhancer GA are depicted in Figure 3.6 and the 
pharmacokinetic parameters are presented in Table 3.9.   
Cmax after F1 without GA was 1.6 times that after Fungizone (P<0.05). A significant 
increase (P<0.05) in AmB Cmax (2.3 fold) with 4.3 fold increase in AUC (332.3%) were 
observed after addition of 1% of GA to the PO formulations, just prior to administration. 
This is an indication of the efficiency of GA as an absorption enhancer for AmB.  The  
Increasing the GA content from 1% (F2-GA-out-1) to 2 % (F2-GA-out-2), showed a 
significant increase (P <0.05) in Cmax (2.97 fold) and in AUC (390.7%) compared to F1 
formulation without GA.  Further increase in GA content to 3% showed no significant 
change in either Cmax or AUC of AmB profile, data not shown. Therefore, GA at 2% was 
selected as the optimum amount to be added to the rest of tested formulations. 
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Figure 3.6. Mean plasma AmB concentration-time profiles (mean ± SD) following single 
oraladministration of 10.0 mg/kg of AmB-loaded PLGA-PEG formulations in rats (n=6).  
 
Table 3.9.Pharmacokinetic parameters of Amphotericin B after a 10 mg/kg siingle oral 
administration of AMB as Fungizone® and AMB-Loaded PLGA-PEG NP formulations in rats (n=6). 
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Time (h) 
F3-GA-in-2 F1-PO F2-GA-out-1 F2-GA-out-2
F2-GA-in-2 F3-GA-in-2 F3-GA-out-2
Parameters F1-PO 
F1-GA-
out-1 
F1-
GA-
out-2 
F1-GA-
in-2 
F2-GA-
in-2 
F2-GA-
out-2 
Fungizone
®
-
PO 
AUC 
(µg.h/l) 
12325.
1 
±1511 
53287.0 
± 24997 
60478.
8 
± 7437 
88307.9 
±36092 
120689.8 
± 30628 
108366.9 
± 19736 
9836.3 
± 1654 
Cmax 
(ng/ml) 
480.2 
± 38.7 
1115.0 
± 172 
1426.3 
± 133 
1239.4 
± 75 
2387.2 
± 294 
2147.2 
± 176 
298.2 
± 28 
ka, /h 
0.994±
0.196 
0.72±0.3
5 
1.244±
0.513 
1.684±1.
374 
1.68±1.1
5 
1.35±0.38 0.904±0.0.72 
t1/2 (h) 
24.0 
± 4.4 
34.6 
± 15.1 
36.0 
± 5.5 
42.7 
± 4.2 
41.3 
± 11.5 
37.1 
± 6.5 
35.3 
± 2.6 
Mean F 0.015 0.063 0.072 0.105 0.072 0.064 0.117 
Mean Frel, F1 - 4.3 4.9 7.2 4.9 4.4 0.8 
Mean Frel, Fungizone 1.3 5.4 6.1 9.0 6.1 5.5 - 
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It was noticed that the addition of GA during preparation process (F2-GA-in) or just 
prior to administration (F2-GA-out) showed no significant difference (P > 0.05) in the 
AUC(13.5%), with a 27.9% increase in the Cmax value.  This is an indication that the 
efficacy of GA as an absorption enhancer for AmB is not changed either GA added just 
prior to administration or during the preparation.   
Increasing the amount of the AmB inside the formulation from 20 to 40 mg (F3-GA-
in-2 and F3-GA-out-2) did not showed any significant increase in the AUC after amount 
normalization comparing to F2 formulations. Therefore, within the tested amount in the 
formulation, AmB shows linear kinetic.   
It should be mentioned that for each  tested formulation the value of ka was much 
greater than the value of k which indicates a fast release of AmB with no sign of the flip-
flop’ model (Gibaldi and Perrier, 1982). The highest ka among the tested formulations was 
F1-GA-in compare to the others. Therefore, the addition of GA during preparation of F1 
resulted in higher release of AmB.  
The absolute bioavailability (F) of AmB from tested AmB loaded to PLGA-PEG 
NP formulation was calculated, Table 3.10.  Upon the addition of 2% GA during the 
formulations, the F was improved from 1.5 to 10.5% (600 folds).  The Frel was improved 
from 332 to 616.5% and 25 to 800% after the addition of GA compared to F1-PO and 
Fungizone

, respectively.  The highest improvement in Frel was detected in formulation F1-
GA-in-2. 
Table 3.10. Bioavailability of AmB in rats after Fungizone® PO administration in comparison to 
different novel AmB-loaded NPs administered intravenously and orally in different doses 
Reference 
Formulation 
/Polymer 
Dose of  
Fungizone, 
mg/kg  
AmB Dose in 
tested 
Formulation, 
mg/kg 
Frel 
to Fungizone % 
Current 
study 
Copolymer 
(PLGA-PEG) 
10 10 798 
(Yang et al., 
2012) 
Cubosomes 
10 10 285 
10 20 702 
(Italia et al., 
2009) 
PLGA 10 10 693 
(Sachs-
Barrable et al., 
2008) 
Peceol/AmB 
50 50 2197 
50 5 8506 
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3.11. Conclusion 
A simple, rapid and sensitive analytical assay was developed and validated for the 
analysis of AmB in rat’s plasma.  One of the advantages of this method is the use of a 
plasma protein precipitation procedure for sample preparation, which is less expensive than 
solid phase extraction, less time consuming and more environmentally friendly than liquid 
extraction since a lot of organic solvent has to be evaporated. Moreover, the method 
requires considerably less plasma, which is important for pharmacokinetic studies 
involving repeated blood sampling. The chromatographic runtime is also short.  Therefore, 
the developed bioanalytical method can be reliably employed as an assay method for 
pharmacokinetic study of any dosage form containing AmB in rats or human. 
In conclusion, employing PEGylated Diblock copolymer (PLGA-PEG) is crucial 
for improving the oral absorption of AmB over the presence of sodium deoxycholate as in 
Fungizone. These polymeric NPs has the ability to cross the mucosal barrier by potential 
endocytic uptake mechanisms thus could enhance lymphatic transport of AmB in the 
particulate form.   In the meantime, the addition of GA 2% to the AmB loaded to PLGA-
PEG shows a tremendous improvement of AmB oral absorption by > 790 % than 
Fungizone.  It should be notice that there is no significant difference when adding the GA 
inside “during” preparation or outside “just prior” to PO administration.  
The amount of AmB could be increased up to 40 mg per patch without affecting the 
stability of the drug. Therefore, in this study an innovative AmB oral formulation was 
developed which would improve the patient adherence with potential reduction of adverse 
effect due to the only route (iv) AmB administration. 
Limitation of this study, this study was a single-dose study in a small number of 
rats. A repeated dose pharmacokinetic study, to maintained AmB levels at steady state, is 
required to design the best dosage regimen for patients.  Although individual variation was 
typical for pharmacokinetic studies, the small sample size is certainly an important 
however; statistical significance was reached in many of the pharmacokinetic endpoints for 
the iv vs. PO comparisons. 
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Chapter IV. In Vitro and In Vivo Cytotoxicity Monitoring of 
Amphotericin- B Loaded to PLGA-PEG Copolymer 
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4.1. Introduction 
Fungal infections due to the fungi Candida and Aspergillus are associated with 
morbidity and mortality in immune compromised individuals and prolonged 
hospitalization.  
 Rapid treatment with AmB or fluconazole is required to reduce the death rate 
observed in these patients(Espuelas et al., 2003).Severe side effects associated with the 
administration of its water soluble intravenous (iv) formulation, Fungizone

, such as 
nephrotoxicity, have restricted the clinical uses of AmB.  AmB-associated nephrotoxicity 
can be classified as glomerular or tubular. The clinical and laboratory manifestations of 
glomerular toxicity include decreases in renal blood flow and glomerular filtration rate. 
Tubular toxicity is manifested by the presence of urinary casts, hypokalemia 
hypomagnesemia, renal tubular acidosis and nephrocalcinosis (Torrado et al., 2008, 
Chuealee et al., 2011, Burgess and Birchall, 1972). 
The anti-fungal activity and anti-leishmanial effect of AmB is correlate to an ion 
channel model, where AmB forms a stable ion channel in the presence of ergosterol found 
in the fungal cell membrane (De Kruijff and Demel, 1974, Gruszecki et al., 2003, 
Yamamoto et al., 2015). The higher selectivity for ergosterol over the mammal 
counterpart, cholesterol, is thought to account for its pharmacological activity. Recently, 
another mechanism called the ‘AmB sponge model’ has also been proposed, in which 
AmB is thought to extract ergosterol from the fungal membrane to form extra-
membranous aggregates (Anderson et al., 2014, Yamamoto et al., 2015). 
AmB toxicity is mainly associated with its binding to the phospholipid bilayer, 
specifically ergosterol and cholesterol, present in fungal and mammalian cells 
respectively. AmB interacts with these components of the cell membrane and forms ion 
channels. These ion channels disrupt membrane functions increasing cell membrane 
permeability leading to loss of cell viability by leakage, first of ions, then other cellular 
contents. A schematic presentation of the interaction between AmB and phospholipid 
bilayers is shown in Figure 4.1.  The selective toxicity of AmB is mainly due to its greater 
affinity towards ergosterol forming larger channel pore sizes than in cholesterol-containing 
membranes in mammalian cells (Brajtburg and Bolard, 1996, Matsuoka and Inoue, 2009). 
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Figure 4.1.Possible sites of Amphotericin atack against fungal cells (a) and mammalian cells 
(b)(Brajtburg and Bolard, 1996). 
 
AmB state (monomers or aggregates) affect its efficacy and toxicity, since 
monomers form are responsible for the therapeutic activity, on the other hand, the    
aggregates forms were  responsible for drug toxicity(Nishi et al., 2007). AmB interact with 
the sterols present in the membranes in different ways. In fact, AmB induces leakage of 
intracellular potassium through formation of self-associated AmB (oligomers) in the 
mammalian cholesterol containing membranes and toxicity in fungal cells related to the 
monomeric form of AmB binding to ergosterol(Brajtburg and Bolard, 1996).  
AmB deoxycholate (Fungizone
®
) related toxicity might be classified as acute or 
chronic. Acute or infusion-related toxicity is characterized by fever, chills, rigors, malaise, 
generalized aches, nausea, vomiting, and headache. Hypertension, hypotension, 
hypothermia and bradycardia are other reported infusion-related toxic effects of 
administration of AmB deoxycholate. 
Nephrotoxicity is the most serious chronic adverse effect of AmB; the serum 
creatinine concentration increases in more than 80% of patients receiving this drug(Sabra 
and Branch, 1990, Tonomura et al., 2009). Nephrotoxicity is defined in most studies as a 
doubling of baseline creatinine (Cr) levels (100% increase from the serum baseline) or 
greater than 2.5 mg/dl (Miller et al., 2004). The incidence of AmB nephrotoxicity is very 
high, varying in studies between 49% and 65%(Deray, 2002).  
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In the conventional solution formulation, the drug is present as micelles. As soon as 
the drug solution enters the bloodstream it separates from the micelles and leads to the 
toxic effects. The Development of three new lipid-based formulations in 1990that are 
clinically used(AmBisome

,Amphocil

, and Abelcet

)on the other hand, release AmB 
slowly, hence are less toxic (Clements Jr and Peacock Jr, 1990, Baginski et al., 2005, 
Torrado et al., 2008).It is retained in the monomer state (active form) and is incapable to 
form the aggregates state (toxic form), resulting in significant increase in AmB activity 
with lower toxicity. (Espuelas et al., 2003). AmB lipid formulation are available as 
parenteral therapy.  However, unpredictable pharmacokinetics, toxic effects at higher 
AmB doses, infusion-related reactions and high costs, have limited the benefit of these 
formulations in clinical settings(Falamarzian and Lavasanifar, 2010a).  
Additional studies  have shown that decrease in AmB toxicity was related to a drop 
in AmB anti-fungal activity (Espuelas et al., 2003). Several studies have shown that higher 
doses of new lipid formulation are needed to attain an equivalent effect of a small dose of 
Fungizone
® 
for fungal infection treatment. 
Alternative to AmB-lipid formulations, the nanostructure-based formulations, such 
polymeric NPs, have demonstrated in several literatures antifungal efficacy and lower 
toxicity, decrease in AmB dose and increase in the accessibility of the drug to organs and 
targeted tissue(Amaral et al., 2009, Laniado-Laborín and Cabrales-Vargas, 2009, Souza et 
al., 2015). Other researchers report that certain carrier vehicles added during the 
formulation process  affect the aggregation state and activity of AmB (Legrand et al., 
1992). Barwicz etal. demonstrated the ability of surfactants to reduce the toxicity of AmB 
via decreasing the aggregation state of the drug (Barwicz et al., 1992, Adams and Kwon, 
2003).  
Most new AmB drug delivery systems have been examined in the context of their 
use as antifungals. Those preparations that have been tested against Leishmania have 
shown variable results though none has proved more effective than the commercial 
formulation. The ideal delivery system would solubilize AmB, have low cytotoxicity and 
heamolytic activity towards cells, actively target macrophages, achieve co-localization 
with the Leishmania parasite and have high anti-leishmanial activity(Brajtburg and Bolard, 
1996). 
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Polymeric NPs to be a drug carrier, must be biocompatible and biodegradable, 
showing no toxic effects in vitro or in vivo(Gaucher et al., 2010, Kumari et al., 2010, Vilar 
et al., 2012). Moreover, PLGA-b-PEG copolymer, is able to form NPs easily, with well 
controllable size and good encapsulation efficiency (Locatelli and Franchini, 2012).  
It was hypothesized that conjugation of AmB to stealth PLGA-PEG copolymer will 
solubilized the drug and decreases the toxicity through slow release of the drug. The 
conjugation of the drug with PLGA-PEG copolymer might thus prevent its aggregation 
and thereby decrease its toxicity toward mammalian cells, while maintaining it in a 
monomeric form that favors  antifungal activity (Brajtburg and Bolard, 1996, Torrado et 
al., 2008).  Furthermore, it was further hypothesized that freeze dried formulations of 
AmB loaded PLGA-PEG could be reconstituted in water and retain therapeutic activity.   
In previous Chapters, non-lipid formulations of AmB utilizing nanotechnology 
through AmB loaded to PLGA-PEG copolymer were developed and characterized. Both in 
vitro and in vivo studies have demonstrated good results, increased solubility, improved 
bioavailability and higher drug loading was observed.  This Chapter will examine in more 
detail the toxicity of selected novel oral AmB –NPs formulations in  in vitro and in vivo 
studies. 
Toxicity has been evaluated by several tests; in vitro measuring of the hemolysis, in 
vitro measuring the antifungal activity,  in vitro analysis of the cell viability by MTT 
assay, and lastly by in vivo nephrotoxicity and histopathological evaluation were 
conducted in rats kidneys and liver.  Clinical chemistry parameters, such as blood urea 
nitrogen (BUN) and plasma creatinine (PCr) were also evaluated to determine the degree 
of toxicity of new developed AmB formulations. 
 
4.2. Materials and Apparatus 
4.2.1. Materials 
RPMI 1640 medium, Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine 
serum, penicillin and streptomycin were purchased from Gibco-BRL. Sabouraud Dextrose 
Agar (SDA) plates (RODAC™) obtained from BD Diagnostics. 
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All other chemicals were of analytical reagent grade, and solvents were of HPLC grade and 
were obtained from local commercial suppliers. 
4.3. Methods 
Novel oral formulations of AmB NPs were prepared by an emulsification diffusion 
method as previously described using stealth AmB loaded PLGA-PEG copolymer see 
Chapter II for more details. The drug amount in each formulation was 20 mg with the 
exception of C7 formulations which contained 40 mg of AmB.  The selected formulations 
listed in Table 4.1, were used in in vitro and in vivo toxicity investigations. 
 
Table 4.1.The composition of the selected formulations used in toxicity studies 
Formulation Carrier/ Polymer 
Fungizone® Colloidal dispersion of AmB and sodium deoxycholate 
A6 Diblock, PLGA–PEG 6000;  Lactic to glycolic acid ratio  (1:1) with 
10%PEG , 5000 Dalton molecular weight(RGPd 50105) 
B6 Triblock, PLGA–PEG 6000-PLGA;  Lactic to glycolic acid ratio  (1:1) 
with 10% PEG , 6000 Dalton molecular weight (RGPt 50106) 
C6 Diblock, PLGA-PEG (Lactic to glycolicacid ratio1:1 molar ratio)with 15% 
PEG; molecular weight 6000 Dalton RGPd 50155 
C7 Diblock, PLGA-PEG (Lactic to glycolicacid ratio1:1 molar ratio)with 15% 
PEG; molecular weight 6000 Dalton RGPd 50155 
D6 Diblock PLGA–PEG 6000;  Lactic to glycolic acid ratio  (1:1) with 5% PEG , 
5000 Dalton molecular weight RGPd 5055 
 
4.3.1. In vitro Assessment the Hemolytic  Activity of AmB 
In vitro hemolytic activity of AmB-loaded PLGA-PEG copolymer formulations 
were assessed using isolated rat red blood cells (RBCs) according to Jain and Kumar (Jain 
and Kumar, 2010). Briefly, blood from healthy Sprague-Dawley male rats (250-350 g) was 
collected by cardiac puncture (with technician aid from research center) under anesthesia 
directly in to heparinized blood collecting vials. The red blood cells (RBCs) were separated 
by centrifuging the whole blood at 3000 rpm for 15 minutes, and then discarded the 
supernatant. Thrice washed of the RBCs with isotonic phosphate buffer saline (PBS- 0.15 
M) at pH 7.4.  Then RBCs was dispersed in PBS to obtain 1% hematocrit. RBCs were used 
on the same day for further experiments. Subsequently, 1.0 ml of the RBCs suspension was 
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mixed in 1.0 ml of PBS containing 20, 50 and 100 µg/ml AmB equivalent formulation 
(Fungizone® and selected formulations of freeze-dried AmB-NPs;A6, B6, C6, C7 and D6) 
and incubated at 37
0
C in a shaking water bath at 100 rpm. The experiment was performed 
in triplicate. After 8 and 24 hours of incubation (Serrano et al., 2015), haemolysis was 
stopped by reducing the temperature to 0
0 
C and unlysed RBCs were removed by 
centrifugation for 10min at 3000 rpm. The supernatant was collected and the erythrocyte 
pellet was lysed with sterile distilled water then analyzed for the extent of haemolysis using 
a spectrophotometer set to 540 nm (the absorption maximum of haemoglobin). Control 
RBC (2 × 10
8
 cells per ml) incubated with PBS alone were used to estimate the total 
haemoglobin content. Results were expressed as a percentage of hemolysis as given in the 
following equation: 
% Hemolysis = [(AbsS− Abs0) / (Abs100− Abs0)]× 100 
Where AbsS is the absorbance of the sample, Abs0 is the average absorbance of the 
buffer; negative control, and Abs100 is the average absorbance of the lysed samples (in 
purified water; positive control).The remaining haemoglobin was calculated as a percentage 
of the total content. Results are given as the mean of one experiment representative of three 
experiments carried out with each concentration in triplicate. 
4.3.2. In vitro Antifungal Activity 
One yeast strains C. albicans was used for susceptibility testing. The minimum 
inhibitory concentrations (MICs) of AmB-loaded PLGA-PEG copolymer formulations 
(Fungizone® and selected formulations of freeze-dried AmB-NPs; A6, B6, C6, C7 and D6)  
were determined by broth dilution according to the National Committee for Clinical 
Laboratory Standard “NCCLS document M27-A,(Standards, 2002). Briefly, Candida 
albicans (ATCC 90028) cell suspensions of 1x 106 cells/ml were diluted 1:50 in RPMI-
1640 growth medium and 100 µl dispensed into a microliter tray containing a serial 
concentration of AmB 0.05-1.5 µg/ml. A solution of 5 mg/mL was prepared in DMSO for 
free AmB and in water for the selected created formulations AmB-NPs copolymer 
immediately before use. 
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The tray was then incubated for 24 and 48 hours at 37
0
C.  Yeast inoculation were 
cultures grown on Sabouraud Dextrose Agar (SDA) plates and inoculated into RPMI 1640 
broth medium to yield a final inoculum concentration of 10
4
 yeast cells/ml and checked by 
doing a viable colony count on SDA plates. Two wells containing drug-free medium and 
inoculum were used as controls. The inoculated plates were incubated at 35
0
C for 24 hours.  
The growth in each well was then estimated visually. The MIC was defined as the lowest 
drug concentration (MIC) that resulted in complete inhibition of visible growth. The MIC 
was recorded to be the lowest concentrations of the AmB that prevented visible growth of 
C. albicans and expressed in µg/ml. The end point was determined as the concentration to 
produce optically clear wells (MIC-0). 
 
4.3.3. In vitro Cell Viability and Cytotoxicity Assays 
All three cell lines (AR42J-B13,Jurkat and HL60) were grown at 37 
0
C in an 
humidified air atmosphere containing 5% CO2. 
AR42J-B13 Cells: Rat pancreatic cells that differentiate to hepatocyte cells, by 
adding 10 nM dexamethasone, many of the cells underwent a phenotypic alteration to a 
form referred to in the present paper as B-13/H cells, over a period of two weeks (Marek et 
al., 2003).Cells were cultured in low glucose Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS), 20 mM HEPES, and 5 mM 
NaHCO3. Cells were routinely cultured in T75 flasks (corning) at a cell density between 3-
9 x10
5
 /ml until required for specific experiments. 
Jurkat Cells; Human T cell lymphoblast. Jurkats are suspension cells routinely 
grown in Roswell Park Memorial Institute Medium: RPMI 1640 supplemented with 10% 
fetal bovine serum (FBS), 2mM glutamine and 10 U/ml of penicillin/streptomycin (all from 
sigma). Cells were routinely cultured in T75 flasks (corning) at a cell density between 3-9 
x10
5
 /ml until required for specific experiments. 
HL60 Cell; Human caucasian promyelocyctic leukemia cell line. Cultures were 
maintain in T75 flasks (corning) at a cell density between 1-9  x10
5
 /ml in RPMI 1640 with 
2 mM glutamine and 10-20% FBS until required for specific experiments. 
The MTT (3-(4,5dimethylthiazoly)-2,5-diphenyl-tetrazolium bromide) colorimetric 
assay, as developed by Mosmann 1983(Mosmann, 1983), and modified by Edmondson 
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1988(Edmondson et al., 1988), was employed to assess the cytotoxicity of the selected 
prepared novel oral AmB-loaded NPs (Fungizone® and selected formulations of freeze 
dried AmB-NPs; A6, B6, C6, C7 and D6) on the cell lines. Cells were seeded in 12 well 
plates at a density of 3 x 10
5 
cells per well, suspended in 1.0 ml medium. After incubation 
for 24 hours, cultures were treated with 125, 250 and 500, ng/µl and 100 µl culture medium 
alone (control), or with standard AmB or AmB-loaded PLGA-PEG copolymer selected 
formulations and incubated for another 2, 4, 6 and 24 hours.  The cells were then pelleted 
by centrifugation at 1000 rpm for 3.0 minutes and then supernatant discarded prior to re-
suspension in 0.5ml fresh medium without FBS (0.5 ml). The cells were then incubated 
with MTT through addition of 500 µg/ml of MTT and incubation for a further 2 hours at 
37
o
C and 5% CO2 in air. 800 µl of isopropranolol was then added to each well and the 
absorbance at 570 nm determined after 10 minutes incubation using a 96 well plate reader.  
The numbers of viable cell in the treated well were compared to those in the untreated well 
and estimated as % viability. 
 
4.3.4. In vivo Nephrotoxicity and Hepatotoxicity Study 
Nephrotoxicity studies were performed on male Sprague Drawly rats weighing 200-
300 g. The animals were housed under standard conditions of temperature (22 ±2 
0
C), light 
and dark cycle (12/12 hours). The animals were kept on standard pellet diet and water ad 
libitum. The animals were randomly divided into eight groups (n=3). Group-I was kept as 
control without any treatment; Group-II was treated with Fungizone® as a slow intravenous 
(iv) injection; Group-III received iv blank NP with no AmB; Group-IV received iv 
administration of A6; Group-V received iv administration of B6; Group-VI received iv 
administration of C6; Group-VII received iv administration of D6; Group-VIII received iv 
administration of C7. The iv Blood samples were withdrawn from the retro-orbital plexus 
and plasma was separated by centrifugation at 3,000 rpm for 15 min.  
A single dose experiment consisted of a single dose of AmB or its equivalents dose 
as 1.0 mg/kg of body weight from each of the selected AmB-NP formulations (Fungizone® 
and selected formulations of freeze dried AmB-NPs; A6, B6, C6, C7 and D6). The 7-days 
repeated dose experiment consisted groups that were dosed with 1.0 mg/kg body weight of 
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AmB from each formulation.  24 hours post-dose, blood samples were withdrawn from the 
retro-orbital plexus and plasma was prepared by centrifugation at 3000 rpm for 15 min.  
Blood urea nitrogen (BUN) and plasma creatinine (PCr) were measured using an automatic 
analyzer 7180 (Hitachi High-Technologies Co., Tokyo, Japan). Alkaline phosphatase (ALP 
IU/L), -glutamyltransferase (-GT, IU/L), alanine aminotransferase (ALT. IU/L) were 
determined Automatic analyzer 7180 (Hitachi High-Technologies Co., Tokyo, Japan). 
For histopathological analysis, one kidney from each rat was fixed in neutral 
buffered 10% formalin for ≥48 h, bisected and embedded in paraffin. Sections of 5.0 µm 
thickness were cut from each kidney, and stained with haematoxylin and eosin. For 
histopathological analysis of liver, a piece of median lobe from the livers were removed 
from each rats and placed immediately in 10% neutral buffered formalin. Sections of 5.0 
µm thickness were cut and stained with haematoxylin and eosin similarly to kidney tissue. 
 
4.3.5. Statistical Analysis 
The Student t-test was used to examine the difference and one-way analysis of 
variance (ANOVA) was employed to evaluate the reproducibility of the assay. Other tests 
were used using IBM SPSS Statistics 21. A p-value < 0.05 was considered significant. 
 
4.4. Results and Discussion 
4.4.1. In vitro Hemolysis Test 
AmB is it reported to be highly toxic in its aggregated state than in its monomer 
form (Brajtburg and Bolard, 1996, Nishi et al., 2007). In solution, AmB exists in three 
different forms; monomers, oligomers and aggregates. The soluble form of AmB exists in 
monomeric form (Brajtburg and Bolard, 1996, Nishi et al., 2007). 
The extent of AmB aggregation can be measured by the ratio of absorbance at 348 
nm to 409 nm (Legrand et al., 1992). Barwicz et al. (Barwicz et al., 1992) report the ratio to 
be 2 for aggregated species. Fungizone

 has a value of 2.9 (Mullen et al., 1997). For AmB-
loaded PLGA-PEG copolymer, the values obtained were less than 1.14 showing that AmB 
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was not aggregated in the novel oral formulation. Therefore, it is essential to measure the 
heamolytic toxicity for any new AmB formulation. 
The degree of hemolysis observed after incubation of RBCs with selected 
formulations (A6, B6, C6, D6 and C7) of AmB-NPs in comparison with Fungizone® is 
depicted in Figure 4.2.  After 8 h of incubation, the hemolysis rate was high (84%) with 
Fungizone® at 100 µg/ml and it was reduced to 43% at lower concentration of 20 µg/ml. 
Therefore, Fungizone® is likely to be toxic, even at the lowest concentration used in the 
experiment and it was higher than water since AmB lyses RBCs by active process of pore 
formation.  It was also noticed that the hemolysis was dose dependent.  At a similar 
concentration, AmB-loaded to the selected NPs formulations showed negligible hemolysis. 
Regarding the degree of hemolysis, the different tested formulations were classified as low 
hemolytic toxicity 4 to 8 times hemolysis reduction in comparison with Fungizone®, both 
C6 and C7 formulation showed the lowest hemolysis.  
The lower hemolysis observed for the AmB-loaded PLGA-PEG copolymer, perhaps 
reflects a better control over the rate of AmB diffusion from these selective formulation 
over the Fungizone
®
, indicating that the release of AmB from the PLGA-PEG copolymer is 
slow.  
The obtained hemolysis data for all  AmB-loaded PLGA-PEG copolymer, after 24 
hour incubation, showed similar results as after 8 hour incubation,  indicating that the 
releases of AmB from these formulations is slow.  
Fungizone® caused higher extent of hemolysis because Fungizone® formulation 
consist of micellar dispersion of AmB with sodium deoxycholate, which act as surfactant 
and can encourage hemolysis itself in addition to the hemolysis caused by AmB. 
Fungizone
®
   is acknowledged for causing hemolysis mostly due to pore formation altering 
electrolyte balance in erythrocytes (Yu et al., 1998, Fukui et al., 2003b, Bang et al., 2008, 
Nahar et al., 2008, Italia et al., 2009, Falamarzian and Lavasanifar, 2010a, Jain and Kumar, 
2010, Shao et al., 2010b, Sheikh et al., 2010, Asghari, 2011). 
The lack of hemolysis activity may be reflect the release of monomeric AmB from 
AmB-loaded PLGA-PEG Diblock copolymer as opposed to Fungizone
®
, which release 
both aggregated and monomeric forms of the drug (Yu et al., 1998, Adams and Kwon, 
2003, Brajtburg and Bolard, 1996). During formulation, to dissolve AmB in the polymer 
 
 
137 
 
phase, a very small aqueous solution for acidification was added for  2 N HCL, thus 
precluding self-association or aggregation.  
The results obtained therefore, indicates the protective effect of the PLGA-PEG 
Diblock copolymer in preventing the RBCs lysis of the formulations. 
 
 
Figure 4.2.In vitro RBCs haemolysis following incubation of RBC with Fungizone® and 
different AmB-NPs formulation at concentrations of 20, 50 and 100 µg/ml. Values represent 
mean ± SD (n=3). 
 
4.4.2. In vitro Antifungal Activity 
Table 4.2. shows the antimicrobial activity of pure AmB, Fungizone® and three 
selected formulations of AmB-loaded to PLGA-PEG Diblock copolymers in Candida 
albicans after 24 and 48 h incubations. The MIC-0 for pure AmB was 0.5 µg/ml after 24 h 
and 1.0 µg/ml after 48 h incubation. Similar results were obtained by different researchers 
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(Nishi et al., 2007).  Meanwhile, the MIC-0 for AmB-loaded to PLGA-PEG copolymer 
formulations was reduced ≥ 4-foldµg/ml. 
AmB at concentrations > 0.5-1  fold the MIC had a fungicidal activity, while AmB 
at concentrations < 0.5-1 fold the MIC had a  fungistatic activity, a finding that has been 
described previously by different groups of investigators (Tasset et al., 1992, Pfaller and 
Barry, 1994, Risovic et al., 2003, Belkherroubi-Sari et al., 2011). The MIC of AmB-
loaded PLGA-PEG copolymer against C. albicans was reduced 2-3 fold compared with 
free AmB (Table4.2).  This result indicates that developed AmB-NPs, have high 
therapeutic efficacy and are useful for the treatment of fungal infection including 
candidiasis. 
 
Table 4.2.Checkboard assay of amphotericin B against C. albicans 
 MIC-0 (µg/ml) after 24 h MIC-0 (µg/ml) after 48 h 
AmB 0.5 ± 0.01 1.0 ± 0.01 
Fungizone®  0.5 ± 0.01 1.0 ± 0.01 
A6 0.25 ± 0.01 0.25 ± 0.01 
B6 0.25 ± 0.01 0.25 ± 0.01  
C6 0.125 ± 0.01 0.125 ± 0.01  
D6 0.25 ± 0.01  0.25 ± 0.01 
C7 0.125 ± 0.01 0.125 ± 0.01 
 
4.4.3. In vitro Cell Viability and Cytotoxicity Assays 
The toxicities of AmB and the selected NPs formulations were tested in three cell 
lines (B-13/H, Jurkat and HL60) at different concentrations 125, 250 and 500 ng/ml tested 
after 2, 4, 6 and 24 h incubations. The Fungizone
® 
was toxic in all tested cells (B-13/H, 
Jurkat and HL60) since the cell viability was < 80% (Figure 4.3- 4.5).   These data showed 
variations in cell viability after testing different formulations, most of them were likely to 
be safe for the used cell lines, since in all cases > 80% of the three cell lines remained 
viable, even at 500 ng/ml. Moreover, these data showed a dose-dependent reduction in 
viability (with increasing the dose there is greater loss of viability). It can be concluded that 
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AmB-loaded to PLGA-PEG copolymer NPs of selected formulations were less toxic than 
the Fungizone
®
. 
This observation is also consistent with what was obtained at 4, 6 and 24 h for the 3 
cell lines (Figures4.4- 4.6).  Another observation worthy of note is the effect of exposure 
time on cell viability. Increased cytotoxicity was observed with the B-13/H, Jurkat and 
HL60 cell lines as the duration of treatment increased from 4 h to 6 and 24 h. 
 
Figure 4.3. The viability of B-13/H cells after exposed to AmB (125,  250 , 500 ng/µl  and 
control) in selected nanoparticles formulations after 2, 4 and 6 h determined by MTT assay 
(n=3) 
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Figure 4.4. The viability of Jurkat cells after exposed to AmB (125,  250 , 500 ng/µl  and 
control) in selected nanoparticles formulations after 2, 4 and 6 h determined by MTT assay 
(n=3) 
 
Figure 4.5. The viability of HL60 cells after exposed to AmB (125,  250 , 500 ng/µl  and 
control) in selected nanoparticles formulations after 2, 4 and 6 h determined by MTT assay 
(n=3) 
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At higher AmB concentrations (above 250 and 500 µg/ml) there was no decrease in 
cell viability. In addition, with increasing the time, there was no significant (P> 0.005) 
differences in the cytotoxicity in all the three cell lines. Similarly, it was reported that AmB 
conjugated to carbon nanotubes had relatively small toxicity towards Jurkat cells, derived 
from a human T-cell leukemia (Wu et al., 2005). Furthermore, the effect of AmB 
conjugates on other cell types is still unclear.  Although a cell line (such as Jurkat cells or 
HL60) is highly valuable to address questions regarding cytotoxicity, the results should be 
validated with primary cells such as hepatocyte cells. Studies with NPs of different 
chemical composition suggest that cancer cells are more resistant to NPs-mediated toxicity 
than primary cells found in the human body (Shakeri et al., 2015).  Another study was 
conducted by Zahra  and his coworkers (Um-i-Zahra and Zhu, 2015), on AmB-NPs 
cytotoxicity on three different hepatic cell lines (GRX, Hep G2  and ARL-6). They found 
that in an in vitro setting, AmB was able to selectively induce the cytotoxicity of GRX 
without affecting the liver parenchymal cells.  
 
4.4.4. In Vivo Nephrotoxicity and Hepatotoxicity Study 
AmB-induced nephrotoxicity is expressed by renal failure and abnormalities in 
tubular function. An elevated levels of both BUN and PCr are indicative of renal 
dysfunction or acute nephrotoxicity (Italia et al., 2009, Tonomura et al., 2009). 
In this study, several functional and morphological renal changes were observed 
following single or multiple doses (for 7 days) of AmB or its selected NPs formulations. 
These changes were observed by analysis of blood chemistry and pathological examination. 
There was no mortality after iv dosing for a week of any of the rats during the study. 
Relevant changes in serum chemistry are summarized in Table 4.3. A significant increase 
in biochemical parameter’s to test the kidney function (BUN, PCr) and liver function (ALP, 
-GT, ALT) after Fungizone® iv administration was observed in comparison to control 
group. 
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Table 4.3. Biochemical parameters after single and multiple i.v. dose administration of AmB 
and AmB-loaded PLGA-PEG copolymer as 1.0 mg/kg body weight to rats (n=3) 
  Control 
 
A6 B6 C6 D6 C7 Fungizone
®
 
BUN 
(mg/dl) 
SD 
17.67 ± 
3.05 
41.67 ± 
3.21 
38.00 ± 
3.51 
20.0 ± 
5.0 
23.33 ± 
4.16 
18.67 ± 
3.21 
51.33 ± 
2.0 
 MD 18.67 ± 
3.05 
38.67 ± 
4.62 
36.00 ± 
1.15 
25.33 ± 
3.05 
31.00 ± 
2.52 
20.67 ± 
2.08 
50.67 ± 
1.15 
Cr 
(mg/dl) 
SD 
0.31 ± 
0.03 
0.57 ± 
0.06 
0.64 ± 
0.03 
0.35 ± 
0.06 
0.44 ± 
0.06 
0.34 ± 
0.02 
0.76 ± 
0.02 
 MD 
0.28 ± 
0.02 
0.55 ± 
0.06 
0.59 ± 
0.03 
0.31 ± 
0.03 
0.41 ± 
0.05 
0.34 ± 
0.03 
0.73 ± 
0.05 
ALP 
(IU/l) 
SD 457.00± 
49.87 
560.00
± 42.03 
553.00
± 36.05 
516.33± 
48.13 
559.00± 
21.50 
452.33± 
26.63 
583.00± 35.30 
 MD 442.33± 
30.43 
549.33
± 15.95 
529.33
± 35.13 
521.00± 
41.79 
556.67± 
15.52 
456.67±
15.27 
593.33± 25.17 
-GT 
(IU/l)
SD 
0.98±    
0.22 
0.96±  
0.31 
1.07± 
0.27 
0.81± 
0.25 
0.99± 
0.23 
0.89± 
0.18 
1.13±      0.17 
 MD 0.78±   
0.53 
1.02±   
0.22 
1.17± 
0.16 
0.93± 
0.25 
0.99± 
0.15 
0.93± 
0.18 
1.12±      0.23 
ALT 
(IU/l) 
SD 29.66 ± 
4.16 
55.33± 
6.03 
44.33± 
6.51 
22.33± 
6.24 
24.33 ± 
7.09 
28.33 ± 
10.15 
45.00±    7.55 
 MD 25.67± 
4.18 
57.33± 
9.23 
39.67± 
5.69 
25.33 ± 
5.68 
33.00 ± 
6.56 
31.00± 
8.56 
35.67±    8.33 
SD: Single dose; MD: multiple doses 
 
The main concern of this study was to determine the in vivo nephrotoxic potential of 
AmB in the selected NPs formulations.  A substantial nephrotoxicity effect of Fungizone® 
was determined in rats with significant increase (P=0.003 and P=00.1) in BUN and PCr 
levels, respectively, as compared to the results in the control rats.  In the meantime, a 
minimal nephrotoxicity (P<0.05) was observed with lower BUN and PCr levels in the rats, 
after iv administration the selected NPs formulations as compared to the Fungizone® 
(Table 4.3). The observed lower toxicity of AmB-NPs could be attributed to the slow 
release of AmB from the NPs formulations compared to its release from the deoxycholate 
micelles in Fungizone®.  AmB is known to induce vasoconstriction, which leads to a 
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decrease of blood flow in the kidney. The observed reduction in the PCr is believed to be 
caused by a decrease in blood pressure that is associated with a decrease in blood flow in 
the glomerulus (Tasset et al., 1992, Tiyaboonchai et al., 2001, Risovic et al., 2003, Nahar et 
al., 2008, Italia et al., 2009, Tonomura et al., 2009, Belkherroubi-Sari et al., 2011). 
The present study was further focused on the significance of the biomarkers, BUN 
and PCr for their sensitive detection of renal injury induced by AmB in rats. The rats 
measured BUN after the administrations of NPs formulations C6, D6 and C7 were within 
the normal level for rat plasma in these treatment groups, while after Fungizone
®
,  A6 and 
B6, the mean BUN concentrations were > 40 mg/dl which consistent with moderate renal 
toxicity. 
After C6 and C7 administrations the PCr values in rats were around 0.31 mg/ dl 
,which is within the normal range for rat plasma.  However, for the other treatment groups 
as shown in Table 4.3,  the mean PCr was within the moderate renal toxicity (>0.4 mg/dl).  
The histopathological analysis of kidney tissue after iv administrations of the NPs 
formulations of AmB and Fungizone
®
, did not confirm any unusual sign of necrosis in all 
treated groups except in the Fungizone
® 
treated group.  It showed a distinctive necrosis of 
various degree as presented in Figure 4.6, which has been approved by the PCr results in 
the same study. 
Similar results were concluded with histopathology examination of liver tissues.  It 
did not show any abnormalities in all treatment groups, except the Fungizone
®
 one, which 
has clear necrotic hepatocytes and bile duct damage as indicated in Figure4.7. 
As a conclusion, all the iv administrations of the developed AmB-loaded to PLGA-PEG 
Diblock copolymer investigated, showed minimal renal damage compared to the reference 
formulation Fungizone, over a short duration of treatment.  
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Figure 4.6.  Typical kidney tissue alterations verified in rats treated with AmB or its 
equivalents dose as 1.0 mg/kg of body weight as iv administration of different AmB-PLGA-
PEG copolymer. 1) Normal kidney tissue; 2,3,4,5,6 and 7) Varying degree of nephrotoxicity 
necrosis related to iv administration of as A6, B6, C6, D6, C7 and Fungizone® respectively.  
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Figure 4.7. Typical liver tissue alterations verified in rats treated with AmB or its equivalents 
dose as 1.0 mg/kg of body weight as iv administration of different AmB-PLGA-PEG copolymer. 
1) Normal liver tissue; 2,3,4,5,6 and 7) Varying degree of hepatocellular vacuolation related to 
iv administration of A6, B6, C6, D 6, C7 and Fungizone® respectively.  
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4.5. Conclusion 
Novel oral biodegradable stealth polymeric nanoparticles have been successfully 
fabricated using the commercially available PLGA-PEG copolymer and loaded with AmB 
by an emulsification diffusion method. Drug loaded to PLGA-PEG has been characterized 
in vitro previously.  Drug content and release studies demonstrated that A6, B6, C6, D6 and 
C7 formulations had the best drug release characteristics and higher drug content. 
The freeze dried powder of the selected A6, B6, C6, D6 and C7 formulations 
produce milky colloid solution immediately after reconstitution in water.  They drastically 
reduce the in vitro hemolytic activity of AmB as compared to Fungizone
®
. The lack of 
hemolysis activity may reflect the slow release of the drug from its PLGA-PEG Diblock 
copolymer.  On a cellular level, AmB loaded to PLGA-PEG Diblock copolymer showed a 
potent activity against in vitro C. albicans in parallel with decreased cytotoxicity against 
three in vitro tested cell lines. Additionally, no pathological abnormalities were observed in 
rats given iv administrations of AmB NPs formulations in contrast to Fungizone
®
 
administration. 
AmB induced nephrotoxicity could be detected by BUN and PCr measuring after 
administration in rats.  A significant nephrotoxicity was detected after iv Fungizone
®
.  The 
in vitro and in vivo studies of the selected AmB NPs formulations showed  a minimal 
occurrence of the undesirable side effects caused by this drug, especially nephrotoxicity. 
Additionally, NPs did not induce hemolysis. Together all these results confirm the novelty 
of the developed oral NPs delivery system of AmB-loaded to PLGA-PEG Diblock 
copolymer formulations which could be a promising oral dosage form of AmB for the 
treatment of fungal infections.  Formulations C6 and C7 were the best among the other 
tested ones. 
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Chapter V. General Discussion 
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In this study a innovative oral delivery of AmB have been developed, with 
solubility and bioavailability improved associated with lower toxicity. The optimization of 
the oral formulations have been passed through many stages, including; selection of the 
copolymer used PEGylated polymer, which consist of PLGA-PEG, having two parts a 
hydrophobic polyester part (PLGA) and a hydrophilic (PEG) part. Both parts have been 
approved by FDA for oral and parenteral administration in humans, additionally, both of 
these parts have been improved the solubility and bioavailability of different groups of 
drugs when used individually. 
AmB loaded to PEGlyated polymer (PLGA-PEG) were successfully fabricated 
using the emulsion diffusion method, this method was efficient and reproducible with 
considerable efficient drug content.   
Other factors were affecting the nanosized of the produced AmB-loaded NPs such 
as the stirring rate, cosolvency, pH, the addition and concentrations of stabilizers ans/or 
surfactant used. 
 In vitro characterizations of the AmB loaded to PLGA-PEG formulations showed 
the highest main particles size (MPS) of 1,068.1 ± 489.8 nm corresponding to A3 (RGPd 
50105) and the lowest MPS 23.8 ± 4.8 nm corresponding to C6 (RGPd 50155). The 
decreasing in the MPS is mainly related to increasing the stirring rate from 8000 rpm to 
24000 rpm and due to the addition of stabilizer PVP, miglyol and Vitamin E (TPGS). All 
these factors were contributed to the significant reduction in the MPS. The best polymer 
used during the study was C (RGPd 50155) consisting from diblock PLGA-PEG copolymer 
with 15% PEG in comparison to other used polymers A (RGPd 50105) consisting of 
diblock PLGA-PEG copolymer with 10% PEG, polymers B (Rgp t 50106) consisting of 
triblock PLGA-PEG copolymer with 10% PEG, polymers D (RGP d 5055) consisting of 
diblock PLGA-PEG copolymer with 5% PEG, and lastly polymers E (R 203 H) consisting 
of monoblock poly(D,L-lactide).The reduction of the MPS of the novel oral AmB loaded 
PLGA-PEG was associated with increment of drug entrapment efficiency (DEE). The 
maximum drug entrapment efficiency of AmB was increased up to 56.7%, with 92.7% drug 
yield.  
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Other physicochemical studies were evaluated also for the newly formulated AmB 
loaded to PLGA-PEG such as scanning electron microscope (SEM) and transmission 
electron microscope (TEM). The SEM and TEM images indicate isolated and non-
agglomerated nanometric circular particles. Furthermore the Fourier infrared spectroscopy 
(FTIR) changes obtained from different AmB loaded to PLGA-PEG NPs formulations 
suggesting some sort of interaction between the drug and the polymer used.  
A new simple, fast, accurate and reliable HPLC method for the in vitro 
investigations (drug content and drug release from the formulated NPs) of AmB has been 
developed. It is involving of reverse phase high performance liquid chromatography using 
acetonitrile as main constituent of the mobile phase and protein precipitation method and 
Nicardipine used as internal standard. A linear relationship has been obtained with the 
absorbance of the AmB and the concentrations used which in the range of 250-5000 
g/ml.The intra-day and inter-day variability were ≤ 6.2% with excellent linearity 
(R
2
=0.9982) and reproducibility, short run time, with the average retention times of 2.87 ± 
0.05 for the AmB 4.20 ± 0.09   min for the Nicardipine (IS), respectively with no 
interfering peaks. Thus, this HPLC method was reliable for determination of the AmB 
concentration and has been used for drug content calculation and the percentage drug yield 
as well as in vitro drug dissolution studies. 
The main conclusion from the formulation of the AmB loaded to PLGA-PEG and 
physicochemical characterizations of the newly formed AmB-NPs, is the selection of the 
best following formulations (A6, B6, C6, C7 and D6) according to the more particle size 
reduction occurred and maximum drug content with best drug dissolution obtained from 
these newly formulations. Although the ingredients are the same for all newly formed 
formulations, except the type of the polymer used, the best of all these formulation is the 
C6 (RGPd 50155) consisting from diblock PLGA-PEG copolymer with 15% PEG. The 
high percentage of the PEG (15 %) may contribute to this result in comparison to other 
used polymer have 5 and 10 % for the D and A polymer, respectively.   
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All tested formulations have shown slow initial release with 24.8 % in AmB loaded 
to PLGA-PEG polymer A3(RGPd 50105) to 61% in AmB loaded to PLGA-PEG polymer 
C6(RGPd 50155) release within 24 h in phosphate buffer containing 2% sodium 
deoxycholate. The release rates of AmB from these formulations were best fit to the 
Korsmeyer–Peppas model followed by Higuchi model for 24 h profile. These mathematical 
models are indications for mechanisms of drug release from the polymer. Therefore, a 
diffusion release model is the best to characterize the in vitro release of AmB from these 
polymer formulations. Korsmeyer Peppas constant ‘n’ = 0.245 which is the beyond the 
limits of Korsmeyer Peppas model. It cannot be predicted clearly. The mechanism of the 
drug release from the polymer may be explained as complex mechanism of swelling, 
diffusion and erosion. 
 A second method of AmB drug determination has been applied in this study for in 
vivo evaluations, a new selective, sensitive and precise liquid mass spectroscopy (LC 
MS/MS) method was developed to measure AmB concentrations after oral and parenteral 
administration of selective formulations. An excellent relationship has been obtained with 
the absorbance of the AmB and the concentrations used (100-4000 g/ml) throughout the 
study.  The precision and accuracy of the newly developed LC MS/MS method show no 
significant difference among inter- and-intra-day analysis (P> 0.05). Linearity was 
observed over the investigated range with correlation coefficient, R
2
> 0.9943 (n = 6 day).  
The assay was able to detect all the drug concentrations for pharmacokinetics and 
bioavailability estimation after oral dosing of AmB loaded to PLGA-PEG compared to its 
parenteral administration in rats.   
Fungizone

 (commercially available iv dosage form of AmB), was administered to 
the rats as orally dose 10 mg/kg as single dose. Detectable low AmB concentrations 
obtained. When AmB loaded to PLGA-PEG (C6) orally administration, at similar dose (10 
mg/kg to rats, a statistically significant higher AmB concentrations was observed. 
Moreover administration more pronounced significant higher AmB concentrations were 
obtained after C6 administered as parenteral dose even it is one tenth of the dose (1 mg/kg). 
Both oral and parental administration showed than AmB were rapidly absorbed, distributed, 
and then slowly eliminated in a two compartment open model.   
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Glycyrrhizic acid (GA) it is a natural absorption enhancer, it is approved by many 
published literatures to increase the absorption of many drugs when added during the 
formulation procedure or added just prior to oral dose administration. The addition of GA 
to oral administration of C6 formulation showed significantly (P<0.05) increased AmB 
AUC and Cmax (2 - 3 folds) in comparison to oral administration of Fungizone

 at similar 
dose 10 mg/kg.  There was no significant change (P=0.09) in adding GA during 
formulation or just mixing before oral administration.  A tremendous improvement of AmB 
oral absorption of C6 in rats by > 790 % than Fungizone

 is observed after GA Addition.  
AmB is known to be nephrotoxic, it is very important to screen the in vitro and in 
vivo toxicity of the selected AmB novel oral formulations (A6, B6, C6, C7 and 
D6)Fungizone

 was used as the reference standard for comparison. The toxicity tests 
including several in vitro assays; hemolysis, antifungal activity and analysis of the cell 
viability by 3-(4,5dimethylthiazoly)-2,5-diphenyl-tetrazolium bromide (MTT) assay.  AmB 
loaded to PLGA-PEG of the all selected formulations showed a significant reduction (P< 
0.05) in the in vitro hemolytic activity as compared to Fungizone

, Both C6 and C7 
showed the lowest hemolysis toxic level. On another hand, AmB loaded to PLGA-PEG 
showed a potent activity against the in vitro C. albicans with a parallel decrease in the 
cytotoxicity against in the in vitro tested cell lines (Jurkat, HL60 and B-13/H cells) after 
exposure to 125, 250, and 500 ng/ml of AmB or its equivalents.The data obtained 
showed variations in cell viability after testing different formulations, most of them were 
likely to be safe for the used cell lines, since in all cases > 80% of the three cell lines 
remained viable, even at higher AmB concentration (500 ng/ml). Moreover, these data 
showed a dose-dependent reduction in viability (with increasing the dose there is greater 
loss of viability). It can be concluded that AmB-loaded to PLGA-PEG copolymer NPs of 
selected formulations were less toxic than the reference standard Fungizone
®
. 
Histopathological evaluations were done after iv multiple administrations of 1.0 
mg/kg body weight of the selected AmB-NPs formulation (A6, B6, C6, C7 and D6) in 
comparison with Fungizone
®
. No significant abnormalities were observed in rats given iv 
administration of AmB-NPs of the selected AmB novel oral formulations (A6, B6, C6, C7 
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and D6) except after Fungizone

 administration which showed significant necrosis of the 
liver and the kidney. 
The in vivo nephrotoxicity and histopathological evaluation of AmB were 
performed in both rats' kidneys and liver using forty eight rats divided into eight groups 
after single and multiple iv administrations of 1.0 mg/kg of the selected AmB-NPs 
formulation (A6, B6, C6, C7 and D6) in comparison with Fungizone
® 
for one week. AmB 
induced nephrotoxicity was also estimated in these rats by measuring blood urea nitrogen 
(BUN) and plasma creatinine (PCr). A significant (P<0.05) nephrotoxicity was observed 
after Fungizone
®
 administration compared to all AmB loaded to PLGA-PEG selected 
formulations (A6, B6, C6, C7 and D6). The histopathological study of the isolated kidney 
tissues confirmed this finding.  Furthermore, the incidence of the liver toxicity due to the 
selected AmB loaded PLGA-PEG formulations has been reduced significantly as 
investigated through in vivo analysis (histopathological and biochemical tests) in 
comparison with Fungizone

.  
In conclusion, a successful novel AmB oral formulation were developed using 
dicblock PLGA-PEG polymer with improved solubility, bioavailability, efficacy and with 
less toxicity to the kidney and the liver.  C6 (RGPd 50155)which consist of the diblock 
PLGA-PEG with 15% PEG was the best tested formulation. Further investigations are 
needed in the near future for this formulation to be in the market as an oral delivery system 
of AmB. 
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Chapter VI. Further Work 
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Although the enlargement of development of new antifungal agents, AmB remains 
one of the most effective drug in the treatment of systemic fungal infections. The most 
serious adverse effects associated with AmB therapy is nephrotoxicity with sodium 
depletion. Several approaches have been studied to prevent these side effects. Loading 
AmB in liposomes or various lipid formulations seems to be the best strategy to reduce its 
nephrotoxicity and improve drug delivery to target sites. While these formulations are 
proven to be effective, they still used as parenteral administrations and need of certain 
safety issues associated with this administration and high drug cost. 
An oral formulation of AmB is appropriate to treat infections and provide or 
prophylactic therapy for high-risk patients. This PO route will also increase compliance and 
prevent parenteral side effects.  
Several strategies can be considered for enhancing the anti-leishmanial activity of 
oral AmB-NPs. Enhancing particle uptake by macrophages. The particle uptake by 
macrophages is mostly dependent on two main factors, the particle size and the 
hydrophobicity/hydrophilicity. Increasing the particle size can improve the particle uptake 
by macrophages; however, it adversely affects its intestinal uptake. Altering the 
hydrophobicity of the particles may enhance the particle opsonization and subsequent 
uptake by macrophages.  The other strategy could be the altering of release profile of AmB-
NPs. Increase in rate of AmB release from AmB-NPs can increase the concentration of free 
AmB available for killing the parasites, which may lead to improved anti-leishmanial 
activity. PLGA-PEG is a copolymer, made up of polylactic glycolic acid and polyethylene 
glycol. As PLGA being more hydrophobic than PEG, hydrophobicity and degradation rate 
of PLGA mainly depends on the molar ratio of lactic and glycolic acid in the polymer 
chain. By varying copolymer composition of PLGA, degradation rate (and thus drug 
release) or hydrophobicity of the AmB-NPs can be optimized to obtain higher 
antileishmanial activity. On the other hand, NPs can actively be targeted to macrophages by 
functionalizing the particles using specific ligands. 
Preliminary studies have shown that freeze-dried AmB-NPs loaded by PLGA-PEG 
showed significant reduction in the MPS, enhanced the DEE and high yield obtained. The 
SEM and TEM images indicate that the presence of both isolated and agglomerated 
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particles of spherical shape (in the nanometer size range). The results of the FTIR show sort 
of interaction between the drug and the polymer, which suggest the loading of the into the 
polymer. In addition to SEM, TEM and DSC further physicochemical confirmation can be 
done using X ray diffraction, show the pattern of the AmB-NPs either crystalline or 
amorphous state. Moreover, atomic force microscopy (AFM) displays the three dimension 
image of the AmB-NPs and can confirm the size distribution of the particle size for the new 
formulations.   
Furthermore, additional studies can be carried on different addition of excipient as 
and different concentration to investigate its effect on the AmB-NP formulations. 
Additionally stability test (at room temperature and accelerated stability test) should be 
done the for the new formulation on short and long term stability studies.   
A simple, fast, accurate and reliable analytical HPLC method for measuring AmB 
in in vitro was developed during this study. It is sensitive for AmB, can measure as low as 
250 ng/ml, under the assay conditions, the retention times for AmB and IS were around 2.8 
and 4.2 min, respectively. 
The release profiles indicate biphasic release of AmB from PLGA-PEG-NPs 
formulations. In the first phase an initial rapid release of about 21-51%, depending on the 
formulation, followed by a slower phase, after 6 h, where only about 11% was released.  
Further studies are suggested to assess the stability of oral AmB loaded PLGA-PEG 
copolymer over short and long period of time.  
A new developed simple, rapid and sensitive analytical UPLC Ms/Ms method was 
utilized and validated for the analysis of AmB concentrations in rat’s plasma after 
administration of the AmB loaded to PLGA-PEG tested formulations as either iv or PO 
administration. The lower detectable concentration was 100 ng/ml at a signal-to-noise ratio 
of >10, with the corresponding R.S.D. of 14 %. 
AmB should not be kept in the auto sampler more than overnight analysis to ensure 
reproducibility of the assay; it is unstable at room temperature. Exposing AmB to drastic 
conditions revealed that AmB is stable in acidic medium even after boiling, losing only 
5.7% of its nominal value.  In the meantime, both water and basic condition showed 
 
 
156 
 
complete loss of AmB even without boiling for all tested samples.   A further study should 
be done , the long-term stability studies (as per ICH guidelines) should be considered to 
determine the influence of a variety of environmental factors such as temperature, humidity 
and light to establish a shelf life for the drug product and recommended storage conditions. 
Since the formulation is intended to be administered orally, the formulation should be 
essentially palatable. To improve the palatability, various additional excipients such as 
sweetening and flavoring agents need to be incorporated in the formulation. Since these 
additives can affect the stability of the formulation, their effects on the stability of the final 
formulation should be evaluated.  
The present studies demonstrated pharmacokinetic proof of concept in feasibility of 
the oral delivery of AmB as nanoparticulate formulation resulted in considerable intestinal 
absorption into the systemic circulation and with considerable therapeutic efficacy in rats. 
The plasma pharmacokinetics of orally administered AmB resembles those of Fungizone

-
PO.  The addition of GA significantly improve the bioavailability of AmB, unexpectedly, 
the GA addition just prior to oral administration or combined it during the formulation 
process does not significantly affect the bioavailability. Further study should be done on 
administration of AmB tested formulations for more than 24 h, multiple doses and of large 
number of rats, since the pharmacokinetic of the AmB still unclear. 
The present study also investigates the selected AmB-NPs loaded to PLGA-PEG for 
in vitro and in vivo toxicity tests.  The in vitro and in vivo studies done for the selected 
AmB loaded to PLGA-PEG nanoparticles resulted in significant lower side effects 
especially nephrotoxicity in comparison to Fungizone
®
. No adverse effects were identified 
in liver and kidney in vivo, as it is shown by histopathology analysis and quantification of 
serum biochemical parameters. Additionally nanoparticles did not induce hemolysis. 
Furthermore, the prepared AmB-NP, have high therapeutic efficacy and are can be useful 
for the treatment of fungal infection including candidiasis. Together these results 
demonstrate the novel oral tested AmB-NPs loaded with PLGA-PEG formulation could be 
a promising oral dosage form of AmB for the treatment of fungal infections. 
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Further studies is suggested to assess the antifungal activity of oral AmB loaded 
PLGA-PEG copolymer over short and long period of treatment to assess both antifungal 
activity and survival of the animals upon the long treatment. 
The overall physicochemical tests for its pharmacokinetics and in vitro and in vivo 
cytotoxicity studies showed that PLGA-PEG copolymers were a safe excipient as well as 
an alternative carrier for oral drug delivery for AmB. 
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